Impaired Organ Perfusion:Assessment of Early Diagnosis and Interventional Strategies by Morariu, Aurora
  
 University of Groningen
Impaired Organ Perfusion
Morariu, Aurora
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2005
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Morariu, A. (2005). Impaired Organ Perfusion: Assessment of Early Diagnosis and Interventional
Strategies. s.n.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
Impaired Organ Perfusion:
Assessment of Early Diagnosis
and Interventional Strategies
Aurora Mihaela Morariu
Financial support by the Netherlands Heart Founda-
tion and the Research Institute for Biomedical Sci-
ence and Application for the publication of this thesis
is gratefully acknowledged.
“Impaired Organ Perfusion: Assessment of Early Diagnosis and
Interventional Strategies”
by Aurora Mihaela Morariu
Department of Biomedical Engineering,
University Medical Center Groningen,
The Netherlands.
31st October 2005
Cover: Bright field microscopy of University of Wisconsin–induced branched red
blood cell rouleaux networks; magnification 500×.




Assessment of Early Diagnosis and Interventional Strategies
Proefschrift
ter verkrijging van het doctoraat in de
Medische Wetenschappen
aan de Rijksuniversiteit Groningen
op gezag van de
Rector Magnificus, Dr. F. Zwarts
in het openbaar te verdedigen op




geboren op 20 augustus 1974
te Botosani (Roemenie)
Promotores: Prof. Dr. Ir. H.J. Busscher
Prof. Dr. P.W. Boonstra
Prof. Dr. R.J. Ploeg
Copromotores: Dr. W. van Oeveren
Dr. G. Rakhorst
Beoordelingscommissie: Prof. Dr. L.P.H.J. Aarts
Prof. Dr. G. Molema
Prof. Dr. L. Eijsman
isbn 90-6464-3350
“Declare the past, diagnose the present, foretell the future; practice
these acts. As to diseases, make a habit of two things:






1.1 General considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
1.2 Theoretical background . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
1.3 Aim of research . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
2 Organ Perfusion During Cardiopulmonary Bypass: Therapeutic Effect of Dex-
amethasone.
“Dexamethasone: Benefit and Prejudice for Patients Undergoing On–pump Coro-
nary Artery Bypass Grafting” 27
2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
2.2 Patients, Materials and Methods . . . . . . . . . . . . . . . . . . . . . 30
2.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
2.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
2.5 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
3 Organ Perfusion During Cardiopulmonary Bypass: Hematocrit, Blood Trans-
fusion and Temperature Effect on Organ Viability.
“Combined Strategy to Limit Perioperative Myocardial, Renal and Intestinal Tissue
Injury in Patients Undergoing On–pump Coronary Artery Bypass Grafting” 49
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
3.2 Patients, Materials and Methods . . . . . . . . . . . . . . . . . . . . . 52
3.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
3.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
3.5 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
4 Organ Perfusion During Cardiopulmonary Bypass: Vascular Endothelium Ac-
tivation.
“Red Blood Cell Aggregation During Cardiopulmonary Bypass: A Pathogenic Co-
factor in Endothelial Cell Activation?” 69
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72
4.2 Patients, Materials and Methods . . . . . . . . . . . . . . . . . . . . . 73
4.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75
4.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
5 Organ Perfusion During Cardiopulmonary Bypass: Blood Rheology and En-
dothelial (Dys)Function.
“Acute Isovolemic Hemodilution Triggers Pro–Inflammatory and Pro–Coagulatory
Endothelial Activation in Vital Organs: Role of Erythrocytes Aggregation” 87
5.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89
5.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90
5.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94
5.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
6 Organ Perfusion in Transplantation: Organ Viability in Brain Dead Donors.
“Consequences of Cerebral Injury in Brain Dead Donors on Organ Viability: Pro-
gression of Pro–Coagulatory and Pro–Inflammatory Endothelial Activation” 107
6.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
6.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
6.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113
6.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117
7 Organ Perfusion in Transplantation: Consequences and Importance of the
Washing Out Procedure.
“Hyperaggregating Effect of HES Components and University of Wisconsin Solu-
tion on Human Red Blood Cells: A Risk of Impaired Graft Perfusion in Organ
Procurement?” 129
7.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 131
7.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 132
7.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 134
7.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 137








Understanding Quality of Life is nowadays of critical importance when providing
health care. Current medical practices and the expanding medical technology lay their
fundamental principles on prolonging Life at all costs. Decisions on what research or
treatments should invest in are closely related to their effect on patient’s Quality of
Life. Conventional medical indicators of Life Quality are the rate of cure, disease–free
survival, side effects, and costs. In order to build a correct diagnosis and treatment
decision, the mentioned factors are taken into consideration together with indicators
of the impact of patient’s personality on the disease, the level of satisfaction, and the
general health condition. The work described in this thesis aims to mediate some of
the today’s clinical controversies, to challenge some of the standard decisions in the
current clinical practice by pointing out both weak and strong points in the algorithm
of diagnosis and treatment of organ injury and dysfunction during disease.
Organ perfusion is a generic physiological term that refers to the process of oxygen
and nutritive delivery of arterial blood to the capillary bed in the biological tissue of
specific organs. A compromised organ perfusion might have a multifactorial etiology:
low cardiac output caused by cardiogenic or hypovolemic shock1, acute respiratory
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failure2, low blood oxygen–carrying capacity3, macro/micro–vascular collapse4,5, sep-
sis with systemic inflammatory response6,7, hypotension and hypoxia as secondary
insults to brain injury8,9. In our approach, we investigated the organ perfusion and
subsequent organ viability during acute organ support, as performed during open
heart surgery with cardiac arrest and cardiopulmonary bypass, and during donor
management and organ procurement prior to transplantation.
1.2 Theoretical background
Acute organ support by means of cardiopulmonary bypass
The father of surgical cardiopulmonary bypass for humans was John H. Gibbon, Jr,
MD.10, whose interest in and determination to develop cardiopulmonary bypass arose
in 1931 when he sat at the bedside of a young woman who was dying of a pulmonary
embolus.
“It is only necessary to . . . withdraw blood from a vein, introduce oxygen
and allow carbon dioxide to escape, and then inject the blood into a pe-
ripheral artery. It would permit, of course, operations within the heart
under direct vision.”
John Gibbon Jr., 1949.
He and his wife, Mary Gibbon, devoted the better part of their lives to the labo-
ratory development of a usable pump and oxygenating system. On May 6, 1953,
John Gibbon made surgical history by using his apparatus for the successful repair
of an atrial septal defect in an 18 years old woman11. Although he subsequently
operated on 2 more patients, both died; he was so disappointed that he never again
performed an open heart operation. However, by the mid–1950s, the first successful
clinical procedures had been reported12. Although it was obvious that the equipment
was primitive and risks were high, the practicality of developing effective treatments
for congenital and valvular heart disease had been demonstrated.
The cardiopulmonary bypass (CPB), or heart–lung machine, is an apparatus through
which blood is temporarily diverted, especially during open heart surgery, to be oxy-
genated and pumped through the body, maintaining circulation until the heart and
lungs are able to return to normal functioning13. The heart–lung machine allows
open–heart surgery to be performed on an arrested heart without the patient suf-
fering from hypoxia. Additional to open heart surgery, extracorporeal circulation is
a promising adjunct to surgical techniques in neurosurgery, thoracic aortic surgery,
complex lung resections, and tumor surgery14. Last but not least, mechanical sys-
temic circulatory support is used successfully during bridging to transplantation, to
10
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Figure 1.1: The principle of the heart–lung machine.
support life in recipient patients waiting for transplantation or to maintain organ
function until organ procurement in transplant donors15.
Cardiopulmonary bypass is accomplished by the use of an extracorporeal circuit and
a pump. The standard CPB circuit (Fig. 1.1) consists of connective tubing, a blood
reservoir, oxygenator, heat exchanger, and filter. A venous cannula is placed in the
vena cava or right atrium to drain unoxygenated blood by gravity through connective
tubing into a blood reservoir. The blood is then pumped to an oxygenator where
oxygenation and carbon dioxide removal takes place. Blood temperature may be ad-
justed by the use of a heat exchanger. Generally, whole body hypothermia is induced
while the patient is on CPB. Hypothermia decreases the body oxygen consumption
and allows lower blood delivery rates. After the surgical correction is performed,
the blood temperature is rewarmed. The blood is filtered to reduce the potential
for an embolism and is pumped back to the body through an arterial cannulation.
Prior to initiation of CPB, the extracorporeal pump circuit is primed with a balanced
crystalloid/colloid solution (e.g. hydroxyethyl starch HES solutions). Once CPB has
been initiated, the heart is allowed to beat or it may be temporarily arrested by the
administration of cardioplegia solution. Cardioplegia is a cold crystalloid or blood
solution that contains a high concentration of potassium. The potassium is used to
induce cardiac arrest. The cold temperature of the cardioplegia solution (4◦ C) along
with other drugs in the solution reduces the oxygen requirements of the myocardium
and helps to preserve the heart during the ischemic arrest period.
Contact of blood components with the artificial surface of the bypass circuit, aortic
cross–clamping, cardioplegic techniques, low perfusion pressures with a non–physiologic
profile (continuous), hemodilution, allogenic blood transfusion, and operative trauma
result in a systemic inflammatory response syndrome (SIRS) and ischemia/reperfusion
11
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injuries, generally acknowledged as a “post CPB syndrome”. The systemic inflamma-
tory response in combination with the ischemia/reperfusion injuries and the multiple
gaseous, lipoprotein and particulate emboli generated during CPB result in organ
dysfunction affecting the heart, brain, lungs, kidneys and intestine.
Special clinical attention is addressed to the pathophysiology of the systemic inflam-
matory response syndrome during CPB. The complex inflammatory reaction set in
motion during exposure of blood to large areas of synthetic materials involve activa-
tion of complement, platelets, neutrophils, monocytes and macrophages triggering the
coagulation, fibrinolytic and kallikrein cascades and increasing blood concentrations
of interleukins, tumor necrosis factor, leukotriens. A subsequent increase in endothe-
lial cell permeability allows transvascular migration of activated leukocytes into the
tissues with additional vascular and parenchimal damage16–18.
Preoperative administration of corticosteroids, with methylprednisolon and dexam-
ethasone being the two most utilized agents, has been demonstrated to inhibit the
activation of the plasmatic and cellular inflammatory response16, to decrease the pro–
to anti–inflammatory interleukins ratio19, and to minimize tissue edema20.
Over the last 50 years increased understanding of the physiology and pathophysiology
of the response to CPB has led to steady improvements in circuit design and a reduc-
tion in postoperative morbidity. The development of more biocompatible polymeric
materials21, arterial in–line filters22, membrane oxygenators23, and centrifugal blood
pumps24 have resulted in less intraoperative hemolysis, less blood activation, and
decreased circulation of emboli25. Surface modification of circuits with heparin26,27
to mimic the native circulatory system and the use of pharmacological agents such as
aprotinin28 have been shown to attenuate blood activation, systemic inflammation,
and organ dysfunction29,30.
Even with these developments, post–CPB inflammation, ischemia/reperfusion injury,
organ injury and organ dysfunction are attenuated but not completely inhibited31–33.
The use of mechanical assistance as a bridge to transplantation or a bridge to recovery
are presently the main indications for mechanical circulatory support in transplant
recipients, allowing a prolonged survival with a reasonable Quality of Life. Special
attention is directed to transplantation in infants and children, where the problem of
organ donor shortage is even worse when compared to the situation in the field of adult
heart transplantations. Newly developed pulsatile, paracorporeal ventricular assist
devices designed for long–term assist in children have demonstrated their ability to
provide excellent results beyond the abilities of extracorporeal membrane oxygenation




Pathophysiology of impaired tissue perfusion and donor management in
organ transplantation
Transplantation has been incorporated into the treatment of patients with end–stage
diseases of most major organ systems in recent years. However, organ supply is the
greatest limitation to organ transplantation, and thus good management of available
donors is a high priority. The majority of donors are heart beating, brain dead ca-
daveric donors from whom multiple organs are procured for transplantation. There
are several steps on the path from potential donor to actual donor. These steps
have been defined as: identification and detection of all potential donors; brain death
determination; approaching potential donor families for consent; and donor medi-
cal management35. Due to brain death and loss of integrated neurological function,
the potential organ donor manifests major physiologic derangements that require
aggressive, labor–intensive management throughout the hospitalization until organ
procurement or cessation of life support in order to maintain organ function. Experi-
mental and clinical brain death studies define as major pathophysiologic mechanisms
the vascular regulation injury and metabolic cellular injury36. Myocardial dysfunc-
tion and impaired systemic vascular tone trigger hemodynamic instabilities leading
to impaired inotropy and chronotropy, dysrhythmias, decreased cardiac output and
hypotension37–39. Arginin–vasopressin production in the pituitary tract generally
ceases after brain death, which commonly leads to diabetes insipidus40. The loss of
free water caused by diabetes insipidus may lead to dehydration, hypovolaemia, and
blood electrolyte abnormalities. Hypokalaemia, hypocalcaemia, hypophosphataemia,
and hypomagnesaemia may contribute furthermore to decrease in cardiac function
and organ blood flow41.
Endothelial activation in brain dead donors has gained lately considerable attention
in the scientific discussion around the pathology of brain death prior to organ re-
trieval. The endothelium is considered to be a dynamic interface between the vascular
compartment and the extravascular space regulating protein flux, local blood flow,
coagulation cascade and the trafficking of the inflammatory cells from the blood into
tissue. The vascular endothelial phenotype changes dramatically under pathophysio-
logic conditions with regards to expression of cell adhesion molecules, cytokines, and
substrates that promote thrombosis and inflammation. In this respect, one of the
earliest events that was demonstrated to develop after brain injury is the expression
of a series of adhesion molecules in sequence by activated vascular endothelium42,43.
Additionally, an immune activation with increased endothelial cell activation and im-
mediate early gene expression is shown to occur after brain death induction44. The
expression of endothelial adhesion molecules (intercellular adhesion molecule–1 and
vascular cell adhesion molecule–1) and the influx of leukocytes in the kidney occurs
faster and is more profound when hemodynamic instability in the brain dead donor is
not corrected45. In this way, the involvement of the activated vascular endothelium
was linked incontestably to the progression of inflammation after brain death.
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Donor management has been considered the most neglected area of transplant medicine.
In support for this affirmation stand statistical data showing that failure to provide
adequate physiological support to potential donors accounts for at least 25% of lost
donor organs, and that adoption of an aggressive protocol for donor management,
including both intensive monitoring and therapy, has allowed the donor retrieval rate
to increase by approximately 30%46–48.
All organs may benefit from aggressive management. Current evidences regarding the
evaluation and management of potential donors led to the recommendation that organ
procurement organizations should use a standard protocol for donor management
which should include application of pulmonary arterial catheterization49,50.
A Critical Pathway for the Organ Donor was described, including five distinct, but of-
ten overlapping phases: Phase I, Donor Referral; Phase II, Declaration of Brain Death
and Consent; Phase III, Donor Evaluation; Phase IV, Donor Management; and Phase
V, Organ Recovery51. Each phase has five subsections that the ICU staff and/or the
organ procurement coordinator can use as a guide for thoroughness of evaluation and
management. These five subsections are: General Management; Laboratory and diag-
nostic Tests; Respiratory Therapy; Treatments; Intravenous Fluids and Medications.
The Critical Pathway is designed to provide the information necessary to evaluate the
functional status of the kidneys, liver, pancreas, heart and lungs and to determine the
management steps which need to be taken to improve and optimize the performance
of each organ. In addition to an invasive monitoring, these patients need a meticulous
attention to their hemodynamic variables.
The early administration of desmopressin to treat diabetes insipidus, differentiated
use of fluid resuscitation and distinct catecholamine support are special features of an
appropriate basic treatment. Hormonal resuscitation (thyroxin, vasopressin, insulin)
has been reported to stabilize and improve cardiac function in brain dead donors.
The administration of corticoids has to be considered if a sufficient circulation can
not be regained52.
As the management of organ donor patients becomes more complex, recovery coordi-
nators often have to change their thinking and resort to extra, nonconventional means
of diagnosis and management. The standard laboratory diagnostic tests are not always
early, specific and sensitive enough, so addition of new biomarkers to diagnose organ
injury is needed. Furthermore, instead of aggressive pharmacologic interventions of-
ten implemented in an attempt to stabilize donor hemodynamics, the addition of an
extracorporeal circulatory assist device might prove beneficial in optimizing organ
perfusion. There are reports in literature showing that cardiopulmonary bypass and
profound hypothermic circulatory arrest may be easily combined with traditional pro-
curement flushing techniques, providing excellent organ preservation for subsequent
transplantation. This approach could optimize organ recovery from hemodynamically
unstable donors, increasing the number of organs available for transplantation53.
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Organ procurement: wash–out and preservation procedures prior to trans-
plantation
In the 1930s, the classical experiments of Carrel and Lindbergh included perfusion
techniques to preserve organs for transplantation. They established ground rules
for organ preservation by continuous ex–vivo perfusion; expert technology, perfect
asepsis, and controlled biological conditions. The Spanish Civil War marked the
advent of blood banks and clinical application of tissue storage techniques. Cold
storage was used to diminish metabolic demand. Fortunately blood, the first widely
preserved and transplanted biological substance, lent itself well to extended storage.
Refrigerated storage was possible for 3 weeks.
The discovery of cryoprotectants by Polge and coworkers in 1949 ushered in a major
extension of preservation times for a variety of simple cells and tissues. Blood cells
and gametes (even embryos) could be stored after freezing. Weeks or months later,
they could be thawed and successfully reimplanted as autografts or allografts. Such
freezing was only successful for isolated cells or undifferentiated multicellular embryos:
complex and heterogeneous organs were highly sensitive to freezing damage. The
biophysical problems of freezing large organs were subsequently defined by Pegg and
other workers. To date no consistent success has been obtained with the use of freezing
to preserve organs such as kidneys, liver, or hearts. Concepts of frozen humans waiting
revival at an appropriate future time on another planet or in an after–life remain
science fiction54.
Nowadays, standard procedures for organ procurement and preservation require each
organ to be flushed free of blood with a specially prepared ice–cold preservation
solution, just prior to being removed from the donor. The organs are then placed in
sterile containers, packaged in wet ice, and transported to the recipient’s transplant
center.
In order to allow inclusion of additional less–optimal donor categories, the organ pro-
curement and initial perfusion technique are key factors toward an improved outcome
in organ transplantation55.
Good organ preservation starts with an effective blood washout of the donor organ.
Major determinants to maintain graft viability, irrespective of the chosen preservation
solution or method, are a rapid decrease in core temperature56 and an equilibration
between the intravascular preservation solution and the parenchyma57. Following the
wash–out procedure, organ preservation is performed, using either static cold storage
or continuous machine perfusion. Using simple cold storage methods, it is easy to
transport organs for transplantation. However, despite the complexity and difficulty of
organ transportation, continuous machine perfusion has some advantages by opening
opportunities for viability assay and pretreatment of organs before transplantation.
Preservation solutions have been designed to ameliorate the adverse physiological and
biochemical effects of ischemia under hypothermic conditions. Three principles are
important in effective cold storage. First, the vascular wash–out during harvest should
15
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rapidly cool the organs, remove the blood and allow balance between the cold storage
solution and the tissue. Second, the cold storage solution should prevent cell swelling
and interstitial edema formation by including substances that are osmotically active
and impermeable to the cell. Impermeants and saccharides achieve homeostasis of the
intracellular water content. Homeostasis of the interstitial compartments is achieved
by counteracting a hydrostatic force during the initial wash–out using colloids. The
intravascular fluid compartment does not need an effective component in static cold–
storage. Third, the cold storage solutions should prevent excessive cellular acidosis by
containing sufficient concentration of hydrogen–ion buffer, histidine or citrate56,58.
Since its introduction by Belzer et al. in the late eighties, the University of Wisconsin
(UW) solution has become the standard solution for the preservation of most organs
in transplantation. Despite the fact that UW solution made extended cold preserva-
tion feasible, some studies have demonstrated that prolonged cold ischemic time of
hepatic allografts enhance bacterial infection59, cause biliary and hepatic artery com-
plications60,61 and increase the frequency of primary non function posttransplant62.
The inclusion and importance of the colloid hydroxyethyl starch (HES) as one of the
components of the UW solution has been both advocated and denied. HES prevents
interstitial edema and has a beneficial effect on matrix metalo–proteinases63 but at
the price of a higher solution viscosity. Due to the presence of HES, the viscosity of
UW solution at 4◦ C increased by a factor of 2.5 when compared with the viscosity
of the same solution at 37◦ C64.
“Folkert O. Belzer, the “father” of the University of Wisconsin preservation solution,
was an outstanding practitioner of transplantation medicine, a brilliant, technically
beautiful surgeon, and a superb educator–trainer of surgeons. However, his methods
in the laboratory might be considered unorthodox. His goal was simple to improve
organ preservation so he could offer his patients a better organ for a long and healthy
life. In the early 1980s, Bob Hoffmann and I were trying to extend kidney preservation
beyond 3 days; we believed that one of the problems was the lack of oxidizable sub-
strates (fatty acids) in the perfusion fluid. We had trouble dissolving these fatty acids
because we were no longer using serum albumin as a colloid but rather hydroxyethyl
starch that did not bind fatty acids. One afternoon, Dr Belzer was drinking coffee
and smoking his pipe in the laboratory, a pastime that consumed his off hours, led to
great discussion between us, and catalyzed his mind. While reading the label on the
coffee creamer carton, he noticed a list of monoglycerides and diglycerides and asked
me about their purpose. I responded that these agents served as emulsifiers to help
keep the lipid materials in solution. It was immediately obvious to me that the lights
went on in his brain because he responded with, “Why not use this coffee creamer
to solubilize fats in the perfusion solution?” I had no good explanation; hence, we
tried the kidney perfusion with the addition of coffee creamer. (By the way, it did




1.3 Aim of research
The aim of this work was to investigate the efficiency of organ perfusion during acute
organ support, as performed during extracorporeal mechanical blood circulation in
cardiac patients, and during donor management, organ procurement and organ preser-
vation prior to transplantation. The investigations were conducted in clinical studies,
animal studies and in–vitro experimental settings. The efforts were concentrated on
testing the diagnostic value of new, specific and sensitive biomarkers for organ injury,
in order to help an early and effective therapeutic strategy. Given the complexity
of this subject and the large diversity of clinical problems associated with impair-
ment of organ perfusion, we approached only main points of debate in the current
clinical world. The questions we addressed in the context of cardiopulmonary bypass
associated morbidity concern the prophylactic use of corticosteroids, the isovolemic
hemodilution, the therapeutic choice for plasma expenders, the myocardial protection
and the corporeal temperature during extracorporeal circulation. In organ donation
and transplantation, we investigated the consequences of cerebral injury in brain dead
donors on organ viability. Impairment of perfusion during organ procurement and or-
gan preservation was investigated in relation with the initial wash–out procedure.
Beside clinical questions, the attention was also distributed towards the pathophysi-
ologic mechanisms involved; vascular endothelial function and red blood cell function
were especially addressed.
DEXAMETHASONE: BENEFIT AND PREJUDICE FOR PA-
TIENTS UNDERGOING ON–PUMP CORONARY ARTERY BY-
PASS GRAFTING – A study on myocardial, pulmonary, renal, in-
testinal, and hepatic injury. (Chapter 2)
Administration of corticosteroids to patients undergoing on–pump cardiac surgery
was demonstrated to inhibit the activation of the plasmatic and cellular inflammatory
response, to decrease the pro– to anti–inflammatory interleukins ratio, to minimize
tissue edema and to optimize the intravascular/extravascular fluid balance. Based on
this constellation of findings, a routine prophylactic administration of corticosteroids
was instituted in a multitude of clinical centers when performing on–pump heart
surgery, assuming that inhibition of the systemic inflammatory response is automat-
ically associated with clinical benefits. However, only a few clinical trials have been
conducted to extend these results and to investigate the effect on clinical outcome in
patients receiving corticosteroids.
As an original contribution to the issue of CPB related inflammatory response and
organ injury, we document the effect of dexamethasone on perioperative myocardial,
pulmonary, renal, intestinal and hepatic injury, as assessed by newly available specific
and sensitive (bio)markers. Furthermore, to describe the effects of corticosteroids
on the systemic inflammatory response, we measured cytokine response and systemic
tryptase release as a marker of mast cells activation. Finally, a new hypothesis relating
17
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tryptase to the attenuation of perioperative organ injury is discussed.
COMBINED STRATEGY TO LIMIT PERIOPERATIVE MY-
OCARDIAL, RENAL AND INTESTINAL TISSUE INJURY IN
PATIENTS UNDERGOING ON–PUMP CORONARY ARTERY
BYPASS GRAFTING (Chapter 3)
The available scientific data concerning the effectiveness and safety of cardiopul-
monary bypass (CPB) for patients undergoing coronary artery bypass grafting (CABG)
brings to attention several key principles to serve as basis for practical guidelines.
Encouraged and generally accepted techniques are cold crystalloid cardioplegia, mild
corporeal hypothermia and hemodilution to a hematocrit as low as 20%. Our thera-
peutic strategy aimed to explore, advance and optimize simultaneously more than one
method of protection by eliminating several potential stress factors that might lead to
injury and dysfunction during CPB: inadequate hypothermic cardioplegia, excessive
hemodilution with subsequent need for perioperative blood transfusion, and corporeal
hypothermia.
An experimental operative protocol was developed to meet multiple objectives: (1)
homogeneous cooling of the myocardium by combining cold crystalloid cardioplegia
technique with an additional intracavitary cooling of the heart; (2) prevention of
excessive hemodilution by autologous priming of the extracorporeal circuit and partial
recovery of the cardioplegic fluid; (3) corporeal normothermia.
The consequences on the postoperative organ injury and clinical outcome of the pa-
tients were investigated.
RED BLOOD CELL AGGREGATION DURING CARDIOPUL-
MONARY BYPASS: A PATHOGENIC COFACTOR IN EN-
DOTHELIAL CELL ACTIVATION? (Chapter 4)
The relations between a low hematocrit and the adverse outcomes in patients un-
dergoing CPB is extensively discussed in the literature66. There are also reports
addressing the mechanical trauma of red blood cells67 and the decrease in red blood
cell deformability during extracorporeal circulation68. In our opinion, a complete
chapter has been excluded from the discussion around the pathogenesis of the “post–
CPB syndrome”: modifications induced in red blood cell aggregation and potential
consequences on microcirculation. The present study aimed to test the potential effect
of priming solutions and the extracorporeal circulation on red blood cells aggregabil-
ity and endothelial cell activation. We document the effects induced by two different
prime solutions often used in the clinical practice, HAES–steril 6% and Voluven 6%.
The clinical relevance and possible correlation between the pathophysiological mech-
anisms implicated are discussed.
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ACUTE ISOVOLEMIC HEMODILUTION TRIGGERS PRO–
INFLAMMATORY AND PRO–COAGULATORY ENDOTHELIAL
ACTIVATION IN VITAL ORGANS: ROLE OF ERYTHROCYTES
AGGREGATION (Chapter 5)
The essential role of erythrocytes as oxygen carriers is historically well established,
however, their function to aggregate with consequences on homeostasis is strongly
under debate. The aggregation property of red blood cells is mainly considered to be
pathophysiologic, since aggregation is elevated in many disease states such as diabetes
mellitus69 and hypertension70.
To date and rather remarkable, the scientific approach unravelling this subject has
completely ignored the pathogenic potential of low erythrocyte aggregation states.
Some authors have postulated the possibility that normal levels of aggregation may
serve homeostasis, having functional significance for normal physiology, since red cell
aggregation is normally present in humans and other “athletic” species71,72. This
hypothesis, however, has never been investigated before, and also, never been placed
in a clinical relevant context.
The pathogenicity of low erythrocyte aggregation could have major implications for
hemodiluted patients. This situation routinely occurs in cardiac patients undergoing
on–pump cardiopulmonary bypass who are severely hemodiluted due to therapeutic
preoperative isovolemic hemodilution, priming of the extracorporeal circuit and large
fluid infusions perioperatively. Excessive hemodilution prevails also during sustained
fluid resuscitation in traumatic–hemorrhagic shock patients. In addition to the con-
sequences of hypoxic stress, the implications of low erythrocyte aggregation during
acute hemodilution might prove to be essential for a good understanding of microcir-
culation impairment and deteriorated tissue perfusion in these patients. Considering
the sensitivity of vascular endothelium to variations in blood rheology, we hypothe-
sized that low erythrocyte aggregation will be responsible for activation of vascular
endothelium during acute isovolemic hemodilution.
CONSEQUENCES OF CEREBRAL INJURY IN BRAIN DEAD
DONORS ON ORGAN VIABILITY: PROGRESS OF PRO–
COAGULATORY AND PRO–INFLAMMATORY ENDOTHELIAL
ACTIVATION (Chapter 6)
Endothelial activation in brain dead donors has gained lately considerably attention in
the discussion concerning the pathology effects of brain death on donor organ quality
prior to retrieval. In this respect, previous studies conducted in our laboratory suggest
that an immune activation with increased endothelial cell activation and immediate
early gene expression occurs after brain death induction44. Moreover, the expression
of endothelial adhesion molecules (intercellular adhesion molecule–1 and vascular cell
adhesion molecule–1) and the influx of leukocytes in the kidney occurs faster and
is more profound when the hemodynamic instability in the brain dead donor is not
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corrected45. In this way, the involvement of the activated vascular endothelium was
linked incontestably to the progression of inflammation after brain death.
As an original contribution, this study aimed to analyze and document the time
sequence for the progression of pro–inflammatory and pro–coagulatory endothelium
activation, oxidative stress and organ viability in brain dead rat donors. Further-
more, this study investigated for the first time to our knowledge, extrahepatic fib-
rinogen synthesis in brain dead donors. We hypothesized that activated endothelium
in the brain dead donor expresses and releases pro–inflammatory and pro–coagulatory
factors into the circulation that will mediate inflammation, platelet adhesion and pos-
sibly promote microthrombosis. In addition, we expected that due to activation of
endothelium and hypoxic stress, the oxidative stress and brain death related organ
dysfunction are enhanced.
This investigation could pinpoint the time points necessary for anti–inflammatory and
anti–coagulatory therapeutic interventions, that could effectively reduce endothelial
activation, prevent platelet adhesion and leukocyte infiltration, and possibly slow
down an ongoing organ deterioration during brain death.
HYPERAGGREGATING EFFECT OF HYDROXYETHYL
STARCH COMPONENTS AND UNIVERSITY OF WISCONSIN
SOLUTION ON HUMAN RED BLOOD CELLS: A RISK OF IM-
PAIRED GRAFT PERFUSION IN ORGAN PROCUREMENT?
(Chapter 7)
The viability of organ grafts depends on several factors such as cold ischemia time,
the perfusion procedure, preservation methods and reperfusion quality. The efficacy
of perfusion during the initial wash–out procedure, however, has to be also considered
a major determinant of functional recovery after transplantation55,73.
Preservation solutions have been designed to ameliorate the adverse physiological
and biochemical effects of ischemia under hypothermic conditions. The inclusion and
importance of the colloid hydroxyethyl starch (HES) as one of the components of
the University of Wisconsin (UW) solution has been both advocated and denied. In
an experimental setting analyzing the effect of HES on the rheological properties of
blood, Corry and collaborators have drawn the attention to the aggregating effect of
HES on erythrocytes74.
The present study aimed to test the effect of HES and UW solution on red blood cell
aggregability and to correlate aggregation parameters with HES molecular weight. In
addition, the study aimed to detail the extent and kinetics of HES–induced human
RBC aggregation, as well as the morphological characterization of these aggregates. It
could be possible that by identifying the RBC hyperaggregating effect of UW solution
as an etiology–related factor for these complications immediate function, patient and
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Abstract
Study Objectives
Cardiac surgery with cardiopulmonary bypass (CPB) results in perioperative or-
gan damage caused by the systemic inflammatory response syndrome (SIRS) and
ischemia/reperfusion injury. Administration of corticosteroids before CPB has been
demonstrated to inhibit the activation of the systemic inflammatory response. How-
ever, the clinical benefits of corticosteroid therapy are controversial. This study was
designed to document the effects of dexamethasone on cytokine release and periop-
erative myocardial, pulmonary, renal, intestinal and hepatic damage, as assessed by
specific and sensitive (bio)markers.
Design and Patients
A prospective, double–blind, placebo–controlled, randomized trial for dexametha-
sone was conducted in 20 patients, receiving either dexamethasone (1mg/kg before
anesthesia induction and 0.5mg/kg after 8 hours) (n=10) or placebo (n=10). Differ-
ent markers were used to asses the SIRS: Interleukin–6 (IL–6), Interleukin–8 (IL–8),
Interleukin–10 (IL–10), C–reactive protein (CRP), tryptase, and organ injury: heart
(plasma heart–type fatty acid binding protein H–FABP, Troponin I, Creatine ki-
nase MB, CK–MB), kidneys (N–acetyl–glucosaminidase, NAG, microalbuminuria),
intestine (intestine/liver–type FABP, I/L–FABP), liver (αGlutathione S–transferase,
αGST).
Results
Dexamethasone modulated the SIRS with lower pro–inflammatory (IL–6,8) and higher
anti–inflammatory (IL–10) interleukin levels. CRP and tryptase were lower in the
dexamethasone group. Cardiac Troponine I values were lower in the dexamethasone–
group at 6 h ICU (p=0.009). Patients in dexamethasone group had longer time to
tracheal extubation (18.86±1.13 h versus 15.01±0.99 h, p=0.02) with lower oxygena-
tion index at that time (PaO2/FiO2 ratios: 37.17±1.8 kPa versus 29.95±2.1 kPa,
p=0.009). Postoperative glucose (10.7±0.6mmol/L versus 7.4±0.5mmol/L, p=0.005)
was higher in the dexamethasone group. Serum glucose was independently associated
with intestinal injury (urine I–FABP peak: R2=42.5%, B=114.4±31.4, Sig.=0.002,
urine L–FABP peak: R2=47.3%, B=7714.1±1920.9, Sig.=0.001) and renal injury
(urine NAG: R2=32.1%, B=0.21±0.07, Sig.=0.009). Tryptase peaks correlated nega-




Even while inhibiting SIRS, dexamethasone treatment offered no protection against
transient, subclinical, perioperative abdominal organ damage. Tryptase release could
have a preconditioning effect, offering protection against perioperative intestinal and
renal damage. Dexamethasone treatment resulted in more pronounced postoperative
pulmonary dysfunction, prolonged time to tracheal extubation and initiated postop-
erative hyperglycaemia in patients undergoing elective on–pump CABG.
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2.1 Introduction
Organ damage after cardiac surgery with cardiopulmonary bypass (CPB) is caused
by two related pathophysiological mechanisms: the systemic inflammatory response
syndrome (SIRS) and ischemia/reperfusion injury.
SIRS is triggered by the exposure of blood to large areas of synthetic materials of the
extracorporeal circuit. It causes a complex inflammatory reaction involving activation
of complement, platelets, neutrophils, monocytes and macrophages with increased
blood concentrations of cytokines and leukotriens. Additionally, SIRS initiates acti-
vation of the coagulation, fibrinolytic and kallikrein cascades. A subsequent increase
in endothelial cell permeability allows transvascular migration of activated leukocytes
into the tissues with additional vascular and parenchymal damage1,2.
The ischemia/reperfusion injury is triggered mainly in heart and lungs secondary to
aortic cross–clamping and cardioplegic arrest3,4. During aorta cross clamping the
heart is excluded from the circulation, being protected by cardioplegia and hypother-
mia. The lungs are deprived as well of pulmonary blood flow. Ischemia/reperfusion
injury has been documented also in other organs such as kidneys and intestine, prob-
ably due to alterations in blood flow at the microcirculatory level5,6. Preoperative
administration of corticosteroids to patients undergoing cardiac surgery with CPB
has been demonstrated to inhibit the activation of the plasmatic and cellular inflam-
matory response7, to decrease the pro– to anti–inflammatory interleukins ratio8, and
to minimize tissue edema9. Based on these findings corticosteroids are routinely used
in a considerable number of institutions. The studies on the clinical benefits, how-
ever, show conflicting results when referring to changes in hemodynamic, pulmonary
function and glucose metabolism10–13. Recent clinical investigations by Chaney et
al.12,13 indicated that methylprednisolone offers no clinical benefit, and may in fact
be detrimental by initiating postoperative hyperglycemia and delaying postoperative
tracheal extubation for undetermined reasons.
As an original contribution to the issue of CPB related SIRS and organ injury, we
document the effect of dexamethasone on perioperative myocardial, pulmonary, renal,
intestinal and hepatic damage, as assessed by newly available specific and sensitive
(bio)markers. Furthermore, to describe the effects of corticosteroids on the systemic
inflammatory response, we measured cytokine response and systemic tryptase release
as a marker of mast cells activation14. Finally, a new hypothesis relating tryptase to
the attenuation of perioperative organ injury will be discussed.
2.2 Patients, Materials and Methods
Patients
The study was designed as a prospective, double blind, placebo–controlled, random-
ized trial for dexamethasone. After approval by the hospital ethics committee and
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written informed consent, patients scheduled for first time coronary artery revas-
cularization were studied. All patients included in the study had coronary artery
disease with normal renal function (as assessed by a serum creatinine of less than
120µmol.liter−1), normal hepatic, cerebral and cardiac function (ejection fraction >
45%). Patients with diabetes, recent myocardial infarction, unstable angina, or re-
cent use of radiocontrast agents and corticosteroids were excluded, as these conditions
might be associated with increased baseline levels of the markers used in this study.
Anesthetic management
Patients (n=20) were randomized in a double–blinded fashion to receive either dexam-
ethasone or placebo. A baseline serum glucose sample was obtained after overnight
fasting. In the treatment group patients received dexamethasone 1mg.kg−1 at in-
duction of anesthesia and 0.5mg.kg−1 8 hours later. Patients in the control group
received a placebo at the same time points. Anesthesia was provided according to a
fixed protocol15. Premedication consisted of oral diazepam 10–15mg 2 hours preop-
eratively. After insertion of peripheral venous and radial cannulae under local anal-
gesia, general anesthesia was induced with sufentanil (2.5µg.kg−1) and midazolam
(0.1mg.kg−1). Tracheal intubation was achieved with pancuronium (0.1mg.kg−1)
and the lungs were ventilated with air and oxygen (FiO2=0.4). A flow–directed
pulmonary artery catheter was inserted into the right internal jugular vein, and an
indwelling bladder catheter was used for urine collection. Anesthesia was maintained
with sufentanil, midazolam, and pancuronium. Cefuroxim (1500mg) was adminis-
tered after induction. Hydroxyethyl starch 200/0.5 6% solution and lactated Ringers
solution were used to obtain a mean arterial pressure (MAP) > 60mmHg, to main-
tain filling pressures and cardiac output. Transfusion of packed cells were given at a
hemoglobin < 4.5mmol.L−1. According to standard care in our clinic, intravenous in-
sulin was started at a serum glucose > 10mmol.L−1. Inotropic support with dopamine
was started at a cardiac index < 2.2 L.min.m−2. Diuretics, mannitol or aprotinin were
not administered during the entire study period. Patient characteristics and periop-
erative variables were recorded prospectively.
Cardiopulmonary Bypass
Non–pulsatile CPB was performed using a roller pump (CAPS HLM, Sto¨kert Instru-
ments, Germany) and a membrane oxygenator (Cobe Optima; Cobe Laboratories;
Lakewood, CO). The extracorporeal circuit was primed with 500ml HES 200/0.5 6%
and 1000ml lactated Ringers solution. During CPB, the flow was maintained at 2.4
L.min.m−2 with moderate hypothermia (32◦ C) and α–stat regulation of blood pH.
Cold St. Thomas solution was infused into the aortic root to maintain cardioplegia
during aortic cross–clamping. During CPB, the mean arterial pressure was allowed
to vary between 60 and 90mmHg. Deviations were corrected with phenylephrine or
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nitroglycerine. The urine collection was divided in six intervals: (1) preoperative
(baseline): during 12 hours prior to surgery, (2) preheparinization: from skin inci-
sion to systemic heparinization, (3) sternum closure: from heparinization to sternum
closure, (4) 2 h ICU: during 2 hours postoperative, (5) 6 h ICU: 2 to 6 hours postop-
erative, (6) 24 h ICU: 6 h to 24 h postoperative. Urinary excretion of the measured
biomarkers was calculated as ratio to urine creatinine concentration and adjusted to
time interval in order to correct for changes in urinary flow:
[Urinary production = measured urine concentration / (time interval for urine
collection × urinary creatinine concentration)]
Blood sampling was performed before induction of anesthesia (preinduction), 5 min-
utes after Aortic cross clamp release (Ao clamp release), 6 h postoperative (6 h ICU),
and 24 h postoperative (24 h ICU). Urine and plasma were stored at –20◦ C until assay.
(Bio)markers
Inflammatory biomarkers
• Interleukin–6 (IL–6), Interleukin–8 (IL–8), Interleukin–10 (IL–10) – solid–phase,
enzyme–labelled, chemiluminescent sequential immunometric assay (IMMULITE,
EURO/DPC Ltd, USA)
• C Reactive protein – high sensitive ELISA (HaemoScan, Groningen, The Nether-
lands).
• Tryptase (proteolytic trypsin–like enzyme released from activated mast cells) –
enzymatic assay (HaemoScan, Groningen, The Netherlands).
• Serum glucose concentration was determined using a Vitros analyzer (Ortho
Clinical Diagnostics; Beerse, Belgium).
Myocardial injury biomarkers
• plasma heart–type fatty acid binding protein (H–FABP–cyrosolic protein re-
leased from injured myocytes) – ELISA kit (HyCult Biotechnology B.V., Uden,
The Netherlands).
• cardiac Troponin I (cTnI–myofibrillar protein released from injured myocytes)
– microparticle enzyme immunoassay (AxSYM, ABBOT Laboratories, USA).





• Urine N–acetyl–glucosaminidase (NAG–enzyme released from injured proximal
renal tubules) – modified enzyme assay according to Lockwood16 at pH 4.5
and corrected for non–specific conversion (HaemoScan, Groningen, The Nether-
lands).
Intestinal injury biomarkers
• Intestinal/Liver–type fatty acid binding proteins (I/L–FABP–cytosolic proteins
in the enterocytes released into the blood stream and excreted by kidney early
in the course of intestinal ischemia17) ELISA kit (HyCult Biotechnology BV,
Uden, The Netherlands).
Hepatic injury biomarkers
• αGlutathione S–transferase (αGST – enzyme released from centrolobular and
periportal damaged hepatocytes reported as having uniform hepatic distribu-
tion, high cytosol concentration, and short half–life18)– enzyme immunoassay
(Biotrin International Ltd., Dublin, Ireland).
Statistical Analysis
The statistical analysis was performed using SPSS (Statistical Package for the So-
cial Sciences). A power analysis, based on previous studies of IL–6 and IL–8 plasma
levels in this population suggested that at least 20 patients have to be studied in
order to detect a 1 SD difference between the two groups, with a reliability of 5% and
a power of 80%. Before analysis, the data was tested for distribution according to
Kolmogorov–Smirnov goodness of fit test. The variation of the urinary and plasma
markers over the study period and the differences between groups were investigated
using repeated measures ANOVA. A total area under curve (AUC) was calculated for
all plasma biomarkers. Continuous variables were compared by means of parametric
(Student T Test) or nonparametric tests (Mann–Whitney). Fishers exact test was
used to compare discrete variables. Correlation analysis between variables was tested
using Spearman correlation test. Regression analysis was used to detect predictors for
organ injury. Statistical significance was accepted at p<0.05. Results are presented
as mean±SEM (unless stated otherwise).
2.3 Results
All twenty patients included completed the study and survived the hospital stay. The
following complications were observed: revision for bleeding (n=2); perioperative
myocardial infarction (n=1); atrial fibrillation (n=1); nosocomial pneumonia (n=1).
Seven patients in the dexamethasone group and two patients in the placebo group
(Fischer’s exact test p=0.025) received dopamine less than 5µg.kg−1.min−1 because
of low cardiac index. Six patients in the dexamethasone group and one patient in
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the placebo group received insulin to regulate serum glucose in the postoperative
period (Fischer’s exact test p=0.057). Fever (highest measured rectal temperature)
was more prominent in the placebo group during the first 24 hours postoperatively.
Additional patients’ characteristics and operative data are shown in Table 2.1. The
patients in the dexamethasone group were slightly older than the patients in placebo
group. However, the age did not prove to be a predictor for any of the biomarkers
tested. Marked blood loss occurred in one patient in the dexamethasone group, who
received 13 units of blood more than 6 h after bypass. As this would affect only the
last time point of the study, this patient was included in the analysis.
Placebo Dexamethasone
group group P value
Mean±SEM Mean±SEM
No. of patients 10 10 /
Male/Female 9/1 8/2 /
Age 95%CI (mean) (y) 53.4-65.5 63.4-72.1 0.02
(59.5) (67.8)
Body surface area (m2) 1.96±0.07 1.92±0.03 0.58
Perfusion time (min) 95.9±7.6 115.7±8.8 0.10
Aorta clamping time(min) 61.7±5.7 74.8±6.9 0.16
MAP Preoperative 90.4±5.6 96.1±4.8 0.52
MAP ICU admission 73.7±4.8 74.2±4.4 0.79
MAP 24h ICU (mmHg) 80.9±3.4 93.8±4.5 0.053
SVRI Preoperative 2263±212 2429±251 0.85
SVRI ICU admission 2134±283 1889±181 0.57
SVRI 24h ICU 1630±151 2030±239 0.35
(dynes/cm5/m2)
CI Preoperative 2.6±0.2 2.6±0.4 0.79
CI ICU admission 2.8±0.3 2.8±0.3 0.63
CI 24h ICU (L/min/m2) 3.7±0.3 3.6±0.3 0.96
preoperative PaO2/FiO2 52.68±4.91 51.65±4.54 0.63
extubation PaO2/FiO2 (kPa) 37.17±1.8 29.95±2.1 0.009
Intubation time (h) 15.01±0.99 18.86±1.13 0.02
Highest measured 37.9±0.8 37.2±0.3 0.02
rectal temperatures (◦ C)
Units of blood transfused 2.2±3.6 1.3±1.6 0.51
Table 2.1: Patient characteristics and operative data (mean ± standard error of the
mean). MAP = Mean arterial pressure, SVRI = systemic vascular resistance index,
CI = cardiac index, PaO2/FiO2 = oxygen index. Statistics: Continuous variables
where compared by means of parametric (Student T Test) or nonparametric tests




Plasma levels of pro–inflammatory cytokines IL–6 and IL–8 increased significantly
(Wilks Sig.<0.001) in both groups, with a lower response in the dexamethasone group
(lower total AUC in dexamethasone group for both IL–6 and IL–8, p<0.001). The
peak values were measured at 6 h ICU for IL–6, and during the sternum closure for IL–
8 (Fig. 2.1a,b). The IL–6 values were significantly lower in the dexamethasone group
at 6 h and 24 h ICU (p<0.001). IL–8 was significantly lower in the dexamethasone
group after aortic clamp release (p=0.023), during sternum closure (p<0.001), at 6h
ICU (p=0.003), and total AUC (p<0.001).
IL–6 values at 24 h ICU were higher than baseline values in both groups (p<0.001).
IL–8 values returned to baseline values after 24 hours in both groups.
Plasma IL–10 increased significantly (Wilks Sig.<0.001) in both groups. In the dex-
amethasone group plasma IL–10 had a ≈4 fold higher peak at sternum closure. The
differences between groups were statistically significant after aortic clamp release and
sternum closure (p<0.001), 6 h ICU (p=0.029), and total AUC (p<0.001) (Fig. 2.1c).
The IL–10 values returned to baseline values after 6 h ICU in both groups.
Plasma levels of CRP did not increase during the operation. The differences be-
tween groups on their overall plasma CRP were statistically significant (p=0.048).
The dexamethasone group had lower total AUC (p=0.028), and lower CRP levels
at 6 h ICU (4.9±1µg/ml in dexamethasone group versus 39.5±24.9µg/ml in the
placebo group, p=0.043), at 24 h ICU (842.7±524µg/ml in dexamethasone group
versus 2463.5±968µg/ml in the placebo group, p=0.028).
Tryptase increased significantly during operation in both groups
(Wilks Sig.=0.018) (Fig. 2.1d). In the dexamethasone group, tryptase concentra-
tions increased only moderately with peak values at sternum closure. In the placebo
group, the values rose abruptly reaching peak values immediately after releasing the
aortic cross–clamp, and decreased after sternum closure. The tryptase values were
significantly lower in the dexamethasone group after aortic clamp release (p=0.015),
during sternum closure (p=0.009), and total AUC (p=0.05). Tryptase values returned
to baseline values after 6 h ICU in both groups.
Myocardial injury biomarkers
The release patterns of the myocardial damage markers had a different time course.
Plasma H–FABP (Fig. 2.2a) started to rise directly after aortic cross clamp release,
reaching peak values after 1.23 hours (95%CI=0–2.66 h), which was significantly
earlier (p<0.001) than the peak values of cTnI and CK–MB (cTnI: mean=14.1 h,
95%CI=6.36–21.84 h; CK–MB: mean=16.35, 95%CI=9.23–23.47 h). The only differ-
ence between the treatment groups, was observed at 6 h ICU, with a lower value of
cTnI in the dexamethasone group (p=0.009) (Fig. 2.2b).
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Figure 2.1: Pro–inflammatory interleukins (Interleukin–6, Interleukin–8), anti–
inflammatory interleukin (Interleukin–10), and mast cell degranulation product
(Tryptase). The values are represented as mean (symbols) and standard error of
the mean (bars). ??, ? Differences between groups are significant at the .01, .05 level,
respectively.
Renal injury biomarkers
Glomerular and tubular function in this very group of patients was recently described
elsewhere19. Briefly, urinary NAG increased significantly in time (Wilks p=0.009),
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Figure 2.2: Myocardial injury biomarkers: Heart–type fatty acid binding protein (H–
FABP) and cardiac Troponin I (cTnI). The values are represented as mean (symbols)
and standard error of the mean (bars). ?? Differences between groups are significant
at the .01 level.
reaching peak values at 2 h ICU, with no significant effect for the dexamethasone
treatment (Fig. 2.3).
Microalbuminuria increased during CPB, with peak values in the urine collected dur-
ing CPB for both groups (mean 7.9mg/mmol creatinine, 95%CI=(4.8–10.9)).
Intestinal injury biomarkers
Urinary I–FABP and L–FABP (Fig. 2.4a,b) increased significantly during CPB (Wilks’
p=0.02 I–FABP, and p=0.013 L–FABP) in both groups, reaching peak values in the
urine collected during the first postoperative 2 h and 6 h, respectively. The change in
mean urinary L–FABP production was significantly dependent upon dexamethasone
treatment (Wilks’ p=0.026), with higher values in the dexamethasone group. Ana-
lyzing each individual time point, no statistical significant differences between groups
were detected for I–FABP and L–FABP.
Hepatic injury biomarkers
αGST increased promptly after initiation of CPB in both groups, with peak values
during sternum closure (Wilks’ p<0.001) (Fig. 2.5). There were no differences between
the groups (time points and total AUC). ALT remained constant for the duration of
the investigation. AST increased moderately in both groups with maximum values
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Figure 2.3: Renal injury biomarker: urine N–acetyl–glucosaminidase (NAG). The
values are represented as mean (symbols) and standard error of the mean (bars)19.
Figure 2.4: Intestinal injury biomarkers: urine intestinal–type (I–FABP) and liver–
type (L–FABP) fatty acid binding proteins. The values are represented as mean
(symbols) and standard error of the mean (bars).
at 24 h ICU (58.9±10.8 U/L).
Serum glucose (Fig. 2.6). Dexamethasone treatment increased significantly the serum
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glucose levels (p=0.009). During sternum closure the values reached the peak values
of 10.7±0.6mmol/L in the dexamethasone group, and 7.4±0.5mmol/L in the placebo
group. The glucose values in the dexamethasone group were significantly higher than
in the placebo group during sternum closure (p=0.005), 6 h ICU (p=0.007) and 24 h
ICU (p=0.023).
Figure 2.5: Hepatic injury biomarker:
plasma αGlutathione S–transferase
(αGST). The values are represented as
mean (symbols) and standard error of
the mean (bars). NS=not significant.
Figure 2.6: Serum glucose level. The val-
ues are represented as mean (symbols)
and standard error of the mean (bars).
??, ? Differences between groups are sig-
nificant at the .01, .05 level, respectively.
Predictors of organ injury
Peak serum glucose values (mmol/L) were significant independent predictors for urine
I–FABP peak values (R2=42.5%, regression coefficient B=114.4±31.4, Sig.=0.002),
urine L–FABP peak values (R2=47.3%, regression coefficient B=7714.1±1920.9, Sig.=0.001),
urine H–FABP peak values (R2=48%, regression coefficient B=2829.5±694.5, Sig.=0.001)
and urine NAG peak values (R2=32.1%, regression coefficient B=0.21±0.07, Sig.=0.009).
Perfusion duration (minutes) was a significant independent predictor for urine I–
FABP peak values (R2=22%, regression coefficient B=6.7±3, Sig.=0.03), urine L–
FABP peak values (R2=26.6%, regression coefficient B=476±186.4, Sig.=0.02), and
urine H–FABP (R2=37.7%, regression coefficient B=206.3±62.5, Sig.=0.004).
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Correlations
Inflammatory biomarkers: The statistical correlations found between the inflamma-
tory markers are shown in Table 2.2. CRP at 6 h ICU correlated positively with peak
cTnI concentrations (corr. 0.49, p=0.02). Tryptase peak values correlated negatively
with peak plasma I–FABP (corr. –0.445, p=0.04), peak urinary I–FABP (corr. –0.474,
p=0.03), peak urinary L–FABP (corr. –0.647, p=0.002), peak urinary H–FABP (corr.
–0.60, p=0.005), peak urinary NAG (corr. –0.609, p=0.004), peak microalbuminuria
(corr. –0.559, p=0.01).
Spearman’s corr. CRP 6h Peak
ICU Tryptase
Peak Peak
IL–6 .568?? .474? IL–6
Peak Peak
IL–8 .498? .520? .555? IL–8
Peak
IL–10 ns –.411 (p=0.072) –.412 (p=0.071) –.630??
Table 2.2: Statistical correlations (non-parametric Spearman’s correlation) between
the peak values of the pro inflammatory (Interleukin–6–IL–6,Interleukin–8–IL–8),
anti–inflammatory interleukins (Interleukin–10–IL–10) and tryptase. ? Correlation
is significant at the .05 level (2–tailed), ?? Correlation is significant at the .01 level
(2–tailed), ns=not significant.
Myocardial biomarkers: cTnI AUC correlated significantly with plasma H–FABP
(AUC corr. 0.469, p=0.03; peak corr. –0.444, p=0.05) and CK–MB (AUC corr. 0.80,
p<0.001, peak corr. 0.77, p<0.001).
Intestinal biomarkers: Urine I–FABP correlated significantly with urine L–FABP
(peak corr. 0.81, p<0.001).
Renal biomarkers: the urinary peak of H–FABP correlated strongly and significantly
with the urinary peak of NAG (corr. 0.65, p=0.002) and peak microalbuminuria (corr.
0.66, p=0.001). In addition, the peaks of intestinal damage markers correlated sig-
nificantly with the peak values of renal damage markers (I–FABP∼NAG: corr. 0.55,





In the present study we have found that administration of dexamethasone inhibited
the SIRS in patients undergoing elective on–pump CABG. However, administration
of dexamethasone did not offer protection against pulmonary, renal and intestinal pe-
rioperative damage. Even more, dexamethasone–induced hyperglycemia was found as
a strong independent predictor of intestinal and renal perioperative damage. Postop-
erative pulmonary function was adversely affected by dexamethasone, with decreased
PaO2/FiO2 ratio and prolonged time to tracheal extubation in the dexamethasone
group of patients.
Myocardial injury
Dexamethasone seemed to offer, to a small extent, myocardial protection during the
first 6 h of reperfusion as shown by lower concentration of cardiac Troponin I, but with
no further protection after 24 h of reperfusion. Additionally, the protective effect was
not noticeable when estimating the myocardial damage by the plasma concentration
of heart–type fatty acid binding protein. The recently introduced marker H–FABP
is a cytosolic protein abundant in the myocardium, with a 10 fold lower expression
in the skeletal muscles, kidney (distal tubules), lung, brain and endothelial cells20,21.
H–FABP has been introduced as a plasma marker for an early assessment of myocar-
dial tissue injury with a peak as early as 3 h after acute myocardial infarction and 2 h
post–reperfusion after CABG22,23. The early plasma peak also present in our study
promotes H–FABP as a valuable myocardial injury marker, since peak levels of the
Troponine T and I occur only much later, around 18 hours post reperfusion24.
Pulmonary Injury
Dexamethasone treatment resulted in more pronounced postoperative pulmonary dys-
function and prolonged time to tracheal extubation. The detrimental consequence of
dexamethasone on lung function was clinically relevant in terms of significantly lower
PaO2/FiO2 ratio immediately after extubation, and the significantly prolonged time
to tracheal extubation in the patients in the dexamethasone group. These adverse
effects of dexamethasone treatment on pulmonary function confirm the findings re-
ported recently by Chaney et al.12,13, after treatment with methylprednisolon in a
similar group of patients.
Renal Injury
Urinary N–acetyl–glucosaminidase (enzyme released from injured proximal renal
tubules) and microalbuminuria increased significantly during CPB, with no effect
of dexamethasone. Measurements of urinary H–FABP proved to be a better indi-
cation of kidney damage than of myocardial damage, because the urinary peak of
H–FABP did not correlate with the other cardiac markers, but correlated strongly
and significantly with the urinary peak of NAG (proximal tubules injury) and peak
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microalbuminuria (glomerular injury). This measurement might be explained by a
urinary release of H–FABP from the damaged distal renal tubules. H–FABP has been
associated before with early release following injury of the distal renal tubules25,26
Intestinal injury
I/L–FABP are cytosolic proteins readily released into the circulation following ente-
rocytes damage, with a 40 fold higher content of L–FABP, reported as useful urine
markers for the detection of intestinal injury27–29. Elevated I–FABP in relation to
gastrointestinal complications following cardiopulmonary bypass was described ear-
lier29. The increased values of I/L–FABP during CPB reported in our study confirm
the indirect line of evidence suggesting mucosal integrity loss during CPB reported
previously as a reduction in intramucosal pH, increase in gut permeability and en-
dogenous endotoxemia30–32. Significantly elevated I–FABP urine levels in critical ill
patients correlated with clinical development of the systemic inflammatory response
syndrome33. In our study, 20% in the variation of intestinal injury markers and 30%
in the variation of renal injury markers were explained by the CPB duration.
Hepatic injury
αGlutathione S–transferase (αGST) increased promptly after initiation of CPB in
both groups, with peak values during sternum closure, without effect for the dex-
amethasone treatment. Increased levels of αGST as indication of hepatocytes injury
were reported before in patients undergoing CPB34.
Inflammatory response
The release of pro–inflammatory interleukins was inhibited by dexamethasone, while
the anti–inflammatory interleukin IL–10 was increased. The acute phase protein CRP
was found in lower concentrations during the first day postoperative in the plasma of
the patients receiving dexamethasone. These data confirmed that the administered
dose of dexamethasone (1mg/kg before induction of anesthesia and 0.5mg/kg after 8
hours) was therapeutically effective. In the first 24 postoperative hours, rectal tem-
perature was moderately but significantly higher in the placebo group. In a recent
study postoperative temperature was controlled by active surface cooling to prevent
cerebral damage35. The present study demonstrates that temperature can be con-
trolled as effectively with medication. The modulation of the humoral inflammatory
response and lower postoperative rectal temperatures as a result of dexamethasone
treatment observed in this study are in agreement with previous studies published
on the subject. Glucocorticoid administration prior to CPB was shown to attenuate
inflammatory response, as based on biochemical analysis of serum inflammatory me-
diators, to reduce the incidence of postoperative febrile episodes in pediatric cardiac
surgery36 and to decrease incidence of postoperative hyperthermia in adult surgery11.
Only limited amount of data characterizing mast cell activation with subsequent
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tryptase release during CPB is available in the literature37,38. The present study
reports an important mast cell degranulation (activation), with a peak in the sys-
temic release of tryptase as early as the release of the aorta cross clamp. Dexam-
ethasone was effective in inhibiting tryptase release. Tryptase is a serine proteinase
with trypsin–like properties, being released in peripheral blood subsequent to mast
cell activation in lungs, heart, stomach, spleen, skin, colon and kidneys39,40. Ex-
tracellular release of tryptase is known to recruit inflammatory cells, to induce IL–8
secretion from airway epithelial cells, and to promote airway inflammation41. In our
study, tryptase correlated positively and significantly with IL–6 and IL–8 (Table 2.2).
Surprisingly, we also found a negative correlation between tryptase and the organ
damage markers. Lower levels of tryptase correlated significantly with higher levels
of intestinal injury (plasma I–FABP, urinary I–FABP, urinary L–FABP), and high
levels of proximal tubular (urine NAG), distal tubular (urine H–FABP) and glomeru-
lar (microalbuminuria) renal damage during the first two hours of reperfusion post
CPB.
These data support the hypothesis of a preconditioning effect of tryptase: early release
of tryptase might offer protection against perioperative intestinal and renal damage.
By amplifying the signal for histamine release42, and thus inducing an endothelial–
NO dependent vasodilator effect, tryptase might counteract the vasoconstriction in-
duced by the hyperglycemia and ischemia/reperfusion injury. This hypothesis is sup-
ported by data showing that histamine–induced vasodilatation mediated by endothe-
lial derived NO was attenuated under hyperglycemic conditions43. In our study, we
found high serum glucose levels in patients undergoing CPB receiving dexamethasone.
Serum glucose levels had strong positive predictive value for the postoperative intesti-
nal and renal damage. The variation in serum glucose concentration explained more
than 40% in the variation of intestinal damage biomarkers (I–FABP and L–FABP)
and more than 30% in the variation of renal tubules damage markers (NAG and urine
H–FABP). In addition, the patients in the dexamethasone treated group tended to
require more insulin treatment.
To explain our results on the effect of acute hyperglycemia on organ injury, we refer to
the recent published results of Vanhorebeek et al.44, showing in a study on critically
ill patients that hyperglycemia was associated with organ injury, as demonstrated by
mitochondrial ultrastructural abnormalities with increased production of reactive oxy-
gen species in the hepatocyte of hyperglycemic patients (10–11.1mmol.L−1). Using
animal experiments, Bohlen and colleagues45,46 demonstrated that oxygen radicals
formed during acute hyperglycemia affect flow–mediated endothelium regulation in
the intestinal vasculature due to depression of nitric oxide, resulting in reduced blood
flow.
Our data quantifies for the first time the effect of hyperglycemia on organ injury.
These results might provide an explanation for the increased morbidity and mortality
among critically ill patients in the surgical intensive care unit when blood glucose
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level is above 6.1 .L−1 47. A limitation of this study is that, despite randomization,
patient characteristics were slightly different. In the dexamethasone group patients
were slightly older and therefore the possibility of confounding exists. However, this
influence seems limited because age did not prove to be a predictor for any of the
biomarkers tested. Moreover, baseline values of a large number of sensitive markers
were similar in both groups, and there was no correlation between age and the baseline
levels of the tested markers. The patients in this study had little co–morbidity and
thus belong to the “healthy” CABG group. Dexamethasone in patients of a higher risk
profile could have different effects on inflammatory response and organ injury. Finally,
this study was not powered to analyze effects on mortality, or possible differences in
wound healing and postoperative infections.
2.5 Conclusions
Dexamethasone, as administered in this study, offered no protection against tran-
sient, perioperative renal, intestinal and hepatic injury in patients undergoing on–
pump CABG. Dexamethasone treatment resulted in more pronounced postoperative
pulmonary dysfunction, prolonged time to tracheal extubation and initiated postop-
erative hyperglycaemia. Given the strong positive predictive value of hyperglycaemia
for renal and intestinal tissue injury, a stricter management of serum glucose may
offer beneficial effects.
As a contribution to the efforts made for understanding the complex pathophysiologic
mechanism of the “post–CPB” syndrome, this study verified theories existent in the
literature and brought under attention new essential aspects: (1) higher glycemic
values as strong predictors for higher intestinal and renal damage; (2) preconditioning
effect of mast cells activation and tryptase release for the subsequent postoperative
intestinal and renal injury.
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Abstract
Study Objectives
An experimental operative protocol was developed aiming to eliminate several poten-
tial stress factors that might lead to injury and dysfunction during coronary artery
bypass grafting (CABG) with cardiopulmonary bypass (CPB): (1) cold–crystalloid
cardioplegia and atrial intracavitary cooling, (2) autologous priming and partial re-
covery of the cardioplegic fluid; (3) corporeal normothermia.
Methods
Prospective, pseudo–double blind, randomized clinical trial, investigating the clinical
benefits of a new experimental intraoperative protocol. Clinical outcome and tran-
sient postoperative injury of the myocardium (creatine kinase–MB, CK–MB), renal
tubules (urine N–acetyl–glucosaminidase, NAG) and small–intestine (intestinal–fatty–
acid–binding–protein, I–FABP) were investigated.
Results
Hematocrit values during, and immediately postoperative (experimental group
27.8±0.6%; standard group 24.4±0.7%) were significantly different (p=0.002). Post-
operative CK–MB, NAG and I–FABP were significantly lower in the experimental
group. In the standard hypothermic group of patients, the rectal temperatures mea-
sured after 60min of CPB correlated negatively with postoperative I–FABP. The
hematocrit explained 38% and 37% in the variability of postoperative NAG and I–
FABP, respectively. An extra 21.5% of the NAG variability and 10% of the I–FABP
variability, that could not be explained by the variation in hematocrit, were explained
by the blood–transfusion requirements
Conclusions
The addition of an intracavitary cooling system to the standard cold crystalloid car-
dioplegia during on–pump CABG offered a better protection of the myocardium, with
decreased postoperative plasma CK–MB. Partial recovery of intra–atrial cardioplegic
fluid and autologous–blood priming limited the extent of intra–operative hemodilu-
tion and blood transfusion requirements. An important attenuation of the transient
renal and intestinal postoperative injury was observed. Additional protection on renal




The available scientific data concerning the effectiveness and safety of cardiopul-
monary bypass (CPB) for patients undergoing coronary artery bypass grafting (CABG)
brings to attention several key principles to serve as basis for practical guidelines.
Encouraged and generally accepted techniques are cold crystalloid cardioplegia, mild
corporeal hypothermia and hemodilution to a hematocrit of 23%.
Myocardial protection against ischemic injury during heart arrest and aorta cross
clamping is achieved by hypothermia, which reduces oxygen demands and prolongs
tolerable ischemic arrest time. Hypothermia can be induced using various techniques,
such as cold saline/ice flush in the pericardial sac, cold crystalloid cardioplegia (4◦ C,
high potassium, cold fluid perfused through coronary arteries), cooling jackets (cold
fluid perfused through a very small cooling mattress that is pressed directly against the
outside of the heart) and intracavitary cooling (intern cooling of the heart chambers).
Systemic protection against global ischemic injury during extracorporeal circulation:
contrary to conventional thinking about the benefits of corporeal hypothermia, an
increasing number of clinical studies support corporeal normothermia. It was demon-
strated that hypothermic CPB is responsible for a greater platelet activation and
endothelial dysfunction than normothermic CPB, leading to more profound changes
in the hemostatic and inflammatory systems1. Furthermore, a significant positive in-
fluence of normothermic CPB temperature was registered on perfusion management,
postoperative hemodynamics and blood loss2.
Normothermic cerebral protection during CPB was also confirmed by studies showing
similar patterns of S–100β release3 and less pronounced subclinical impairment of
cognitive brain function in patients undergoing normothermic CPB as compared with
mildly hypothermic CPB4,5.
Hemodilution is encouraged by the current CPB management guidelines, with the
rationale based on the reduction of blood viscosity by hemodilution, and thus an im-
proved regional blood flow in the setting of hypoperfusion and hypothermia6. How-
ever, excessive hemodilution may lead to organ ischemia via a reduction of oxygen–
carrying capacity uncompensated by autoregulatory and/or rheologic increase in or-
gan blood flow. In animal models, magnetic resonance and near–infrared spectroscopy
suggested that brain injury might be caused by hypoxic–ischemic injury as a result of
currently recommended protocols for hemodilution during CPB7. In clinical studies,
a significant independent association was found between the lowest hematocrit dur-
ing bypass and acute renal injury8, with significant benefits on renal function after
reduction of the bypass prime volume9.
Besides lowering the oxygen carrying capacity, hemodilution was shown to be responsi-
ble of endothelial cell activation during CPB. By decreasing red blood cell aggregation
and plasma viscosity, hemodilution is expected to modify homeo–rheological variables
responsible for a constant shear stress at the endothelial wall, inducing mechanical
endothelial activation10.
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Our therapeutic strategy aimed to explore, advance and optimize simultaneously more
than one method of protection by eliminating several potential stress factors that
might lead to injury and dysfunction during CPB: inadequate hypothermic cardiople-
gia, excessive hemodilution with subsequent need for perioperative blood transfusion,
and corporeal hypothermia.
An experimental operative protocol was developed to meet multiple objectives: (1)
homogeneous cooling of the myocardium by combining cold crystalloid cardioplegia
technique with intracavitary cooling of the heart; (2) prevention of excessive hemod-
ilution by autologous priming of the extracorporeal circuit and partial recovery of
the cardioplegic fluid; (3) corporeal normothermia, possible on the account of a more
efficient topical cooling of the heart. The consequences on the postoperative organ
injury and clinical outcome of the patients were investigated.
3.2 Patients, Materials and Methods
The clinical study was performed at the VU University Medical Center Amsterdam,
The Netherlands.
The study was designed as a prospective, pseudo–double blind (blinding of the patient
and lab investigator), randomized clinical trial, investigating the clinical benefits of a
new experimental intraoperative protocol that combined cold crystalloid cardioplegia
with intracavitary cooling, autologous priming and corporeal normothermia.
After approval by the hospital ethics committee, patients scheduled for elective first
time CABG were prospectively screened according to entry criteria. All patients in-
cluded (n=40) in the study were 45 to 70 years of age, had coronary artery disease with
normal renal function (as assessed by a serum creatinine lower than 150µmol.liter−1
and normal urinalysis), normal hepatic, cerebral and cardiac function (ejection frac-
tion > 45%). Written informed consent forms were obtained in all cases.
Patients with preoperative immunosuppressive therapy, preoperative use of NSAID,
intra aortic balloon support, requiring aneurysmectomy, insulin–dependent diabetes
mellitus, recent myocardial infarction, unstable angina, or recent use of radiocontrast
were excluded.
Anaesthetic management
On the day of operation, patients received their usual early morning dose of antiang-
inal medication, 5mg of lorazepam, but no diuretics were administered. Anesthesia
was induced using 3–7µg.kg−1 intravenous sufentanil forte, 0.1mg.kg−1 pancuroni-
umbromide and 0.1mg.kg−1 midazolam. General anesthesia was maintained by a
continuous infusion of propofol 5–15mL.h−1 (20mg.mL−1). After endotracheal intu-
bation, patients were ventilated using an inspiratory mixture of 50% oxygen and 50%
of air at a frequency of 14–18 breaths.min−1 and 5 cm H2O of PEEP.
After induction of anesthesia patients received 1mg.kg−1 dexamethasone and 1500mg
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cefuroxime. Radial artery and thermodilution pulmonary artery catheters were in-
serted for hemodynamic monitoring and blood sampling.
A continuous positive airway pressure of 5 cm H2O and a FiO2 of 21% was maintained
in the lungs during CPB. Nitroglycerin infusion of 1mg.kg−1.min−1 was started in the
rewarming period. In case of hemodynamic instability, fluid replacement and inotropic
support with dopamine (4mg.ml−1) and/or nitroglycerin were the first steps taken
to stabilize the patient. The mean arterial blood pressure was maintained between
65 and 80mmHg, pulmonary artery wedge pressure between 8 and 12mmHg.
Transfusion of packed cells were given at a hemoglobin < 4.5mmol.L−1.
Extracorporeal circuit
In both groups we used a S3 heart–lung machine (Sto¨ckert Instrumente GmbH, Mu-
nich, Germany) with a centrifugal pump (Delphin, Terumo Europe NV, Leuven, Bel-
gium), a heat exchange device (Sto¨ckert Instruments GmbH), polyvinyl tubing sys-
tem (Medtronic Inc., Minneapolis, MN, USA), a hollow fiber oxygenator (Affinity,
Medtronic), a soft shell collapsible venous reservoir (MVR 1600, Medtronic), an ar-
terial line filter (Affinity, 38 mic, Medtronic), and a cardiotomy reservoir (Intercept
cardiotomy, Medtronic).
In the control group, the total priming volume consisted of 1400ml: 1000ml mod-
ified fluid gelatin (Gelofusin, Braun, Melsungen, Germany), 50ml lactated Ringer’s
solution, 200ml of aprotinin, 100ml mannitol and 50ml sodium bicarbonate (8.4%)
containing 1500mg cefuroxime and 5000 IU bovine heparin.
In the experimental group, retrograde autologous priming was performed using 500ml
autologous blood, collected in a transfer bag during the bicaval cannulation procedure.
The priming was completed using the priming solution described for the control group.
Coronary sinus drainage was achieved by cold crystalloid antegrade cardioplegia (St.
Thomas solution) delivery through the aortic root. Use of the experimental cannula
allowed partial recovery of the cardioplegic solution. In the middle of the cannula’s
balloon, on the cardiac site, a side hole is positioned. This specific side hole is con-
nected to a suction line. During and after cardioplegia infusion, the cardioplegia
solution (and/or residual systemic blood) from the right atrium was recovered via the
suction tubbing.
Cardiopulmonary bypass
Standard group: standard cannulation technique using a two stage venous cannula
placed in the inferior vena cava and right atrium.
Experimental group: bicaval cannulation through the superior caval vein using a dual–
stage bicaval atrial cooling cannula. This cannula is a cardiopulmonary dual stage
venous catheter with an integrated cooling balloon. The system is designed to cir-
culate cold saline (0.9% NaCl) in the right atrium enabling homogeneous cooling of
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the atrium. The cannula is a polyvinyl chloride (PVC) fashioned into an “L” shape.
An opening at the elbow of the L curve collects venous blood from the superior vena
cava. The distal end of the cannula has a cone shape with openings to collect venous
blood from the inferior vena cava. Between these two collection areas, a 9 cm long
medical grade silicon balloon has been attached. The balloon has a maximum volume
capacity of 40ml. Inflation and deflation of the balloon depends on the saline volume
added in the attached closed circuit. Immediately prior to aortic cross–clamping the
balloon was filled with saline solution, and thereafter total CPB was initiated. A
heat–exchanger (Bentley HE–30) cooled the saline to 4◦ C and a small roller pump
maintained the saline circulation at a flow rate of 300ml.min−1.
CPB was initiated after systemic heparinization (300 I.U. kg−1), with a celite ac-
tivated clotting time higher than 480 seconds. The target hematocrit during CPB
was higher than 23%. The non–pulsatile blood flow rate was maintained between
2.2–3.0 L.min−1.m−2 with mild hypothermia in the standard group (30–33◦ C), and
normothermia (35–36◦ C) in the experimental group.
Recovered cardioplegia fluid and suctioned blood were discarded.
Electrocardiograms were obtained preoperatively, on intensive care unit admission,
and on postoperative days 1 and 2.
Organ injury biomarkers
Myocardial injury biomarker: creatine kinase MB (CK–MB) activity – Vitros analyzer
(Ortho Clinical Diagnostics; Beerse, Belgium).
Kidney injury biomarker: urine N–acetyl–glucosaminidase (NAG) release in urine
signifies renal damage and ischemia localized at the proximal tubules level11. The
method of detection was a modified enzyme assay according to Lockwood12 at pH 4.5
and corrected for non–specific conversion (HaemoScan, Groningen, The Netherlands).
Intestinal injury biomarkers: intestinal fatty acid binding protein I–FABP, ELISA
kit (HyCult Biotechnology BV, Uden, The Netherlands) is a cytosolic protein readily
released into the circulation following enterocytes damage, reported as sensitive and
specific urine markers for the detection of intestinal injury and prediction of gastroin-
testinal complications after cardiopulmonary bypass13,14.
Urine NAG and I–FABP concentrations were measured preoperative (baseline) and
postoperative, in the urine collected during the first 2 hours postoperative, as previous
investigations showed peak values of both markers coming during the first 2 hours
after the end of the surgical procedure15.
Urinary excretions of NAG and I–FABP were calculated as ratio to urine urea con-
centration in order to correct for urine dilution.
In addition to these organ injury biomarkers, standard laboratory investigation were
performed every 24 hours until hospital discharge. Standard laboratory investigations
included: hemoglobin, serum glucose, HCO−3 , sodium ions, potassium ions, urea,




Lactate concentrations in the venous whole blood (Rapidlab 865; Chiron Diagnostics
Corp., East Walpole, MA) – end product of anaerobe glycolysis in skeletal muscle,
brain and erythrocytes; lactate was measured to give an indication on systemic expo-
sure to hypoxia.
Statistical Analysis
A power analysis based on previous studies in this population on peak postoperative
CK–MB plasma activity suggested that at least 40 patients have to be studied in
order to detect a 1 SD difference between the two groups, with a reliability of 5% and
a power of 80%.
Before analysis, the data was tested for distribution according to Kolmogorov–Smirnov
goodness of fit test. Continuous variables were compared by means of parametric (Stu-
dent T Test) or nonparametric tests (Mann–Whitney). Fisher’s exact test was used
to compare discrete variables. Correlation between variables was tested using Spear-
man correlation test. Linear regression analysis was used to detect predictors in the
model. Results are presented as mean±SEM (unless stated otherwise). Independent
predictors were tested using linear regression analysis. Multivariate analysis was used
to find significant predictor models.
3.3 Results
Twenty patients were randomized to each group. Patients’ demographic and clini-
cal characteristics, operating times, perioperative fluid management, hemodynamics,
coagulation variables and blood loss are presented in Table 3.1. Phenylephrine was
administered intraoperatively to three patients in the experimental group (0.83±0.16)
and ten patients in the standard group (0.85±0.31), (Fisher’s exact test 1–sided
p=0.02).
The following complications were diagnosed: re–thoracotomie (n=2, 1 of surgical and
1 of non–surgical etiology) and postoperative atrial fibrillations (n=8). The distribu-
tion of complications was similar in both groups. No clinical diagnose of postoperative
myocardial infarction, cerebral vascular accidents/transitory cerebral ischemic acci-
dents, acute renal injury or gastrointestinal complications was established. In–hospital
mortality was 0% for both groups.
Temperature
The minimum corporeal (intrarectal) temperatures measured during CPB were 32.9±0.2◦ C
in the standard hypothermic group and 35.9±0.1◦ C in the experimental normother-
mic group.
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In the standard hypothermic group of patients, the rectal temperatures measured after
60min of CPB correlated negatively with postoperative I–FABP urine concentrations
(Spearman’s corr. –0.501, p=0.029). In other words, lower rectal temperatures during
CPB were associated with higher intestinal damage.
Standard Experimental
group group P value
Mean±SEM Mean±SEM
No. of patients 20 20 /
Male/Female 18/2 5/5 0.41
Age (y) 60.9±1.8 59.4±1.7 0.55
Body surface area (m2) 2±0.03 2.03±0.03 0.61
Distal anastomoses per patient 3.7±0.2 4.2±0.1 0.09
Priming volume (ml) 1377±38 857±44 <0.001
Cardioplegic volume (ml) 1382±84 1373±49 0.69
Recovered cardioplegic volume (ml) 0 576±46 /
Fluid balance during CPB 1742±117 771±48 <0.001
Fluid balance 1st POD 1286±240 1091±296 0.41
CPB time (min) 100±5 97±5 0.62
Aorta cross-clamping time (min) 67±5 69±4 0.83
lowest MAP during CPB (mmHg) 53.8±1.4 53.1±1 0.91
CI preoperative (L/min/m2) 2.43±1.14 2.22±0.13 0.31
CI postoperative (L/min/m2) 3.2±0.15 3.15±0.19 0.91
CRP preoperative (mg/l) 8.6±4 6.1±1.1 0.41
CRP 2nd POD (mg/l) 60.6±13.3 58.2±8.4 0.78
CRP 3rd POD (mg/l) 94.4±14.2 80.6±13.3 0.44
max ICU APTT (sec) 46.7±1.7 43.8±1.3 0.1
max ICU INR 1h 1.55±0.03 1.58±0.03 0.64
Total blood loss postoperative (ml) 828±89 822±76 0.85
Time to tracheal extubation (h) 10.8±1.11 10.2±0.9 0.71
ICU stay (days) 1.1±0.1 1.05±0.05 0.65
Table 3.1: Patient characteristics and operative data (mean±standard error of the
mean). CPB=cardiopulmonary bypass, ICU=intensive care unit, MAP=Mean ar-
terial pressure, CI=cardiac index, APTT=activated partial thromboplastin time,
INR=international normalized ration. Statistics: Continuous variables where com-
pared by means of parametric (Student T Test) or nonparametric tests (Mann–
Whitney). Fisher’s exact test was used to compare discrete variables.
Hematocrit
Hematocrit values were measured systematically for 24 h, starting with a preoperative
baseline time point (Fig. 3.1). The values measured in the beginning of CPB (“1st
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value during CPB”: standard group 24.5±0.7% versus experimental group 28.3±0.7%)
and at the end of CPB (“post-CPB”: standard group 24.4±0.7% versus experimental
group 27.8±0.6%) were significantly different (Mann–Whitney p=0.002 both time
points).
Transfusion requirements
Seven patients in the standard group (1.6±0.2 units/patient) and two patients in
the experimental group (1 unit/patient) received packed cell (PC) transfusion in the
operating room (Fisher’s exact test 1–sided p=0.064). In the ICU, twelve patients in
the standard group (1.6±0.3 units/patient) and six patients in the experimental group
(1.5±0.5 units/patient) received PC transfusion (Fisher’s exact test 1–sided p=0.055).
No other blood products (single donor plasma or platelets concentrates) were admin-
istered in the operation room or ICU to the patients included in this study.
Organ injury biomarkers (Fig. 3.2)
Myocardial injury
Electrocardiographic modifications: ECGs were obtained preoperatively, on intensive
care unit admission, and on postoperative days 1 and 2. No postoperative develop-
ment of new Q waves was registered at any time point.
CK–MB (Fig. 3.2a) increased abruptly during the operation in both groups, with
significantly different postoperative CK–MB activity between groups (4 h ICU: Mann–
Whitney p=0.021, 8 h ICU: Mann–Whitney p=0.024). The peak values of CK–MB
measured after the patients were transferred in the ICU were significantly higher in
the standard protocol group than in the experimental protocol group (22.6±2.3U/l
versus, 15.5±1.3U/l respectively; Mann–Whitney p=0.026).
Renal injury
Serum creatinine values stayed within normal ranges for the entire investigated pe-
riod, with no differences between groups. The peak values of serum creatinine mea-
sured during the investigated period were 91.3±2.1µmol/l in the standard group, and
93.5±2.3µmol/l in the experimental group.
Postoperative urine N–acetyl–glucosaminidase (NAG, Fig. 3.2b) concentrations reached
significantly higher values in the standard protocol group than in the experimental
protocol group (213.6±54.5mU/mmol urea versus 51.2±11.8mU/mmol urea, Mann–
Whitney p<0.001).
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Figure 3.1: Hematocrit measurements in the blood of 40 patients undergoing on–
pump CABG according to an experimental CPB protocol (n=20) or the standard
CPB protocol (n=20). The values are represented as mean (symbols) and standard
error of the mean (bars). ? p<0.05 ,?? p<0.01
Intestinal injury
Postoperative urine concentrations of intestinal–type fatty acid binding protein (I–
FABP, Fig. 3.2c) was significantly higher in the standard protocol operated patients
as compared with values of the patients in the experimental protocol group (325.5±34
versus 181.4±24, Mann–Whitney p=0.003).
Lactate concentrations in the venous whole blood stayed at all time points within nor-
mal ranges with no differences between the groups. The lactate values measured dur-
ing CPB (experimental group 1.07±0.04mmol/l, standard group 1.16±0.1mmol/l)
correlated positively with the postoperative I–FABP values (Spearman’s corr. 0.566,
p=0.003) and postoperative NAG values (Spearman’s corr. 0.391, p=0.05).
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Figure 3.2: a) Creatine kinase–MB (CK–
MB) activity in the plasma of 40 patients
undergoing on–pump CABG according to
an experimental CPB protocol (n=20) or
the standard CPB protocol (n=20). The
values are represented as mean (symbols)
and standard error of the mean (bars).
? p<0.05. b) N–acetyl–glucosaminidase
(NAG) excretion in the urine of 40 patients
undergoing on–pump CABG according to
an experimental CPB protocol (n=20) or
the standard CPB protocol (n=20). Uri-
nary excretions of NAG was calculated as
ratio to urine urea concentration in order
to correct for urine dilution. The values are
represented as mean (symbols) and stan-
dard error of the mean (bars). ?? p<0.01.
c) Intestinal–type fatty acid binding pro-
tein (I–FABP) in the urine of 40 patients
undergoing on-pump CABG according to
an experimental CPB protocol (n=20) or
the standard CPB protocol (n=20). Uri-
nary excretions of I–FABP was calculated
as ratio to urine urea concentration in or-
der to correct for urine dilution. The val-
ues are represented as mean (symbols) and
standard error of the mean (bars). ??
p<0.01.
59
Hematocrit, Blood Transfusion and Temperature Effect on Organ Viability
Multivariate regression analysis
The following parameters were examined as potential explanatory variables for the val-
ues of postoperative CK–MB, urine NAG and urine I–FABP production: patient age,
gender, body surface area, co–morbidities (diabetes type II, preoperative TIA/CVA),
perfusion time, cross–clamping time, lowest intraoperative mean arterial pressure,
cardiac output, pre/postoperative hematocrit, PC units transfused in the operating
room, priming volume, cardioplegic volume (total volume minus recovered volume),
lowest core temperature during CPB, administration of peripheral vasoconstrictors.
The postoperative peak of CK–MB correlated at a significance level < 0.2 with the
following variables: gender, body surface area, perfusion time, cross–clamping time,
postoperative hematocrit, and PC units transfused in the operating room. These
variables were introduced in a backward multivariate regression analysis. The best
predicting model (R2=24%, Sig=0.002) included the BSA (B=260.4, Sig.=0.019) and
total perfusion time (B=2.001, Sig=0.011).
The postoperative NAG correlated at a significance level < 0.2 with the following
variables: gender, body surface area, lowest intraoperative MAP, lowest core temper-
ature during CPB, postoperative hematocrit, PC units transfused in the operating
room, administration of peripheral vasoconstrictors, cardioplegic volume and priming
volume. These variables were introduced in a backward multivariate regression anal-
ysis. The best predicting model (R2=56.9%, Sig<0.001) included the gender (higher
NAG concentrations in women, B=181.1, Sig.=0.009), the postoperative hematocrit
(B=–15.19., Sig.=0.054) and PC units transfused in the operating room (B=82.7,
Sig=0.065).
The postoperative I–FABP correlated at a significance level < 0.2 with the following
variables: age, gender, body surface area, lowest intraoperative MAP, lowest core tem-
perature during CPB, postoperative hematocrit, PC units transfused in the operating
room, diabetes, administration of peripheral vasoconstrictors, and priming volume.
These variables were introduced in a backward multivariate regression analysis. The
best predicting model (R2=70%, Sig<0.001) included the gender (higher I–FABP con-
centrations in men, B=-93.4, Sig.=0.048), the postoperative hematocrit (B=–16.19,
Sig.=0.022), PC units transfused in the operating room (B=92.18, Sig=0.002), and
priming volume (B=0.147, Sig.=0.027).
Univariate regression analysis
No predictors were detected for the variability in postoperative peak CK–MB con-
centrations in a univariate regression model.
The post–CPB Htc values were significant independent predictors for the variability
in postoperative NAG concentrations (adjusted R2=38.5%, B=–34.87, p<0.001) and
I–FABP concentrations (adjusted R2=37.4%, B=–27.01, p<0.001). Low hematocrit
values were significantly associated with high levels of NAG and I–FABP.
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Intraoperative PC transfusion was found as significant independent predictor of NAG
release (adjusted R2=44.4%, B=308.2, p<0.001), and I–FABP release (adjusted
R2=31.8%, B=207.1, p<0.001). The patients who received PC transfusion had sig-
nificantly higher NAG and I–FABP levels.
Priming volume predicted significantly NAG variability (adjusted R2=13.2%, B=0.236,
p=0.012) and I–FABP variability (adjusted R2=29.3%, B=0.263, p<0.001). A higher
priming volume was independently associated with higher urine NAG and I–FABP
values.
3.4 Discussion
The data presented in this study documents decreased postoperative myocardial, renal
and intestinal tissue injury in patients undergoing on–pump CABG when using a
modified operative protocol combining cold crystalloid cardioplegia and intracavitary
cooling of the heart, autologous priming, and corporeal normothermia.
Myocardial protection
The protection of the heart during the ischemic arrest time was performed by combin-
ing the standard cold crystalloid cardioplegia with an intracavitary cooling system. A
cold, sterile saline–filled balloon attached to a dual stage bicaval cannula enabled an
additional local, homogeneous cooling of the right atrium. As a consequence, post-
operative myocardial damage, as quantified by plasma levels of creatine kinase MB
(CK–MB), was significantly lower in the patients in the experimental group.
Increased postoperative peak CK–MB values were demonstrated to be strong predic-
tors of adverse outcomes, indicating increased risk of severe postoperative left ventric-
ular dysfunction and mortality within 30 days of coronary artery bypass grafting16.
Renal protection
Transient proximal tubules injury was significantly attenuated in the patients bene-
fiting from the experimental operative protocol, as shown by the urine concentrations
of N–acetyl–beta–D glucosaminidase (NAG). NAG is a lysosomal enzyme of 130 kDa
molecular mass, normally excreted in low amounts in urine as a consequence of the
normal exocytosis process17. NAG was proposed as a valuable marker of tubulo–
interstitial damage in various human glomerular diseases including diabetic nephropa-
thy18, primary and toxic glomerulonephritis17,19. In patients undergoing CPB, mea-
surement of urinary NAG additional to standard clinical tests was demonstrated to
be useful in recognizing early and differentiated changes in renal function20,21.
In our study, NAG levels were in average 4 folds higher in the patients undergoing
CPB according to the standard protocol, as compared to the experimental protocol.
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Intestinal protection
Transient intestinal damage, as quantified by the urinary excretion of intestinal–type
fatty acid binding protein (I–FABP), was significantly decreased in patients under-
going on pump CABG according to the experimental protocol. I–FABP is a 15 kDa
cytosolic protein uniquely located in the mature epithelium of the villi, which are
most susceptible to ischemic injury22. Clinical studies demonstrated that I–FABP is
released into the blood stream and excreted by kidneys early in the course of intestinal
ischemia23,24. Elevated I–FABP urine levels predict the development of gastrointesti-
nal complications after CPB14, and correlate with the clinical development of the
systemic inflammatory response syndrome in critically ill patients25.
In our study, the urinary excretion of I–FABP in the standard protocol group was in
average 2 folds higher than in the experimental protocol group.
Postoperative renal and intestinal injury were independently predicted by three vari-
ables: postoperative hematocrit, transfusion requirements during operation, and prim-
ing volume of the extracorporeal circuit.
Effect of hematocrit
Analysis of variance for linear regression showed that variation in Htc independently
explained 38% and 37% in the variability of postoperative NAG and I–FABP, re-
spectively. A decrease with one unit (1%) in hematocrit predicted significantly an
increase with a quarter of the peak postoperative NAG values. The same decrease
with one unit (1%) in hematocrit predicted significantly an increase of a tenth of the
peak postoperative I–FABP values. In addition, hypoxia during CPB, as quantified
by lactate values, correlated positively with intestinal and renal injury postoperative.
This association could represent an additional indication that a decrease in hemat-
ocrit, with a subsequent decrease in oxygen–carry capacity, might be responsible of
intestinal and renal injury post CPB. With regards to the effect of hemodilution on
post–operative myocardial injury, our study showed no significant predictor values for
the post–operative hematocrit values on the post–operative CK–MB peak concentra-
tions.
These findings quantify for the first time, to our knowledge, the effect of hemodilution
and subsequent hematocrit values on postoperative renal and intestinal injury in the
clinical setting of on–pump CABG.
These data bring additional information to explain previously reported conclusions of
large observational studies reporting a significant greater incidence of postoperative
complications as hematocrit values decrease: renal failure (∼ four–fold), multiorgan
failure (∼ seven–fold), and septicemia (∼ three–fold)26.
The combined operative strategy presented in this study allowed higher intra– and
post–operative hematocrit values as a consequence of the partial recovery of the car-
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dioplegic solution and autologous blood priming of the extracorporeal circuit.
Effect of transfusion requirements
The differences between groups in PC transfusion requirements, both intraoperatively
and in the ICU, were significant at a 10% level. Packed cell transfusion in the op-
erating room predicted independently a variation of 44% in NAG values and 32%
of I–FABP values. However, in order to subtract from this estimation the effect of
low hematocrit of the patients that received transfusion, we introduced in the same
regression model both hematocrit values and transfusion requirements. By analyzing
the proportions of residuals we could conclude that an extra 21.5% of the variability
in NAG and 10% of the variability in I–FABP that could not be explained by the vari-
ation in hematocrit values were explained by the transfusion requirements. In other
words, intraoperative packed cells transfusion to the patients was correlated signifi-
cantly with postoperative renal and intestinal injury, independently of the hematocrit
value.
The effect described by the present data support the previous raised concerns regard-
ing transfusion–associated morbidity such as hemolytic or allergic reactions, infections
(human immunodeficiency virus, cytomegalovirus, hepatitis)27, graft–versus–host dis-
ease28 and an increased incidence of postoperative infections in patients undergoing
coronary artery bypass surgery29.
Effect of priming volume
The volume of the solution used to prime the extracorporeal circuit was an inde-
pendent predictor of renal injury (13% of NAG variation) and intestinal injury (29%
I–FABP variation). However, this effect proved to reflect only the subsequent hemod-
ilution effect on organ injury.
As a consequence of partial cardioplegic volume recovery, the fluid balance was sig-
nificantly lower in the experimental group than in the standard group.
Effect of corporeal temperature
The “cold heart, warm body” principle applied in this study proved to be safe and
effective in preserving myocardial integrity and, in the same time, in attenuating
postoperative intestinal injury. In the hypothermic group, lower intrarectal tem-
peratures measured at 60min of CPB correlated significantly with higher intestinal
damage postoperatively. The association between lower corporeal temperatures with
higher postoperative intestinal injury reflects the findings of Ohri and all.30, showing
significantly reduced gastric mucosal blood flow during cross clamping in patients un-
dergoing hypothermic CPB as compared to patients undergoing normothermic CPB.
Regarding the validity of normothermic cardiopulmonary bypass, the data presented
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in this study support the previous studies evaluating the normothermic CPB asso-
ciated with topical heart hypothermia, that reported it to be safe1–5, to simplify
surgical procedures, and to facilitate postoperative management31.
Additional to the description of the independent predictors for renal and intestinal
injury, a multivariate analysis revealed the importance of patients demographics, peri–
operative variables, medication and co–morbidity for the variability of post operative
cardiac, renal and intestinal damage. High postoperative myocardial damage was
predicted by a large body surface area and long perfusion durations. Post operative
transient renal injury was higher in women, in patients with a low postoperative
hematocrit and those who received packed units intraoperatively. Post operative
transient intestinal injury was higher in men, in patients with a low postoperative
hematocrit, in those patients who had high priming volumes and who received packed
units intraoperatively.
3.5 Conclusions
In conclusion, this chapter describes the experimental infrastructure and clinical ap-
plication of a comprehensive operative strategy that limits postoperative myocardial,
renal and intestinal tissue injury in patients undergoing heart–lung machine assisted
coronary artery bypass grafting.
The addition of an intracavitary cooling system to the standard cold crystalloid car-
dioplegia offered a better protection of the myocardium, with decreased postoperative
plasma levels of creatine kinase MB. Partial recovery of intra–atrial cardioplegic fluid
and autologous blood priming limited the extent of intra–operative hemodilution and
blood transfusion requirements (10% significance level), and resulted in an important
attenuation of the transient renal and intestinal postoperative injury.
Acknowledgements: We acknowledge the entire operating team of the thorax
center of VU University Medical Center Amsterdam, The Netherlands, the perfusion-
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The bio–incompatibility of the cardiopulmonary bypass (CPB) circuit and the use
of artificial colloids trigger massive defense reactions that involve endothelial cells
and several blood cells: platelets, neutrophils, monocytes, red blood cells (RBC) and
lymphocytes.
Investigating the effects on RBC aggregation and endothelial cells activation, the
present study addresses two different prime solutions commonly used in clinical prac-
tice.
Patients, Materials and Methods
RBC aggregation was measured by means of Laser–assisted Optical Rotation Cell
Analyzer, in an in vitro study designed to mimic human blood–material interactions
during extracorporeal circulation.
A clinical study investigating endothelial activation was conducted in 20 patients
undergoing elective coronary bypass surgery, randomly assigned for CPB using two
different priming solutions: HAES–steril 6% (HES 200/0.5) and Voluven 6% (HES
130/0.4).
Results
Circulation trough a Chandler loop of HES–blood mixtures altered significantly RBC
aggregability. The use of HES 130/0.4 resulted in marked decrease in RBC aggrega-
tion (Aggregation Index AI before and after circulation 23.5±3.8 and 18±2.9, respec-
tively), no significant differences being found when compared with Ringer’s lactate
group. The use of HES 200/0.5 resulted in better maintained RBC aggregation (AI
39.7±5.9 and 29.7±4.7 before and after circulation, respectively). The AI measured
for the whole blood (control) sample was 61.9±4.9 before circulation, and 58.1±4
after.
Markers of endothelial activation (von Willebrand factor–vWF, thrombomodulin–
TM, tissue Plasminogen Activator–tPA and E–selectin) significantly increased during
CPB. Differences between HES treatment groups were evident post–bypass. While
the markers of endothelial activation returned to baseline in HES 200/0.5 group, HES
130/0.4 was associated on the first postoperative day with further increase of vWF
and tPA.
Conclusions
RBC aggregation significantly drooped as consequence of blood dilution and blood–
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material interaction. We reason that low RBC aggregation added to plasma viscosity
reduction and non–physiologic flow conditions during extracorporeal circulation, are
important factors contributing to variations in shear stress at the venous endothelial
wall. The variations in shear stress might trigger complex signaling leading to en-
dothelial activation. Additional fundamental research is needed in order to verify the
hypothesis introduced by the present study.
Characterizing the impact of rheologic parameters on endothelial function could prove




Cardiac surgery involving cardiopulmonary bypass (CPB) leads to activation of the
haemostatic–inflammatory systems associated with increased postoperative morbidity
and prolonged hospital stay1. As documented in the literature, extracorporeal circu-
lation triggers massive defense reactions that involve endothelial cells and at least five
blood cells: platelets, neutrophils, monocytes, red blood cells and lymphocytes. The
intensity of the cellular and humoral activation is known to vary with patient factors,
the surface area of biomaterials, duration of perfusion and exposure of blood to the
wound2. As a consequence, a whole–body inflammatory response and microemboli
are generated, leading to fever and leukocytosis, compromised fluid balance, ischemia
and microinfarctions3.
The relations between a low hematocrit and adverse outcomes in patients undergoing
CPB is extensively discussed in the literature4. There are also reports addressing the
mechanical trauma in red blood cells5 and the decrease in red blood cell deformability
during extracorporeal circulation6.
In our opinion, a complete chapter has been excluded from the discussion around the
pathogenesis of the “post–CPB syndrome”: modifications induced in red blood cell
aggregation and potential consequences on microcirculation.
The aggregation property of red blood cells is mainly considered to be pathophysio-
logic, since aggregation is elevated in many disease states such as diabetes mellitus7
and hypertension8. However, red cell aggregation is normally present in humans and
other “athletic” species being most pronounced in those species having the highest
capacity for oxygen consumption, while it is absent in sedentary animals9. This
raised the possibility that normal levels of aggregation may serve homeostasis, having
functional significance for normal physiology10. Earlier experiments conducted in our
group conclusively showed that the physiological function of red blood cells to form
aggregates is significantly affected in the presence of hydroxyethyl starch (HES)11.
Since HES solutions are extensively used as volume substitutes and priming solutions,
RBC aggregation is expected to suffer deviation from normal values during cardiopul-
monary bypass. Additionally, the unavoidable hemodilution associated with the use
of the heart–lung machine is expected to result also in a drop of plasma viscosity.
These hemodynamic alterations could represent mechanical triggers of further en-
dothelial cell activation already exposed to other insults occurring during CPB, such
as hypoxia, inflammatory stimuli, and surgical manipulation. Endothelial activation
is known to disrupt the barrier function, enhance vasoconstriction and increase the
leukocyte adhesion12.
The present study aims to test the potential effect of blood interactions with HES
solutions and extracorporeal circuit on red blood cells aggregability and to document
endothelial cell activation in the presence of two different prime solutions commonly
used in the clinical practice, HAES–steril 6% and Voluven 6%. The clinical relevance




4.2 Patients, Materials and Methods
Red Blood Cell Aggregability, Blood Viscosity and Plasma Viscosity
RBC aggregability was investigated in vitro with a Laser–assisted Optical Rotation
Cell Analyzer (LORCA R&R Mechatronics, Hoorn, The Netherlands). This instru-
ment, based on the ektacytometric principle, is equipped with a video camera for
detection of the laser diffraction–pattern, a thermostation unit and an ellipse–fit com-
puter program calculating the Aggregation Index (AI) of RBCs13. For the determi-
nation of red cell aggregation, the blood is brought under a shear rate of 500 s−1, after
which the shear is stopped (t=0). The backscattered intensity from the blood layer is
measured during 120 s after shear stop. The intensity drops because of red blood cell
aggregation. We considered the beginning point of the aggregation the extrapolated
value of the decay curve towards t=014.
The RBC aggregation measurements were performed at 32◦ C, in samples prepared
by in vitro admixture of HES solutions (either HAES–steril 6% or Voluven 6%) to
human fresh blood from healthy volunteers (n=6), drawn from the antecubital vein,
heparinized (4U/ml) and oxygenated (10min). The blood:prime mixture ratio was
5:2 by volume. In order to asses the effect of dilution alone, we measured also the
RBC aggregation in Ringer’s Lactate (RL)–blood mixtures (blood:RL ratio = 5:2).
We considered as controls AI values measured in whole blood samples.
AI was measured before and after sample circulation trough a Chandler loop15 of sil-
icon tubing, mimicking the blood–material/device interactions during extracorporeal
circulation. Silicon tubing with a total volume of 6.3ml (inner diameter 4mm, length
500mm) was filled with 4.5ml of sample leaving a gas volume of 1.8ml. The tubing
was closed into a loop using PVC connectors and then circulated vertically at 10 rpm,
in a 32◦ C water bath for one hour.
The choice of using the Chandler loop as a model was based on results of numerous in
vitro studies comparing the use of simpler or more complex in vitro models for char-
acterization of blood–material/device interactions. Coagulation parameters, platelets
activity and hematolysis were monitored in each model. In this regard, testing in the
simple Chandler loop model produced findings, which overlapped with observations
from the more complex CPB models16.
Viscosity was measured by means of an automated dynamic shear rheometer with
cone–plane geometry (AR1000 Rheometer, TA Instruments). Viscosity was measured
both in blood–HES samples and plasma–HES samples. The blood–HES samples were
prepared using the same method as used for the RBC aggregation measurements.
The plasma–HES samples were prepared by in vitro admixture of HES solution to
human fresh plasma in a mixture ratio of 5:2. In order to measure the modification
induced by the dilution alone, we also measured viscosity in plasma samples mixed
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with RL in the same ratio. During viscosity measurements the temperature was set
at 32◦ C. Viscosity was measured at four shear rates for blood samples (30 s−1, 60 s−1,
100 s−1 and 200 s−1) and at three shear rates for plasma samples (60 s−1, 100 s−1 and
200 s−1).
Endothelial activation during CPB
A prospective randomized single blind study, approved by the Medical Ethics Com-
mittee of Hospital de Weezenlanden in Zwolle, Netherlands, was conducted in 20
patients, who underwent an elective coronary bypass surgery. The patients were ran-
domly assigned for cardiopulmonary bypass with either HAES–steril 6% or Voluven
6%.
The patients were less than 75 years of age, had a body weight over 65 kg, underwent
a cardiopulmonary bypass time of more than 30 minutes and had signed a written
consent. Exclusion criteria were presence of severe heart failure, renal or liver dys-
function, bleeding diathesis, diabetes mellitus, and the use of platelet inhibiting drugs
within five days before the operation.
Induction and maintenance of anesthesia, surgical techniques and cardiopulmonary
bypass procedures including anticoagulation with heparin and its neutralization with
protamine, were performed in a standardized fashion17.
The extracorporeal circuit consisted of an integrated microporous plate membrane
oxygenator (Cobe–Duo, Cobe, CO, Lakewood, USA), polyvinyl chloride tubing and a
centrifugal pump (Biomedicus, Medtronic, Anaheim, CA, USA). The priming volume
of the circuit was two liters and the priming solution compositions were:
• HAES–steril 6% (Fresenius AG, Oberursel, Germany) 1000ml (6% HES 200/0.5,
median molecular weight 200 kD, degree of substitution 0.5) supplemented with
Ringer’s lactate to a final concentration of 3%.
• Voluven 6% (Fresenius AG, Oberursel, Germany) 1000ml (6% HES 130/0.4,
median molecular weight 130 kD, degree of substitution 0.4) supplemented with
Ringer’s lactate to a final concentration of 3%.
HES solutions served also as plasma substitutes, the dose limitation being 3 litters
in the pre–, during, and post–operative period. After reaching these defined study
colloid dose limits postoperatively, isotonic pasteurized plasma was administered in
case that additional volume was needed. As standard practice in our clinic, 1500 IU
heparin was added to all priming solutions.
During the operative day and on the first postoperative day, three blood samples were
taken for biochemical determinations: after induction of anesthesia (post–induction),
at arrival on the intensive care unit (1 h ICU), and on the first postoperative day




Blood samples were obtained from the radial artery catheter and were mixed with
3.06% sodium citrate, with a volume ratio of 9:1. The samples were kept on ice
during storage. The citrated blood was centrifuged at 1100 g for 12 minutes to ob-
tain platelet poor plasma, stored at –80◦ C until further determinations of biochemical
assays. Plasma concentrations of endothelial and/or platelet release products were in-
vestigated by means of ELISA: vonWillebrand Factor (vWF) (Gradipore, North Ride,
Australia); tissue plasminogen activator (t–PA) (Coaliza, Innogenetics, Belgium); E–
and P–Selectine (R&D Systems, inc, Abingdon,UK); thrombomodulin (TM) (Imu-
bind, American Diagnostica inc, Greenwich, CT, USA).
Statistical analysis
Before data analysis, all individual sample points were tested for distribution ac-
cording to the Kolmogorov–Smirnov goodness of fit test. In case of not normally dis-
tributed data, Mann–Whitney test was used to quantify differences between groups.
Within groups Wilcoxon Signed Ranks test was performed to show differences during
treatment. Correlations between variables was tested using Spearman’s correlation
test.
To detect possible differences in effect of each priming solution, for normal distributed
data, one way analysis of variance (ANOVA) was used to compare groups. If differ-
ences between the groups were significant (p<0.05), post hoc multiple comparisons
were performed to quantify any differences among groups using the Tukey HSD test
with a level of significance p<0.05. A Bonferroni correction was made for multiple
testing. Within groups a paired T–test was performed to show differences during
treatment.
The variables are expressed as mean±SEM, unless stated otherwise.
4.3 Results
Red Blood Cell Aggregation
The AI measured in control samples was 61.9±4.9 before circulation, and 58.1±4
after. Dilution of blood with Ringer’s lactate solution yielded a decrease of AI to
16.6±2.6. Mixture with HES 130/0.4 resulted in low aggregation (AI before and after
circulation 23.5±3.8 and 18±2.9, respectively). No significant differences were found
between Ringer’s lactate group and HES 130/0.4 group. The use of HES 200/0.5
compensated by half the dilution effect on red blood cell aggregation; AI values in
this group were 39.7±5.9 and 29.7±4.7 before and after circulation, respectively (Fig.
4.1). Circulation trough the closed silicone tubing system of blood: HES mixture
significantly reduced red blood cell aggregability (paired Student Test p≤0.01).
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Figure 4.1: Red blood cell aggregation index measured before and after circulation
(C) through a closed silicon tubing in 4 groups of blood treated samples (mixing ratio
5:2): (i) Ringer’s lactate; (ii) HES 130/0.4; (iii) HES 200/0.5; (iv) Control. The
values are represented as mean (symbols) and standard deviation of the mean (bars).
Significant (p<0.05) and highly significant differences (p<0.01) within and between
the groups are indicated with ? and ??, respectively.
Method validation for AI measurements
Measurements of Normal Reference sample showed a mean value of 57.79, a SD of
0.88, a 95% CI of [56.86; 58.72] and a coefficient of variation of 14.66%. Measurements
of Low Reference sample (blood:RL=5:2) showed a mean value of 16.72, a SD of 1.49,
a 95% CI of [15.15; 18.29] and a coefficient of variation of 24.83. The AI was measured
6 consecutive times at 32◦ C.
Blood viscosity
Fig. 4.2a shows the viscosity curve of blood samples measured at 32◦ C and shear
rates 30 s−1, 60 s−1, 100 s−1 and 200 s−1. When measuring at a shear rate of 30 s−1,
the lowest values were registered after mixture with Ringer’s lactate solution (drop to
59% of whole blood viscosity), followed by values given by HES 130/0.4 group (drop
to 64% of control values) and HES 200/0.5 (drop to 72% of control values). ANOVA
showed significant differences between groups (p<0.001). Multiple comparison with
post–hoc test pointed out that differences between the groups were significant at all
tested shear rates (p<0.001). The same ranking was observed when measuring plasma
76
Chapter 4
and plasma–HES mixtures viscosities (Fig. 4.2b). When measuring at a shear rate
of 100 s−1, the addition of RL, HES 130/0.4 and HES 200/0.5 determined a decrease
in plasma viscosity to 75%, 85% and 92% of the initial values, respectively. ANOVA
showed significant differences between the groups. Post–hoc tests demonstrated that
the values between the groups were significantly different at all measured shear rates
(p<0.001), excepting the differences at a shear rate of 60 s−1 between Plasma:RL and
Plasma:HES 130/0.4 groups (p=0.137).
Endothelial activation during CPB
No significant differences were measured between the two groups with regard to age,
sex, weight, body surface area, cardiopulmonary bypass and aortic cross clamp time,
number and origin of grafts or volumes infused. Also, no relevant differences were
found in concomitant diseases or medication between the treatment groups. On the
intensive care unit, 40% of the patients from both HES 130/0.4 and HES 200/0.5
groups received additional isotonic pasteurized plasma, 178ml in average, after the
dose limit of three liters colloid was reached. 40% patients in the HES 130/0.4 group
and 50% patients in HES 200/0.5 group received allogenic blood products.
Von Willebrand Factor (plasma) concentration did not change significantly during
extracorporeal circulation, although in both groups a trend to increase was observed.
Between induction of anesthesia and the end of the surgical procedure vWF concentra-
tions ranged between 60 and 260% of normal pooled plasma, being in average higher
than normal. The values in HES 130/0.4 group started to increase in the reperfusion
period; the concentrations in the first postoperative day were significantly higher than
baseline (Wilcoxon Sig.<0.01). Significant differences were measured between groups,
with higher plasma values in HES 130/0.4 group (Mann–Whitney Sig.≤0.01) (Fig.
4.3).
Tissue–Plasminogen Activator concentrations were significantly higher at 1 h ICU
in comparison with baseline values (Wilcoxon Sig.≤0.05). The values measured in
HES 200/0.5 group were significantly higher than the values in HES 130/0.4 group
(Mann-Whitney Sig.<0.01). During reperfusion time, the values in HES 200/0.5
group declined while the values in HES 130/0.4 group increased further (Fig. 4.4).
Thrombomodulin values significantly increased after the end of extracorporeal circu-
lation (Wilcoxon Sig.<0.05) for patients of both groups, with no difference between
treatment groups. The values went down in the reperfusion period but remained
significantly above the baseline (Wilcoxon Sig.<0.01) (Fig. 4.5).
E–Selectin increased moderately but significantly after CPB in both groups (Wilcoxon
Sig.≤0.01) with no differences between them. During reperfusion time the values
reached baseline levels (Fig. 4.6).
P–Selectin did not change significantly in either group, at any time point (data not
shown).
Correlations: in the HES 130/0.4 treatment group vWF values correlated positively
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Figure 4.2: In vitro viscosity (mPa.s) of treated blood (a) and plasma (b)
samples (mixing ratio 5:2) measured in 4 groups: (i) Blood/Plasma; (ii)
Blood/PL–RL: Blood/Plasma treated with Ringer’s lactate; (iii) Blood/PL–HES
130/0.4: Blood/Plasma treated with HES 130/0.4; (iv) Blood/PL–HES 200/0.5:
Blood/Plasma treated with HES 200/0.5. The values are represented as mean (sym-
bols) and standard deviation of the mean (bars).
with the tPA values (Spearman’s coefficient 0.681, sig.<0.001). In the HES 200/0.5




Figure 4.3: von Willebrand fac-
tor (vWF) plasma concentration
(%) measured in 2 groups of pa-
tients: (i) group HES 130/0.4; (ii)
group HES 200/0.5. The measure-
ments were effectuated at 3 time
points: post induction of anes-
thesia (post–induction), 1 h after
transfer in intensive care unit (1 h
ICU) and in the first postopera-
tive day (1st POD). The values
are represented as mean (symbols)
and standard error of the mean
(bars). ? Significant increase be-
tween groups (p<0.01). + Signifi-
cant increase compared to baseline
(p<0.01).
Figure 4.4: Tissue Plasminogen
Activator (tPA) plasma concen-
tration (ng/ml) measured in 2
groups of patients: (i) group HES
130/0.4; (ii) HES 200/0.5. The
measurements were effectuated at
3 time points (see legend Fig.
4.3). The values are represented
as mean (symbols) and standard
error of the mean (bars). ? Sig-
nificant increase between groups
(p<0.01). + Significant increase
compared to baseline (p<0.05).
Circulating platelet count
The mean platelet number was comparable between the treatment groups within
the evaluation period. The platelet count remained within normal ranges except for
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the initial period after CPB (1 h ICU) when values decreased due to dilution effect.
Corrected values showed no significant differences as compared to baseline values.
Figure 4.5: Thrombomodulin
(TM) plasma concentration (U/L)
measured in 2 groups of patients:
(i) group HES 130/0.4; (ii) HES
200/0.5. The measurements were
effectuated at 3 time points (see
legend Fig. 4.3). The values
are represented as mean (symbols)
and standard error of the mean
(bars). + Significant increase com-
pared to baseline (p<0.01).
Figure 4.6: E–Selectin plasma
concentration (U/L) measured in
2 groups of patients: (i) group
HES 130/0.4; (ii) HES 200/0.5.
The measurements were effectu-
ated at 3 time points (see legend
Fig. 4.3). The values are rep-
resented as mean (symbols) and
standard error of the mean (bars).





The property of red blood cells to form aggregates at low shear rates was profoundly
altered in our in vitro model mimicking the human blood–material interactions dur-
ing extracorporeal circulation. In Ringer’s lactate and HES 130/0.4 treated blood
samples, the aggregation index (AI) dropped to a quarter of the control AI values.
Further decrease was registered as a consequence of blood circulation through silicon
tubing. The use of HES 200/0.5 compensated by half the dilution effect on red blood
cell aggregation.
In parallel with the decrease in red blood cell aggregation, blood viscosity declined
also. The highest viscosity was measured in HES 200/0.5 treated blood samples,
followed by HES 130/0.4 and Ringer’s lactate treated blood samples. The same
ranking was observed when measuring the viscosity of plasma samples.
Current understanding of the rheological effects of red blood cell aggregation suggests
that blood shear stress at the venular wall varies when RBC aggregability varies10,18.
Accordingly, because of RBC aggregation drop, plasma viscosity reduction and non–
physiologic flow conditions, it is expected that the blood shear stress at the venous
endothelial wall would alter during extracorporeal circulation.
Endothelial cells are notorious for their ability to sense variations in mechanical forces,
such as shear stress. Endothelial cells in vivo are normally exposed and presumably
adapted to a normal level of shear stress in the range of 0.5–2Pa. Cells adapted to flow
might be expected to respond to either an increase or decrease in shear stress from
the normal level. Studies investigating the response of flow–adapted endothelial cells
to an abrupt variation in shear stress, showed membrane depolarization, increased
intracellular Ca2+, nitric oxide and reactive oxygen species generation19. In addition
to synthesis and release on demand, several stored compounds are secreted during
endothelial cell stimulation, in a Ca2+ dependent way. Elevation in intracellular Ca2+
triggers release of several vasoactive factors and factors involved in hemostasis and
thrombolysis: nitric oxide, prostacyclins, vWF, tPA, tissue factor, adhesion molecules
and chemoattractant proteins20. In our clinical study vWF and tPA recovered in HES
200/0.5 group while further increasing in the HES 130/0 group.
Because of lack of consensus in literature over the “gold standard” for endothelial
activation, our clinical study was designed to measure several markers related to
endothelial activation: vWF, TM, t–PA, E–Selectin.
von Willebrand factor is a component of platelet–granules and Weibel–Palade bodies
in the endothelial cells. The majority of plasma vWF is derived from endothelial
cells and an increase in plasma levels is generally considered to be mainly a marker
of endothelial activation. However, vWF is also known to be an acute phase reactant
affected by inflammatory cytokines, and as such, may be elevated even in the absence
of definite endothelial damage21,22.
Thrombomodulin is a surface protein of endothelial cells, which acts as a thrombin
receptor and serves as an anticoagulation factor. Soluble fragments of TM, proba-
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bly components of degradation, circulate in plasma. TM is not released in plasma
constitutively or as a response to endothelial activation, but is released after acute en-
dothelial cell injury. As a drawback, TNF–α leads to a reduction in thrombomodulin
expression by endothelial cells22.
Endothelial release of tissue Plasminogen Activator initiates fibrinolysis. tPA may be
used to evaluate endothelial stimulation induced by CPB, denoting a postischemic
antithrombotic function of the endothelium23.
E– and P–selectins belong to the selectin family of adhesion molecules and both have
been reported to increase in circulation or at lesion sites of several diseases reflecting
endothelial activation. The disadvantage of using E–selectin as a marker is the fact
that, E–selectin being an leukocyte adhesion molecule, some may be bound to its
ligand in vivo, and be unavailable for measurement22.
The findings of this study showed functional and/or structural alteration of vascular
endothelial cell during extracorporeal circulation, as documented by elevated plasma
concentrations of vWF, thrombomodulin, tPA and E–selectin. These markers have a
proven endothelial origin, since platelet count was similar in both groups and didn’t
vary extensively during CPB. In the HES 130/0.4 treatment group the increase in
vWF correlated positively with the increase in tPA. In the HES 200/0.5 group a
positive correlation was found between TM and tPA.
Differences between HES groups were evident post–bypass. While the markers of
endothelial activation recovered in HES 200/0.5 group, HES 130/0.4 was associated
on the first postoperative day with further increase of vWF and tPA.
These reports may prove to represent additional help in the decision process of the
clinician who is confronted with cardiac patients of different etiologies. Even if fur-
ther documentation is needed, our results documenting the important rise in von
Willebrand factor suggest the necessity of a more careful selection of HES solutions.
Hypertensive and atherosclerotic patients who have high basal levels of vWF might
benefit from HES 200/0.5. HES 130/0.4 could represent a first choice for patients
with bleeding tendencies and patients with acquired von Willebrand syndrome after
aortic stenosis. In this respect, HES 130/0.4 was proved to be in various clinical
settings at least comparable or better on coagulation parameters, blood loss or blood
product consumption as compared to HES 200/0.517.
Our observations made in vitro on RBC aggregability coupled to the observation made
in vivo on endothelial cell activation suggest a hypothetical new pathophysiological
mechanism implicated in the post–CPB syndrome. We hypothesize that the drop
in RBC aggregation added to plasma viscosity reduction and non–physiologic flow
conditions during extracorporeal circulation, are important factors contributing to
variation in shear stress at the venous endothelial wall. The variation in shear is known
to lead to a complex signaling response eventuating in membrane depolarization,
intracellular Ca2+ accumulation with subsequent release of nitric oxide, prostacyclins,
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vWF, tPA, tissue factor, and generation of reactive oxygen species.
Additional fundamental research is needed in order to verify the hypothesis introduced
by the present study. Characterization of the interrelation between rheologic param-
eters and endothelial function could prove to be valuable in managing complications
in CPB patients.
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Abstract
The essential role of erythrocytes as oxygen carriers is historically well established,
however their function to aggregate with consequences on homeostasis is under debate.
The pathogenic potential of low erythrocyte aggregation might have implications for
patients undergoing on–pump cardiopulmonary bypass who are severely hemodiluted
due to preoperative isovolemic hemodilution (IHD), circuit priming, and large fluid
infusions peri–operatively. Considering the vascular endothelium sensitivity to vari-
ations in blood rheology, we hypothesize that low erythrocyte aggregation will be
responsible for activation of vascular endothelium during acute IHD. To verify this
theory, we induced acute IHD (30ml/kg exchange–transfusion with colloid–solutions)
in an “aggregating species” (pigs, n=15), and investigated the hypoxic oxidative stress
(plasma Malondialdehyde, ex–vivo oxygen radicals production in heart, lung, kidney,
liver, ileum tissue biopsies), erythrocyte aggregation (LORCA), and endothelial acti-
vation (Real Time Quantitative RT–PCR to analyze von Willebrand Factor (vWF),
E– and P–Selectins, endothelial nitric oxide synthase gene–expression in tissue biop-
sies). The production of superoxide and hydroxyl radicals, measured as H2O2 gener-
ation, was similar at all times in sham–operated and hemodiluted animals, proving a
maintained oxygen delivery to tissues. Acute IHD was followed by a dramatic drop
in erythrocyte aggregation and immediate pro–thrombotic (significant vWF mRNA
up–regulation in heart, lungs, kidney, liver, ileum) and pro–inflammatory (significant
E– and P–Selectins mRNA up–regulation in lungs and ileum) endothelial activation.
Low erythrocyte aggregation was statistically significantly correlated with increased
mRNA–expression of vWF (heart, liver, ileum) and P–Selectin (lungs, ileum and
heart). These results suggest that low erythrocyte aggregation can actively trigger





The essential role of erythrocytes as oxygen carriers is historically well established,
however, their function to aggregate with consequences on homeostasis is under de-
bate. The aggregation property of red blood cells (RBC) is mainly considered to be
pathophysiologic, since aggregation is elevated in many disease states such as diabetes
mellitus1 and hypertension2.
Current understandings of blood rheology suggest complex mechanisms related to red
blood cell hyper-aggregation. RBC hyper-aggregation is the main cause of increased
blood viscosity under low shear conditions3. Increased aggregation is expected to
augment the energy cost for breakdown of aggregates as blood approaches the mi-
crocirculation4. Enhanced RBC aggregation tends to promote axial accumulation
of RBC in blood vessels, resulting in a less–viscous, plasma–rich region near vessel
walls5. Decreased local viscosity of the marginal layers in blood vessels might be asso-
ciated with decreased pressure gradients and hence lower wall–shear stresses for some
vessels, thereby affecting vascular control mechanisms that are modulated by shear
stress. Studies investigating the response of flow adapted endothelial cells, either in
vivo or in vitro, demonstrated that positive or negative variation in shear stress at the
vascular wall leads within minutes to membrane depolarization, increased intracellular
Ca2+, nitric oxide and reactive oxygen species generation6. In addition to synthesis
and release on demand, several stored compounds are secreted during mechanical en-
dothelial cell stimulation, in a Ca2+ dependent way. Elevation in intracellular Ca2+
triggers release of several vasoactive factors and factors involved in hemostasis and
thrombolysis: nitric oxide (NO), prostacyclins, von Willebrand factor, tissue factor,
tissue plasminogen activator, adhesion molecules and chemoattractant proteins7. In
this respect, increased RBC aggregation was reported to result in diminished nitric
oxide–dependent vascular control and decreased endothelial NO synthase expression8.
To date and rather remarkable, the scientific approach to unravel this issue has com-
pletely ignored the pathogenic potential of low erythrocyte aggregation states. Some
authors have suggested that normal levels of aggregation may serve homeostasis, hav-
ing functional significance for normal physiology, as red cell aggregation is normally
present in humans and other “athletic” species9,10. This hypothesis, however, has
never been investigated before, and also, never been placed in a clinical relevant con-
text.
The pathogenicity of low erythrocyte aggregation could have major implications for
hemodiluted patients. This situation routinely occurs in cardiac patients undergoing
on–pump cardiopulmonary bypass who are severely hemodiluted due to therapeutic
preoperative isovolemic hemodilution, priming of the extracorporeal circuit and large
fluid infusions peri–operatively. Excessive hemodilution prevails also during sustained
fluid resuscitation in traumatic–hemorrhagic shock patients. In addition to the con-
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sequences of hypoxic stress, the implications of low erythrocyte aggregation during
acute hemodilution might prove to be essential for a full understanding of microcircu-
lation impairment and deteriorated tissue perfusion in these patients. Considering the
sensitivity of the vascular endothelium to variations in blood rheology, we hypoth-
esized that low erythrocyte aggregation will be responsible for activating vascular
endothelium during acute isovolemic hemodilution.
In this study we addresses the pathophysiology of acute isovolemic hemodilution in
a clinical relevant animal model, studying hypoxic oxidative stress, red blood cell
aggregation, and subsequent vascular endothelial activation.
5.2 Methods
This study was set up as a comparative, controlled, pseudo–double blind animal study,
including a total of 15 adult pigs (60–80 kg). The experiments were in accordance
with institutional and legislator regulations and approved by the local Committee for
Animal Experiments. Two colloid solutions commonly used in clinical practice as
plasma expanders were taken to induce acute isovolemic hemodilution (IHD). This
experimental design was also based on our previous studies showing different effects of
different molecular weight of hydroxyethyl starches (HES) on human red blood cells,
with a pro–aggregatory effect increasing with the molecular weight of the colloid11,12.
The animals were randomized in three groups:
• group 1 (n=6) 30ml/kg isovolemic exchange transfusion with HAES–sterile 3%
(HES 200/0.5, median molecular weight 200 kD, supplemented with Ringer’s
lactate to a final concentration of 3%).
• group 2 (n=6): 30ml/kg isovolemic exchange transfusion with Voluven 3% (6%
HES 130/0.4, median molecular weight 130 kD, supplemented with Ringer’s
lactate to a final concentration of 3%).
• group 3 (n=3): control group sham–operated animals.
Anaesthesia was induced with ketamine (i.m. 10mg/kg) and diazepam (i.m. 1mg/kg).
Before intubation, the ventilation was performed using a mixture of O2 and isoflurane
4%. After tracheal intubation, ventilation was performed with isoflurane 1.5–2%.
Isovolemic hemodilution was induced after cannulation of the jugular vein and carotid
artery, by infusing HES at the arterial site, and a simultaneous withdrawal of an
equal volume of blood. The drops in Hematocrit (Hct) and Hemoglobin (Hb) were
monitored throughout the experiment, and adjusted to a constant value of 40% of the
initial value (Fig. 5.1). No inotropic support was included in the protocol.
After 3 hours of maintaining the isovolemic hemodilution, tissue biopsies were ob-
tained from the small intestine (ileum, luminal site), a randomly selected kidney
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Figure 5.1: Hematocrit (%) variation dur-
ing three hours of acute IHD, infused with
either 3% HES 130/0.4 solution or 3% HES
200/0.5 solution. The controls are rep-
resented by sham–operated animals. The
values are represented as mean (symbols)
and standard error of the mean (bars).
(cortex), liver, lung, and heart. The biopsies were snap frozen in liquid nitrogen and
stored at –80◦ C for real time RT–PCR measurements and histological assessments.
Blood samples were collected at three time points: baseline (5min after placement of
the cannulae), post–infusion (5min after induction of isovolemic hemodilution), and
at the end of the experiment (3 hours of isovolemic hemodilution).
Test of red blood cell aggregation
The RBC aggregation measurements were performed on fresh arterial blood samples,
using a Laser–assisted Optical Rotation Cell Analyzer (LORCA R&R Mechatronics,
Hoorn, The Netherlands), and quantified as Aggregation Index (AI). This method
closely mimics the in vivo blood flow conditions by applying a large range (0 to
500 s−1) variations in shear rate and measuring the response in erythrocyte aggrega-
tion as indicated by the variation in the backscattered intensity from the blood layer13.
In short, for the determination of red cell aggregation, the blood was brought under a
shear rate of 500 s−1, after which the shear was stopped. The backscattered intensity
from the blood layer was measured during 120 s after shear stop. The intensity drops
because of red blood cell aggregation14.
Viscosity measurements of plasma samples were performed with an automated dy-
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namic shear rheometer with cone–plate geometry (AR1000 Rheometer, TA Instru-
ments). During measurements the temperature was set at 37◦ C and the shear rate
of operation at 100 s−1.
Test of hypoxic oxidative stress
Plasma Malondialdehyde (MDA) – enzymatic detection, according to the method de-
scribed by Esterbauer and Cheeseman15.
H2O2 production in bioptic tissues: a fluorophore–nitroxide (Molecular Probes, Eu-
gene, OR, USA) was used to image ex–vivo superoxide and hydroxyl radicals gener-
ated by cells16. The reaction of fluorophore–nitroxide with superoxide results in a loss
of electron spin resonance signal intensity concurrent with an increase in fluorescence
emission. The fluorophore–nitroxide also reacts with methyl radicals generated by
the reaction of hydroxyl radicals with DMSO17.
Biopsies from tissue of approximately 2mm3 and dry weight of 2–5mg were incubated
for 10 minutes in a microtiterplate in 50µl of 0.1M Tris–HCl buffer (pH 8.0) containing
2.5mM pyruvate and 5mM succinate to stimulate mitochondrial activity18. Then
50µl Tris–buffer containing 2µM fluorescamine and DMSO (final concentration 2.5%)
was added. The reaction was started after the addition of 5µl FeII-EDTA (final Fe
concentration 2µM) in Tris buffer. In this way, both superoxide and hydroxyl radicals
were converted and measured as H2O2 19. The biopsies were incubated in this mixture
for 10min at room temperature on a plate shaker. After removal of the biopsies the
fluorescence was measured in a multilabel counter (Victor2, EG&G Wallac, Turku,
Finland) by using 390 nm excitation and 510 nm emission filters. Standard curves
were obtained by adding known amounts of H2O2 to the assay medium.
During incubation hemoglobin was released from the biopsies, resulting in quenching
of the fluorescence signal. Thus, a separate standard curve was prepared including
stepwise diluted hemoglobin ranging from 0.1 to 1.2 g/L. The linear relationship be-
tween hemoglobin concentrations and fluorescence signal was used to correct for the
hemoglobin signal quenching. Hemoglobin concentration in the supernatant of the in-
cubated biopsies was measured by the method of Harboe20. Finally, measured H2O2
concentration was corrected for the dry weight of the biopsy.
Diaminobenzidine (DAB) staining – the production of H2O2 by cells in paraformaldehyde–
fixed sections of ileum mucosa was histochemically demonstrated by incubating them
for 30min with 25mg DAB/50ml Tris/HCL pH 7.6, at 60◦ C. Catalase (150µg/ml,
1400U/ml) inhibited the reaction, indicating that H2O2 was required to produce the
chromogenic DAB staining.
Endothelial activation: Real–Time Quantitative Taqman RT–PCR on von Wille-
brand factor, E–Selectin, P–Selectin, and endothelial nitric oxide synthase (eNOS)
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gene expression in heart, lung, kidney, liver and intestinal tissue biopsies.
Total RNA was extracted using RNeasy Mini Kits (Qiagen, Venlo, The Netherlands),
as recommended by the supplier. Total RNA was treated with 2U of DNase I (RNase–
Free DNase, Qiagen, Venlo, The Netherlands) in a volume of 15µl to remove con-
taminating DNA (15min at 37◦ C). First–strand cDNA synthesis: the mix of RNA
(1µg), 0.25µg random hexamer primers and 2 ng of dNTPs (Promega, Leiden, The
Netherlands) was heated for 5min at 65◦ C and incubated on ice for at least 1min,
subsequently. The master mix [200U SuperScript III (Invitrogen, Breda, The Nether-
lands) with 4µl of 5× first–strand buffer, 1µl 0.1M dithiothreitol, and 40U RNase-
OUT ribonuclease inhibitor (Invitrogen)] was added to the samples in a total volume
of 20µl; finally a reverse transcriptase program was performed (5min at 25◦ C, 60min
at 50◦ C, 15min at 70◦ C, ∼ at 4◦ C).
Quantitative PCR amplifications were performed on an ABI Prism 7900HT Sequence
Detection System (Applera Nederland, Nieuwekerk a/d IJssel, The Netherlands).
Primers and probes for von Willebrand factor, E– and P–Selectin, eNOS, CD31 (en-
dothelial marker) and GAPDH (house keeping gene) were developed commercially
(Custom TaqMan R© Assays, Applied Biosystems–Applera Nederland BV, Nieuwekerk
a/d IJssel, The Netherlands). The mRNA coordinates for the exon–exon boundaries
were determined by aligning the human genomic sequences with pig mRNA sequences
(Spidey alignment program, http://www.ncbi.nlm.nih.gov). As a precaution to
prevent amplification of genomic DNA, primer/probe sequences were chosen such
that they span exon junctions or lie in distant exons separated by long introns. The
PCR step contained 1µl of the appropriate RT reaction, 10µl of TaqMan universal
PCR master mix (Applied Biosystems), 200 nM primers, and 100 nM TaqMan probe
in a final volume of 20µl. The PCR cycling conditions were 2min at 50◦ C, 10min
at 95◦ C, and 40 two–step cycles of 15 s at 95◦ C and 60 s at 60◦ C. All samples were
assayed in triplicate.
Relative quantification of the mRNA levels was done by subtracting the GAPDH CT
(threshold cycle) from the investigated gene CT value (∆CT = CT gene – CT GAPDH).
Results were normalized with the average value of the respective gene in control sham–
operated animals, arbitrarily set to 1. Results were finally expressed as
2−∆CT gene / 2−∆CT CD31 which represents an index of the relative amount of mRNA
expressed in each tissue, corrected for the number of endothelial cells presented in
each biopsy.
Plasma concentrations of endothelial vWF were investigated by means of ELISA
(Coamatic von Willebrand Factor kit, Nodia BV, Amsterdam, The Netherlands).
Statistical Analysis
The statistical analysis was performed using SPSS (Statistical Package for the So-
cial Sciences). Before analysis, the data was tested for distribution according to
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Kolmogorov–Smirnov goodness of fit test. The variations over the study period were
investigated using repeated measures ANOVA. To investigate differences between
groups, continuous variables where compared by means of parametric (Student T
Test) or nonparametric tests (Mann–Whitney). Correlation between non–parametric
variables was performed with Sperman’s correlation test. Results are presented as
mean±SEM (unless stated otherwise). Statistical significance was accepted at p<0.05.
5.3 Results
Immediately post–infusion the hematocrit (Hct, Fig. 5.1) reached 39.9±1.9% of base-
line values in HES 130/0.4 hemodiluted animals and 41.3±2.2% of baseline values in
HES 200/0.5 hemodiluted animals, but recovered by the end of the 3 experimental
hours to 65.5±5.9% and 57.9±4.3% of baseline values, respectively. The extraordi-
nary compensating capacity of the circulating number of erythrocytes was probably
achieved by way of mobilizing spleen–trapped erythrocytes. This observation was
supported by a smaller size and pale color of spleens in hemodiluted animals, as
compared with those of sham–operated animals. To exclude the possibility of hemo-
concentration due to loss of infused fluid through urine or extravascular extravasa-
tions, we performed plasma viscosity measurements. The baseline plasma viscosity
levels (1.7±0.05mPa.s) dropped in the hemodiluted animals immediately after infu-
sion (1.39±0.06mPa.s HES 130/0.4; 1.4±0.07mPa.s HES 200/0.5) and remained low
until the end of the experiment (1.35±0.13mPa.s and 1.44±0.06mPa.s, respectively)
proving a comparable level of plasma dilution during the entire experiment.
Baseline Post–infusion 3 hours IHD
MAP (mmHg)
controls 71.8±13.1 64.3±6.3 53.5±2.7
HES 130/0.4 71.0±16.6 46.1±4.8?? 48.3±5.5
HES 200/0.5 67.3±9.0 52.6±17.4 49.5±5.5
HR (beats/min)
controls 100±4 99±1 106±9
HES 130/0.4 90±10 108±13 138±11??
HES 200/0.5 91±9 106±10 124±22
Arterial PO2 (mmHg)
controls 70.1±2.8 70.7±3.1 69.1±1.6
HES 130/0.4 63.9±6.5 70.1±6.8 70.4±5.3
HES 200/0.5 62.4±7.1 68.4±7.8 69.6±7.1
Table 5.1: Mean arterial pressure (MAP), heart rate (HR) and arterial partial oxygen




Mean arterial pressure (MAP) and heart rate (HR) were monitored throughout the ex-
periment (Table 5.1). MAP decreased gradually and significantly (Wilks Sig.<0.001)
in all animals during the experiment. Immediately post–infusion, MAP was signif-
icantly lower in the HES 130/0.4 group (Mann–Whitney p=0.024) than the control
group; after 3 hours of hemodilution no significant differences were seen anymore.
The heart rate increased gradually, with a stronger rise registered in hemodiluted
animals (Wilks Sig. p=0.009). At the end of experiment, the HES 130/0.4 group had
significantly higher heart rates than the control group (Mann–Whitney p=0.024).
RBC Aggregation
RBC Aggregation (Fig. 5.2) decreased significantly after induction of hemodilution
(Wilks Sig.=0.002), with an overall lower aggregation index (AI) in the experimental
animals as compared with sham–operated animals (between subjects effect sig.=0.001).
In HES 130/0.4 group, AI dropped to 39.2±4.8% of baseline values and maintained
low during the experiment with values of 37.05±3.3% of baseline values at the end
of experiment. In HES 200/0.5, AI declined post–infusion to 49.3±5.9% of baseline
values and maintained low with 47.7±6.5% of baseline values at the end of experi-
ment. Although the AI tended to be higher in the HES 200/0.5 group than in the
HES 130/0.4 group, the differences were not significant at any time point.
Figure 5.2: RBC aggregation during three
hours of acute IHD, infused with either 3%
HES 130/0.4 solution or 3% HES 200/0.5
solution. The controls are represented by
sham–operated animals. The boundary of
the box closest to zero indicates the 25th
percentile, the line within the box marks
the median of 6 measurements, and the
boundary of the box farthest from zero
indicates the 75th percentile. Whiskers
above and below the box indicate the 90th
and 10th percentiles. Symbol ◦ represents
the outliers.
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Hypoxic oxidative stress
Arterial PO2 increased moderately but not significantly after hemodilution (Table
5.1), expressing either an improvement in pulmonary gas exchange or a decreased
diffusional oxygen exit.
Plasma Malondialdehyde (MDA), (Fig. 5.3a) dropped significantly right after infu-
sion, due to the dilution effect. The relative increase in plasma MDA during the 3
experimental hours was comparable in the sham–operated animals (0.34±0.09µmol),
HES 130/0.4 infused animals (0.30±0.16µmol) and HES 200/0.5 infused animals
(0.40±0.18µmol).
Oxygen radicals production (Fig. 5.3b). All animals showed a significantly higher
H2O2 production in abdominal organs (ileum, kidney, liver) than in heart and lung
tissues. Oxygen radicals production was comparable in all animals with no significant
difference at any time point between hemodiluted and sham–operated animals.
A DAB staining of H2O2 producing cells in the ileum was performed, as the ileum
seemed to be one of the organs exposed to oxidative stress. Fig. 5.3(c,d) shows a
similar villi morphology, comparable staining intensity and distribution of H2O2 pro-
ducing cells in both hemodiluted (Fig. 5.3c) and sham–operated animals (Fig. 5.3d).
Vascular endothelial activation
Von Willebrand Factor (vWF) mRNA (Fig. 5.4a) was significantly up–regulated in
HES 130/0.4 hemodiluted animals when compared with sham–operated animals in
all organs studied (Mann–Whitney: ileum, kidney, lung and heart p=0.024, liver
p=0.048). The same outcome was found in HES 200/0.5, with the exception of the
lungs, where differences did not reach significance (Mann–Whitney: ileum, kidney,
and heart p=0.024, liver p=0.048, lung p=0.095). vWF mRNA responses did not
differ between HES 130/0.4 and HES 200/0.5 treated animals.
Plasma vWF systemic release (Fig. 5.4b) translates the information found at mRNA
level. Indeed, the relative increase in vWF plasma concentrations during three ex-
perimental hours in HES 130/0.4 group (30.32±4.6%) and in HES 200/0.5 group
(27.9±1.3%) were significantly higher than the control values (0.1±0.01%) in sham–
operated animals (Mann–Whitney p=0.024 for both comparisons).
E–Selectin mRNA (Fig. 5.5a) was significantly up–regulated in the ileum and lungs of
HES 130/0.4 hemodiluted animals, as compared with the sham–operated ones (Mann–
Whitney p=0.048, and p=0.024, respectively). HES 200/0.5 hemodilution resulted in
significantly up–regulated E–Selectin mRNA in the ileum (Mann–Whitney p=0.024)
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when compared with control levels.
Sperman’s correlation Aggregation Index
post–infusion
P Selectin–ileum Correlation Coefficient –0.614
Sig. (2–tailed) 0.015
vWF–ileum Correlation Coefficient –0.539
Sig. (2–tailed) 0.038
eNOS–ileum Correlation Coefficient –0.486
Sig. (2–tailed) 0.066
vWF–liver Correlation Coefficient –0.546
Sig. (2–tailed) 0.035
P Selectin–lung Correlation Coefficient –0.582
Sig. (2–tailed) 0.023
P Selectin–heart Correlation Coefficient –0.496
Sig. (2–tailed) 0.060
vWF–heart Correlation Coefficient –0.632
Sig. (2–tailed) 0.011
Table 5.2: Statistical significant correlations found between RBC aggregation and
markers of endothelial activation in different organs
P–Selectin mRNA (Fig. 5.5b) was up–regulated significantly in the ileum and lungs
of both groups of hemodiluted animals (HES 130/0.4: ileum, lung Mann–Whitney
p=0.024; HES 200/0.5: Mann–Whitney ileum p=0.024, lung p=0.048). Additionally
for HES 200/0.5, the levels measured in the kidney reached significance when com-
pared with controls (Mann–Whitney p=0.048).
Endothelial nitric oxide synthase (eNOS) mRNA (Fig. 5.6) was up–regulated sig-
nificantly in the ileum and lungs in the HES 130/0.4 group (Mann–Whitney p=0.024
for both organs). In the HES 200/0.5 group, eNOS was up–regulated significantly
only in the lungs (Mann–Whitney p=0.024).
Correlations
A significant negative correlation was found between the RBC aggregation index and
levels of different markers of endothelial activation (Table 5.2).
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Figure 5.3: Hypoxic oxidative stress during 3 hours of acute IHD (a) Plasma Malon-
dialdehyde (MDA): The values are represented as mean (symbols) and standard error
of the mean (bars); (b) Hydrogen peroxide (H2O2) production in heart, lung, kidney,
liver, ileum tissue biopsies. Box plots graph data represent statistical values (see leg-
end Fig. 5.2). (c) Diaminobenzidine (DAB) staining of H2O2–producing cells (brown




Figure 5.4: von Willebrand factor (vWF) (a) vWF relative gene expression of in the
heart, lung, kidney, liver, ileum tissue biopsies after 3 h IHD. HES 130/0.4 Mann-
Whitney: ileum, kidney, lung and heart p=0.024, liver p=0.048. HES 200/0.5 Mann–
Whitney: ileum, kidney, and heart p=0.024, liver p=0.048, lung p=0.095. (b) vWF
plasma concentrations.
5.4 Discussion
Using our experimental model of acute isovolemic hemodilution we documented an im-
mediate pro–thrombotic and pro–inflammatory endothelial activation in heart, lung,
kidney, liver, and ileum, accompanied by a dramatic drop in erythrocyte aggregation.
Erythrocyte aggregability correlated significantly with markers of endothelial activa-
tion suggesting a causality effect.
The dynamic rheological properties of blood are defined mainly by the coordinated
self–organization of RBCs advancing in the arterio–venular direction21. RBC hyper-
aggregation is nowadays a generally recognized pathogenic factor, mainly due to clini-
cal observation of increased RBC aggregation during disorders associated with macro
and/or microvascular impairment, e.g. hypertension, diabetes mellitus, and chronic
venous insufficiency1,2,22. Hypo-aggregation of RBCs has been never described in a
pathologic context. Given the strong conditioning effect of RBC aggregation on blood
rheology, and thus on mechanic endothelial activation, we hypothesized low RBC ag-
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Figure 5.5: E–Selectin (a) and P–Selectin (b) relative gene expression of in the heart,
lung, kidney, liver, ileum tissue biopsies after 3 h IHD. E–Selectin: Mann–Whitney
HES 130/0.4: ileum p=0.048, lungs p=0.024; HES 200/0.5: ileum p=0.024. P–
Selectin: Mann–Whitney HES 130/0.4: ileum, lung p=0.024; HES 200/0.5: ileum
p=0.024, lung p=0.048, kidney p=0.048.
Figure 5.6: Endothelial nitric oxide synthase
(eNOS) relative gene expression in the heart,
lung, kidney, liver, ileum tissue biopsies after
3 h IHD. HES 130/0.4 Mann–Whitney: ileum,




gregation to be a pathogenic co–factor in endothelial activation during acute isov-
olemic hemodilution. To verify this hypothesis, we induced acute isovolemic hemod-
ilution in an “aggregating species”, the pig23, and investigated simultaneously the
hypoxic oxidative stress, red blood cell aggregation, and gene regulation of von Wille-
brand factor, E– and P–Selectin, and eNOS, as markers of endothelial activation.
Hemodilution, by reducing the number of circulating RBCs is expected to decrease
the oxygen–carrying capacity of blood and oxygen delivery to the tissue. However,
during moderate levels of hemodilution, reduction of the systemic hematocrit up to
50% is compensated with an increased blood flow velocity and decreased diffusional
oxygen exit from arterioles, resulting in augmented or maintained oxygen delivery to
tissue24. In addition, reduction of systemic Hct during intentional hemodilution is
not mirrored at the microcirculatory level, with capillary Hct sustained near control
levels25, thus maintaining tissue oxygenation.
In an experimental animal study, Deem en al.26 showed that acute normovolemic
hemodilution in healthy rabbits resulted in improved gas–exchange efficiency, as
shown by higher arterial PO2, lower alveolar–arterial PO2 difference, and increased
expired NO. They postulated that the improvement in oxygenation appeared to be
related to increased uniformity of pulmonary blood flow, and/or an increase in con-
centration of the vaso– and bronchodilator substance NO. Our data support this
assumption and consistently show an up–regulation of eNOS in the lung tissue during
acute hemodilution.
In our approach to detect changes in tissue oxygenation, we tested ex–vivo the mi-
tochondrial (dys)function in the vital organs (heart, lung, kidney, liver, ileum) of
hemodiluted animals, reflected by the production of reactive oxygen species when
oxidizing pyruvate and succinate. Thus, we aimed at detecting mitochondria that
were pre–exposed to hypoxia during hemodilution. The production of superoxide and
hydroxyl radicals, measured as H2O2 generation, was similar at all time points in
sham–operated and hemodiluted animals, which indicates that a similar hypoxic ox-
idative stress was present, and oxygen delivery to the tissue during hemodilution was
maintained. However, different organs seemed to have different exposure to hypoxia,
with a more profound mitochondrial dysfunction in abdominal organs (ileum, kidney,
liver) versus a preserved function of mitochondria in the myocardium and lung tissue.
The results found in tissue biopsies were mirrored by the plasma MDA determina-
tions, that showed similar relative increase in systemic lipid peroxidation products
during three experimental hours when hemodiluted animals and sham–operated an-
imals were compared. These results suggest that, at least in this animal model, the
perioperative stress and the anesthetic management are more important triggers of
oxidative stress in abdominal organs, than hemodilution per–se.
Because hypoxic stress seems to be negligible in this model of acute isovolemic hemod-
ilution, we suggest that the effects observed in endothelial activation were mainly due
to the drop in RBC aggregation.
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Erythrocyte aggregation and endothelium–dependent pro–thrombotic activation
First reliable observations on the involvement of red blood cell in the process of
clot formation were made by Turitto et al.27 who showed that under flow conditions
platelet adhesion and thrombus formation increase as hematocrit values increase from
10% to 70%. They hypothesized that red cells may have a significant influence on
hemostasis and thrombosis and the nature of this effect is apparently related to the
flow conditions. More recently, it was demonstrated that erythrocytes markedly in-
crease platelet eicosanoid formation, promote release of intracellular platelet granule
components, and induce recruitment of additional platelets from the microenviron-
ment into the forming thrombus28,29.
The data presented in this study suggest a new pathway for erythrocyte involvement
in clot formation: due to their function to aggregate, erythrocyte could modulate
endothelial activation with von Willebrand factor release, with a subsequent pro–
thrombotic effect. von Willebrand factor, which is stored in the endothelial Weibel–
Palade storage granules, has unique biomechanical properties and a critical biological
role as an adhesive protein. It mediates the adhesion of platelets to an injured vascu-
lar wall by binding on platelet surface and to collagen in the subendothelium. vWF
is one of the most potent activators of platelets. Activation of platelets causes them
to release additional vWF from their α–storage granules. Increased levels of plasma
von Willebrand factor contribute directly to thrombosis, impeding the normal flow of
circulating blood30. In our experiment, acute isovolemic hemodilution was followed
by a dramatic drop in red blood cell aggregation, which resulted in immediate pro–
thrombotic endothelial activation as shown by a systemic increase in plasma vWF
levels. Analysis of vWF mRNA expression levels in different vital organs showed a
concomitant up–regulation in heart, lungs, kidney, liver, and small intestine. In ad-
dition, low red blood cell aggregation states were significantly associated with high
vWF mRNA expression in heart, liver and ileum suggesting maybe a causality effect.
An understanding of how disturbed blood flow might lead to disease is now emerging.
Transferring this knowledge to a clinical relevant situation, as the one of the patients
undergoing on–pump cardiopulmonary bypass, we hypothesize that lower incidence
of thrombotic events could be achieved by avoiding excessive peri–operative hemodi-
lution.
Low erythrocyte aggregation and endothelium–dependent pro–inflammatory response
The presence of a high RBC aggregation proved already its relevance in diagnosing
the patients’ inflammatory status, using clinical observations of positive correlations
between enhanced RBC aggregation and high plasma levels of C–reactive protein and
fibrinogen31. There is also evidence that RBC hyper-aggregation enhances the ten-
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dencies of leukocytes to adhere to the postcapillary endothelium, a process recognized
as essential in inflammation. Pearson et al.32 reported that increased RBC aggrega-
tion was associated with increased adhesion of white blood cells to the endothelium,
possibly because of an enhanced probability of contact between leukocytes and the
postcapillary venular wall.
In this study we discovered that RBC hypo-aggregation, documented in our model
of acute isovolemic hemodilution, was statistically significant correlated with up–
regulation of endothelial adhesion molecules, E– and P–Selectins, especially in lungs
and small intestine. E– and P–Selectins belong to the Selectin family of adhesion
molecules and both have been reported to increase in circulation or at lesion sites
of several diseases reflecting endothelial activation. Selectins play important roles in
the inflammatory responses by facilitating leukocyte rolling and leukocytes activa-
tion33,34.
Translation of these data in clinical terms suggests that acute hemodilution may lead
to inflammatory stress of pulmonary capillaries. Subsequent diffusion limitation may
be expected. Similar, an increased inflammatory response in the small intestine asso-
ciated with acute hemodilution, might contribute to a loss in barrier function of the
intestinal mucosa with subsequent translocation of endotoxins and/or bacteria.
Conclusions
The data presented in this study show that acute isovolemic hemodilution definitely
triggers endothelial activation. Since the effects of hypoxic oxidative stress seem to be
negligible in this model, red blood cell hypo-aggregation could be considered as a new
pathophysiologic mechanism which could be held responsible for pro–inflammatory
and pro–coagulatory endothelial activation. We hypothesize that a reduced inflamma-
tory response and a lower incidence of thrombotic events will be achieved by avoiding
excessive peri–operative hemodilution during on–pump cardiopulmonary bypass.
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Organ Viability in Brain Dead Donors
Abstract
Cerebral injury leading to brain death (BD) causes major hemodynamic instabilities
in potential organ donors that may induce endothelial activation and affect post-
transplant graft function. We investigated pro–coagulatory and pro–inflammatory
effects of endothelial activation after BD with the subsequent oxidative stress and
renal tubular injury.
Brain death was induced by slowly inflating over a period of 30 minutes of a balloon–
catheter inserted in the extradural space. To assess time–dependant changes due to
BD, rats (n=30) were sacrificed 0.5, 1, 2, or 4 hours after BD–induction and compared
to sham–operated controls. E– and P–Selectins, fibrinogen mRNA were abruptly
and progressively up–regulated from 0.5 hours BD onwards; P–Selectin membrane–
expression was increased. Plasma von Willebrand factor was significantly higher after
2 hours and 4 hours BD, reflecting sustained platelet adhesion to the vascular–wall.
Oxidative stress in kidneys was detectable only late, being significantly increased in
2 hours, and 4 hours groups. Urine heart–fatty–acid–binding–protein and N–acetyl–
glucosaminidase, used as new specific and more sensitive markers of proximal and
distal tubular damage, were found to be significantly increased after 0.5 hours, and
maximum at 4 hours.
This study demonstrates immediate pro–coagulatory and pro–inflammatory activa-
tion of vascular endothelium after BD in kidney donor rats, proportional with the
duration of BD. Oxidative stress measurements pointed at ischemia/reperfusion in-
jury during protracted periods of BD. BD–related donor kidney damage was diagnosed




To date, the retrieval of kidneys in brain death donation is primarily dependent on
the logistics concerning the donor operation and the timing of the donor retrieval
team. Following previous work that clearly documented the detrimental effect of
a prolonged state of brain death, the clinicians recognize more and more the need
to retrieve organs as soon as possible, avoiding unnecessary prolongation of organ
procurement, in order to maintain viability.
Due to cerebral injury with subsequent brain death and loss of integrated neurological
function, the potential organ donor is exposed to major physiologic derangements1–3.
To maintain function, an aggressive, labor–intensive donor management is required
throughout the ICU stay.
Endothelial activation in brain dead donors has gained lately considerably attention in
the discussion concerning the pathological effects of brain death on donor organ qual-
ity prior to retrieval. The vascular endothelial phenotype is known to change dramat-
ically under various pathophysiologic conditions, expressing cell adhesion molecules,
releasing cytokines and substrates that promote thrombosis and inflammation. Under
hemodynamic and rheological unstable conditions endothelial cells have demonstrated
their ability to sense variations in mechanical forces such as shear stress, that appear as
a consequence of blood flow and viscosity alterations4,5. Studies investigating the re-
sponse of flow–adapted endothelial cells have shown that variation in shear stress was
followed within minutes by membrane depolarization, increased intracellular Ca2+,
release of nitric oxide, reactive oxygen species, von Willebrand factor, prostacyclins,
tissue factor, tissue plasminogen activator, adhesion molecules and chemoattractant
proteins6,7. Previous studies suggest that an immune activation with increased en-
dothelial cell activation and immediate early gene expression occurs after brain death
induction8–10. Moreover, the expression of endothelial adhesion molecules (inter-
cellular adhesion molecule–1 and vascular cell adhesion molecule–1) and the influx
of leukocytes in the kidney is shown to occur faster and be more profound when
hemodynamic instability in the brain dead donor is not corrected11. Furthermore,
the non–specific inflammatory response activated during brain death was shown to
accelerate acute rejection of organs procured from brain dead donors12.
As an original contribution, this study aims to analyze and document the time se-
quence for the most early progression post–BD induction of pro–inflammatory and
pro–coagulatory endothelium activation, oxidative stress and organ viability in brain
dead rat kidney donors. We hypothesized that activated endothelium in the brain
dead donor will express and release both pro–inflammatory and pro–coagulatory fac-
tors into circulation that will mediate inflammation, platelet adhesion and possibly
promote microthrombosis. In addition, we expect that due to activation of endothe-
lium and hypoxic stress, the oxidative stress and brain death–related organ dysfunc-
tion will arise early after BD–induction.
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6.2 Methods
Animals and Experimental protocols
The experiments were in accordance with institutional and legislator regulations and
approved by the local Committee for Animal Experiments. A total of 30 rats (adult
male Fisher 344 rats, 260–300 g, Harlan, Zeist, The Netherlands) were studied. To
assess time–dependant changes due to brain death (BD), the animals (n=6 per group)
were sacrificed after 0.5, 1, 2, or 4 hours after induction of BD. Controls (n=6)
consisted of sham–operated rats using a trepanation, however without inserting the
balloon catheter to cause cerebral injury. Sham–operated rats remained ventilated
and under anesthesia for half hour. All rats were sacrificed after completion of the
experiment.
Surgical procedures
Animals were anesthetized using oxygen/nitrous oxide/isoflurane 5%; isoflurane was
reduced to 2% after anesthesia induction. Corporeal temperature was maintained
at 37◦ C. After frontolateral trepanation lateral of the bregma, a balloon catheter
(0,75ml 4F EMB, Edward Lifesciences ref 120404F) was inserted and slowly inflated
over a time period of 30min with 0.5ml water using a syringe pump. After ap-
proximately 27min., the rats became apneic and were mechanically ventilated (12–
15mmHg relief, 1–5mmHg positive end–expiratory pressure, Zoovent CWC600AP;
Triump technical services Ltd, United Kingdom.) through a tracheostoma (47/min
frequency, 40% inspiration phase). After BD induction, anesthesia was stopped
and the rats were ventilated with 100% O2 for 30min; subsequently ventilation was
switched to O2/air. Ten minutes before retrieval of organs, the rats were ventilated
with oxygen/nitrous oxide/isoflurane 0.5% to allow muscle relaxation and laparo-
tomy. Brain death was confirmed by the absence of brain stem reflexes, the pupillary
reflex, the corneal reflex and an apnoea test. The mean arterial pressure was continu-
ously measured and recorded using an intra–arterial blood pressure sensor (Truwave,
Edwards Lifesciences, Irvine, USA, recorder Labview 5.1; National instruments Co.,
Austin, USA). A MAP lower than 80mmHg was corrected by colloid infusion (10%
hydroxyethyl starch, HAES, 37◦ C). Kidneys were retrieved after a flush with saline
through the abdominal aorta, snap frozen in liquid nitrogen and stored at –80◦ C.
To study the pro–inflammatory response as a result of the induction of brain death
we investigated endothelial gene expression of E– and P–Selectin (real time RT–
PCR), and membrane expression of P–Selectin (immunohistochemistry). The pro–
coagulatory response during brain death was assessed by investigating circulating




P–Selectin staining (Table 6.1) was performed on cryosection, acetone fixed slides. A
semi–quantitative evaluation of the P–Selectin endothelial expression was performed
in a double–blind fashion by two independent pathologists in parallel. The semi–
quantitative scoring system used for grading P–Selectin endothelial staining had a
scale of 0 to 3 arbitrary units: 0 (none), 1 (mild), 2 (moderate), 3 (intense).
In addition, a P–Selectin positive platelets counting was performed, considering each
time 30 randomly chosen glomeruli per slide and reporting the results as average
platelet number per glomeruli.
Antibody Type Dilution Incubation Company
time
primary rabbit polyclonal antibody 1:25 1 hour BD Pharmigen
antibody against rat P–Selectin
2nd antibody goat anti–rabbit 1:100 30min Vector Laboratories
immunoglobulin antiserum BA–1000
3rd antibody peroxidase conjugated 1:100 30min Vector Laboratories
rabbit anti–goat polyclonal BA–1000
antibody
Table 6.1: Immunohistochemical staining of P–Selectin on cryostat section, acetone
fixed slides of rat kidney tissue. Antibodies were diluted in PBS containing 1% bovine
serum albumin; 1% normal rat serum was added to the secondary antibodies. The
peroxidase activity was developed using 3–amino–9–ethylcarboxide (AEC)/H2O2.
Real time reverse transcriptase PCR for Aα and Bβ fibrinogen chains, E– and P–
Selectin gene expression were assessed using amplification primers designed with
Primer Express software (Applied Biosystems, Foster City, USA). The primers se-
quence and product sizes are included in Table 6.2. Amplification and detection were
performed with an ABI Prism 7900–HT Sequence Detection System (Applied Biosys-
tems, Foster City, USA) using emission from Sybr green. All assays were performed in
triplicate. Gene expression was normalized with the mean of β–actin mRNA content
and calculated relative to controls using the relative standard curve method. Results
were finally expressed as 2−∆CT (CT threshold cycle).
Plasma vWF concentrations were measured by ELISA (Coamatic von Willebrand
Factor kit, Nodia BV, Amsterdam, The Netherlands).
Detection of oxygen radicals production
A fluorophore–nitroxide was used to image oxygen radicals generated during ex–vivo
incubation of kidney biopsies13–15. Both superoxide and hydroxyl radicals were con-
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Gene Forward primer Reverse primer Size
sequences sequences
Aα 5’-GCTCTGTCCTCAGGGTTGAATTA-3’ 5’-GCCTACCCGGAAGTGGTACTC-3’ 73 bp
fibrinogen
Bβ 5’-CGGCGGCTGGTGGTATAA-3’ 5’-CTGTAAAGGCCACCCCAGTAGTAT-3’ 71 bp
fibrinogen
E–Selectin 5’-GTCTGCGATGCTGCCTACTTG-3’ 5’-CTGCCACAGAAAGTGCCACTAC-3’ 73 bp
P–Selectin 5’-TCTCTGGGTCTTCGTGTTTCTTATCT-3’ 5’-GTGTCCCCCTAGTACCATCTGAA-3’ 71 bp
Table 6.2: Primers sequence and product sizes used for Real time reverse transcriptase
PCR for Aα and Bβ fibrinogen chains, E– and P–Selectin gene expression.
verted and measured as H2O2 16. Fluorescence was measured with a multilabel counter
(390 nm excitation and 510 nm emission filters, Victor2, EG&G Wallac, Turku, Fin-
land). Standard curves were obtained by adding known amounts of H2O2 to the
assay medium. A separate standard curve was prepared including stepwise diluted
hemoglobin. The linear relationship between hemoglobin concentrations and fluores-
cence signal was used to correct for the hemoglobin signal quenching. Hemoglobin con-
centration in the supernatant of the incubated biopsies was measured by the method
of Harboe17. H2O2 concentration were corrected for the dry weight of the biopsy.
Kidney injury biomarkers
Urine heart–type fatty acid binding protein (H–FABP) – ELISA (HyCult Biotech-
nology B.V., Uden, The Netherlands). The kit has a minimum detection limit of
0.4 ng/ml and a measurable concentration range of 0.4–25 ng/ml. Samples were di-
luted 10 times before measurement.
Urine N–acetyl–glucosaminidase (NAG) – modified enzyme assay according to Lock-
wood18 at pH 4.5 and corrected for non–specific conversion (HaemoScan, Groningen,
The Netherlands).
Both NAG and H–FABP urine concentrations were corrected for dilution using urine
creatinine values.
Statistical Analysis
The statistical analysis was performed using SPSS (Statistical Package for the So-
cial Sciences).
Before analysis, the data was tested for distribution according to Kolmogorov–Smirnov
goodness of fit test. To investigate differences between groups, continuous variables
were compared by means of parametric (Student T Test) or nonparametric tests
(Mann–Whitney). A p value smaller than 0.05 was considered statistically signifi-





The blood MAP measured prior to balloon inflation was 116±3mmHg. After 10±1
minutes from inflation, the blood pressure decreased sharply and remained in a hy-
potensive state (59±2mmHg) for another 11±1minutes. At the end of the brain death
induction the recording showed a sharp peak (142±5mmHg). 10.31±0.90minutes
after the onset of brain death the blood pressure decreased to 46±1mmHg. Sub-
sequently, a peak in blood pressure occurred, followed by a plateau at levels above
100mmHg (Fig. 6.1).
Basal heart rate was 356±8 beats/minute (bpm). During inflation of the balloon a
slight increase in heart rate was observed. After the peak in MAP had occurred, a
decline in heart rate to its basal level was observed.
Donor management.
During mechanical ventilation the MAP remained at levels above 80mmHg. Five
animals needed colloid infusion (3ml/kg) to correct for hypotension. All five re-
sponded well with a return to basal levels within three minutes. Thirty minutes after
BD induction, the apnea test was found positive for all animals, with no spontaneous
respiration. Corneal and pupillary reflexes were absent as well.
Figure 6.1: Mean arterial pressure (MAP) monitoring during and after progressive
brain death induction. The values are represented as mean (symbols) and standard
error of the mean (bars).
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Figure 6.2: Concentrations of
von Willebrand Factor (vWF) in
plasma of the brain dead rats af-
ter 0.5, 1, 2, or 4 hours since
brain death (BD) induction. The
controls are represented by sham–
operated animals. Box plots
graph data represent statistical
values. The boundary of the box
closest to zero indicates the 25th
percentile, the line within the box
marks the median of 6 measure-
ments, and the boundary of the
box farthest from zero indicates
the 75th percentile. Whiskers
above and below the box indi-
cate the 90th and 10th percentiles.
Symbols ◦ and ? represent the out-
liers and extremes, respectively.
++, + differences between BD
group and controls group are sig-
nificant at the 0.01 and 0.05 level,
respectively.
Plasma von Willebrand factor (Fig. 6.2)
In the 0.5 h BD and 1 h BD groups, plasma vWF values remained in the normal range
or increased moderately but only in sporadic cases. After 2 h of BD, however, vWF
increased sharply, reaching significant different values in the 2 h BD (207±52%) and
4 h (248±88%) groups as compared with controls (Mann–Whitney p=0.002 for both
time points).
Fibrinogen mRNA expression in rat kidney tissue (Fig. 6.3a,b)
Both Aα and Bβ fibrinogen chain mRNAs expression in renal tissue were highly and
significantly up–regulated after 2 hours (Aα fibrinogen 22±12.9 fold induction, Mann–
Whitney p=0.01; Bβ fibrinogen 7.8±4.6 fold induction, Mann–Whitney p=0.016) and
4 hours (Aα fibrinogen 86±36 fold induction, Mann–Whitney p=0.004; Bβ fibrinogen
54.6±29.6 fold induction, Mann–Whitney p=0.004) of brain death.
E–Selectin mRNA expression in rat kidney tissue (Fig. 6.4a) was up–regulated early,
reaching already at 0.5 h post–BD folds ten times higher (10±3.5, Mann–Whitney
p=0.004) than control values. The expression continued to increase in time, so
114
Chapter 6
Figure 6.3: Relative gene expression (mRNA fold induction on a logarithmic scale)
of Aα (a) and Bβ (b) fibrinogen chains in the kidney tissue of brain-dead rats after
0.5, 1, 2, or 4 hours since brain death (BD) induction. The controls are represented
by sham–operated animals. Box plots graph data represent statistical values (see Fig.
6.2).
that the relative gene expression was 13.6±3.7 (fold induction) at 1 h of BD (Mann–
Whitney p=0.002). After 2 h of BD the E–Selectin gene was strongly up–regulated
(54.7±14.2 fold induction, Mann–Whitney p=0.002). The animals brain dead for 4 h
had the most important up–regulation in E–Selectin gene expression (135.9±56.2 fold
induction, Mann–Whitney p=0.002).
P–Selectin mRNA expression in rat kidney tissue (Fig. 6.4b) was significantly up–
regulated starting with 1 h of BD (12.4±3.1 fold induction, Mann–Whitney p=0.002).
P–Selectin gene expression increased progressively starting with 2 h BD (58.9±17.6
fold induction, Mann–Whitney p=0.002), with maximum values at 4 h BD (92.4±26.8
fold induction, Mann–Whitney p=0.002).
P–Selectin Immunohistochemistry (Fig. 6.5a,b)
P–Selectin endothelial membrane expression was absent in control samples (Fig. 6.5a),
while in BD animal samples it started to be observed as early as half–hour after BD
induction. The expression continued to increase, so that at 4 hours BD P–Selectin
was omnipresent on the surface of vascular endothelial cells in the renal tissue (Fig.
6.5b). The arbitrary P–Selectin expression score at 4 h BD (2.2±0.2) was significantly
higher (Mann–Whitney p=0.004) than the score in controls (0.33±0.22). Besides en-
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Figure 6.4: Relative gene expression (mRNA fold induction on a logarithmic scale)
of E–Selectin (a) and P–Selectin (b) in the kidney tissue of brain dead rats after 0.5,
1, 2, or 4 hours since brain death (BD) induction. The controls are represented by
sham–operated animals. Box plots graph data represent statistical values (see Fig.
6.2).
dothelial expression, P–Selectin was stained in platelets trapped in the glomeruli,
after washing–out the organs. After 1 hour of BD the platelet count per glomeruli
(3.09±0.6 platelets/glomeruli) was significantly higher (Mann–Whitney p=0.04) that
the number of platelets trapped in the controls samples (0.96±0.6 platelets/ glomeruli).
Oxidative stress (Fig. 6.6)
H2O2 production in the kidney tissue increased non-significantly during the first hour
of brain death (0.5 h BD 18.6±9.6; 1 h BD 51.6±21.4). H2O2 values became signifi-
cantly higher than control values after 2 h BD (115.7±32, Mann–Whitney p=0.004).
After 4 h BD, H2O2 production (401.7±95, Mann–Whitney p=0.004 vs. controls)
reached values about 30 times higher than control values and 8 times higher than the
values at 1 h BD.
Tubular renal injury (Fig. 6.7a,b)
Heart–type fatty acid binding protein (H–FABP), was below detection limits in plasma
of all animals, showing minimal release into the circulation of this protein from heart,
skeletal muscle, lungs, and brain. H–FABP was also below detection limits in the
urine of sham–operated animals. Urine H–FABP concentrations started to rise above
detection limits to as early as 0.5 h BD (14.2±5.06 ng/mmol creatinine) and continued
to increase after 1 h BD (21.6±5.4 ng/mmol creatinine). Urine H–FABP concentra-
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tions at 2 h and 4 h BD were 51.3±7.8 ng/mmol creatinine, and 52.6±8.8 ng/mmol
creatinine respectively.
N–acetyl–glucosaminidase (NAG) urine concentrations started to increase
non–significantly after 0.5 h of BD, reaching significant higher values 1 h after BD
induction (4.2±1mU/mmol creatinine, Mann–Whitney p=0.01) when compared with
control values. Urine NAG continued to increase, reaching the maximum at 4 h BD
(2 h BD 6.6±0.2mU/mmol creatinine, Mann–Whitney p=0.002 vs. controls; 4 h BD
10±2.3mU/mmol creatinine, Mann–Whitney p=0.002 vs. controls). Urine H–FABP
and NAG concentrations correlated significantly (Spearman’s correlation coefficient
0.733, sig.<0.001).
6.4 Discussion
The present study demonstrates that brain death induces immediate pro–inflammatory
and pro–coagulatory activation of vascular endothelium in rat donor kidneys, which is
proportional with the duration of brain death. BD–related donor kidney damage and
oxidative stress became subsequently evident, with enhanced injury with prolonga-
tion of the BD state. For this study we have used a simple, reproducible and clinical
relevant animal brain death rat model in which induction of brain death was obtained
by gradual expansion of an intracranial balloon over 30 minutes time period19. The
model represents an adjustment of brain death models published before by Tilney et
al.20, where the brain death induction was performed over a period of 15 minutes.
The model described here is closely related to the clinical condition of BD due to
intracranial haemorrhage, nowadays the most frequent diagnosis of organ donors.
This approach stands in contrast to previous studies by our group and by others,
where brain death was induced using an explosive onset model with massive brain
destruction and critical hypotensive periods reflecting major head trauma. The major
benefit of pseudo–stable hemodynamics in the brain death period is that no inotropic
medical support is required, which is known to have an effect on organ injury and
could bias results in studies concerning brain death related organ damage. Because
intracranial hypertension often develops gradually in the clinical setting, we feel that
the clinical situation is better represented by this model.
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Figure 6.5: Immunohistochemistry using P–Selectin labelled antibody to stain (brown
coloration) activated endothelial cells and trapped platelets in rat kidney tissue of a
sham–operated animal (a) and a 4 hours brain death animal (b).
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Figure 6.6: Oxidative stress, as quantified by ex–vivo H2O2 generation in rat kidney
tissue after 0.5, 1, 2, or 4 hours since brain death (BD) induction. The controls are
represented by sham–operated animals. Box plots graph data represent statistical
values (see Fig. 6.2).
Figure 6.7: Renal tubular injury, as quantified by heart–type fatty acid binding pro-
tein (H–FABP, distal tubular injury, (a) and N–acetyl–glucosaminidase (NAG, proxi-
mal tubules injury, (b) in the urine of rats after 0.5, 1, 2, or 4 hours since brain death
(BD) induction. The controls are represented by sham–operated animals. Box plots
graph data represent statistical values (see Fig. 6.2).
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Hemodynamics
After the onset of brain death the blood pressure decreased to 45mmHg, most likely
due to changes in the vasomotor tone caused by an imbalance between sympathetic
and vagal stimulation of the rostral ventrolateral medulla. A gradual increase in
blood pressure was observed afterwards, considered a physiological response (Cushing
response) to increased intracranial pressure. Subsequently, a peak in blood pressure
occurred, followed by a plateau at levels above 100mmHg. A possible explanation
for pseudo–normotension instead of the frequently reported hypotension is that a
gradually expanding intracranial mass allows the brain to accommodate, with less
distortion in the remaining rostral ventrolateral medulla21.
Recent studies reported strong evidences of causality between hemodynamic impair-
ment and the systemic inflammatory response. Even if the mechanisms remain un-
known, Avlonitis et al.22 concluded that the sympathetic discharge triggered systemic
inflammation, which was further enhanced by neurogenic hypotension.
The endothelial wall has demonstrated abilities to sense small hemodynamic, rhe-
ologic and humoral variations with prompt responses to various mechanical (shear
stress, viscosity) and inflammatory (interleukins, TNF–α) stimuli. Once activated,
the endothelial cells change phenotype to release and synthesize on–demand several
vasoactive factors and factors involved in hemostasis and thrombolysis, such as nitric
oxide, prostacyclins, vWF, tPA, tissue factor, adhesion molecules and chemoattrac-
tant proteins23. In our study, we approached endothelial activation by studying the
acute release of von Willebrand factor, and expression of E– and P–Selectin. As
an additional indicator of increased thrombogenicity we studied the gene expres-
sion induction of Aα and Bβ fibrinogen chains. Oxidative stress and kidney injury
biomarkers were included in the investigation in order to quantify the clinical relevant
end–effect of brain death on organ viability.
Von Willebrand Factor (vWF)
von Willebrand Factor, stored in the endothelial Weibel–Palade storage granules, has
unique biomechanical properties and a critical biological role as an adhesive protein; it
mediates the adhesion of platelets to injured vascular wall by binding on platelet sur-
face and to collagen in the subendothelium. vWF is one of the most potent activators
of platelets, causing them to release additional vWF from their α–storage granules.
Increased levels of plasma von Willebrand factor contribute directly to thrombosis,
impeding the normal flow of circulating blood24.
Allograft survival, arteritis and irreversible acute or sub–acute rejection have been
reported to be highly associated with intensive staining for vWF on endothelial cells
and platelets aggregating in large, medium and small arteries25. Furthermore, in-
creased plasma vWF represents a major risk factor for atherosclerosis and vascular
disease26. It has to be considered as a potential predictor for the development of the
alloatherosclerosis of donor organ vessels and chronic rejection through endothelial
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injury–induced proliferation of smooth muscle cells.
In our experiment, plasma von Willebrand factor started to rise prominently and
significantly two hours after brain death induction, with maximum values after four
hours of brain death in this rat model. The elevation in plasma level was significant,
reaching levels of more than two times higher than in sham–operated controls.
Fibrinogen
Fibrinogen is a plasma protein whose principal function is exerted through its con-
version into soluble fibrin during the process of blood coagulation. In addition, by
virtue of its capacity to support platelet aggregation, fibrinogen plays a dual role in
thrombus formation. Historically, fibrinogen is known to be synthesized exclusively
by hepatocytes and stored in α–granules of megakaryocytes27,28. In light of the re-
cently published studies, it is clear that epithelial cells of extrahepatic origin are able
to express fibrinogen genes and to secrete intact fibrinogen. Baumheuter et al.29
found that in addition to being present in the liver, fibrinogen can be expressed on
epithelial cells in the kidney, intestine, and spleen. Haidaris30 demonstrated that,
while hepatocytes synthesize and secrete fibrinogen constitutively and on demand,
lung epithelial cells synthesize and secrete little intact fibrinogen constitutively. How-
ever, after induction with proinflammatory mediators, significant levels of fibrinogen
are synthesized and secreted.
Our experiments conclusively demonstrate the expression of both Aα and Bβ fibrino-
gen chains in the kidneys of brain dead rats. Aα and Bβ fibrinogen chain mRNAs,
while poorly expressed in kidneys of sham–operated rats, were abruptly and pro-
gressively up–regulated from two hours of brain death onwards, providing evidence
that kidneys contribute to changes in acute phase proteins during brain death. The
synthesis of fibrinogen in extrahepatic tissue may be triggered in the context of a sys-
temic inflammatory response to brain death. Furthermore, fibrinogen up–regulation
might attempt to restore homeostasis by contributing to wound repair or extracellular
matrix remodelling after injury.
E– and P–Selectins
E– and P–Selectins belong to the Selectin family of adhesion molecules and play an
important role in the inflammatory response, eliciting leukocyte rolling. Both P– and
E–Selectins are reported to be critically involved in the early development of acute
graft rejection31. Up–regulation of gene expression and membrane E– and P–Selectin
expression was described before in models of explosive brain death induction, and in
recipients of transplanted grafts from brain dead donors32,33. A P–Selectin positive
expression in a donor biopsy present before transplantation has been shown to predict
a high risk of acute rejection34.
Complementary to the existing data on E– and P–Selectins in brain dead donors, we
show an abrupt and progressive up–regulation of E– and P– Selectins starting very
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early in the course of brain death, already after half hour from induction and persisting
until four hours later. As verified by immunohistochemistry, mRNA up–regulation
was closely followed by endothelial cells membrane expression of synthesized selectins.
P–Selectin was detected on the surface of endothelial wall starting with half hour of
brain death. The intensity and distribution of the staining increased with time, so
that in the four hours brain death group P–Selectin was ubiquitously present on the
surface of the vascular endothelium. In addition to expression on endothelial cells,
P–Selectin labelling revealed the presence of an increased number of platelets in the
kidney glomeruli. Since all organs were washed–out consistently and in a standardized
manner, a progressively increasing number of platelets in time might reflect enhanced
platelet adhesion to the vascular endothelium. These findings are consistent with
the data showing increased plasma vWF levels in brain dead rats, a factor known to
support platelet adhesion to the vascular wall.
Clinical and experimental studies investigating the therapeutic role of administrating
recombinant proteins targeted against P–Selectin showed a marked improvement in
graft outcome, blocking neutrophil and lymphocyte infiltration and thus decreasing
inflammatory response and ischemia–reperfusion injury35,36. Different therapeutic
approaches were studied, administrating the P–Selectin blocker to the donor (after
6 h BD–kidneys perfused in situ, or 3 h BD–intravenous injection) or to both donor
and recipient (after 3 h BD intravenous injection to the donor and at the time of
reperfusion in the recipient). The results of the present investigation show E– and
P–Selectin up–regulation and expression already after half hour from brain death dec-
laration, pointing out the need to introduce blocker therapy a lot earlier in the course
of brain death donation.
Oxidative stress
Different authors have found reactive oxygen species (ROS) formation to be a reli-
able predictor of allograft rejection, especially in the early ischemic post–transplant
period37. High levels of ROS are also known to contribute to the development
of atherosclerosis of organ donor vessels and chronic rejection through endothelial–
injury–induced proliferation of smooth muscle cells38.
In our approach, we have tested ex–vivo the mitochondrial (dys)function in kidney
tissue of brain dead animals, as reflected by ROS–production when oxidizing pyru-
vate and succinate. General evidence for the source of ROS production points at
dysfunctional mitochondria in cells pre–exposed to hypoxia–reoxygenation, activated
endothelial cells and infiltrated inflammatory cells39–41. The production of super-
oxide and hydroxyl radicals, measured as H2O2 generation, started to increase one
hour after BD induction, reaching levels significantly higher only two hours after brain
death induction, and maximum values after four hours. It is important also to analyze
these results in the time sequence presented here: oxidative stress arises only after the
pro–inflammatory response during brain death. This observation might solve a very
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important mechanistic issue – it is the inflammatory response and not the hypoxia
that is triggered first after brain death!
Kidney injury (bio)markers
To date, sensitive and specific biomarkers to assess donor organ viability are lacking.
Non–invasive and easy accessible biomarkers assessing renal tubular injury are heart–
type fatty acid binding protein (distal tubular injury) and N–acetyl–glucosaminidase
(proximal tubular injury). Both markers were included in this study to investigate
BD–derived renal damage.
Heart–type fatty acid binding protein (H–FABP) is a cytosolic protein abundant in
the myocardium, but also expressed in kidneys (distal tubules), skeletal muscles, lung,
and brain42. H–FABP has been associated before with early release following injury
of distal renal tubules43.
The levels below detection limit of this marker we found in the plasma of all animals
proved a primary release of urinary H–FABP from kidneys, with minimal release of
this protein from heart, skeletal muscle, lungs or brain in this model.
Urine N–acetyl–glucosaminidase (NAG) release signifies renal damage localized at
the level of proximal tubules. Urinary NAG has been measured in renal transplant
recipients soon after transplantation to predict acute rejection or chronic allograft
nephropathy44.
In our study, H–FABP and NAG urine concentrations reached significantly higher val-
ues as early as half hour and one hour, respectively, after brain death induction, when
compared with sham–operated animals. A highly positive correlation was documented
between the two renal tubule markers, suggesting a similar pathophysiologic mech-
anism and consolidating the diagnose of renal tubular damage during brain death.
Both proximal and distal renal tubules injuries were early diagnosed in the course of
brain death, even before an oxidative hypoxic stress (as shown by H2O2 generation)
took place. The trigger responsible for this early organ injury might be represented by
the inflammatory response, shown in our experiments to arise immediately after brain
death induction. The values continued to increase progressively during the studied
period, which points at an enhanced loss of organ viability with prolongation of the
state of brain death.
In summary , this study demonstrates immediate pro–inflammatory and
pro–coagulatory activation of vascular endothelium after BD in kidney donor rats,
proportional with the duration of BD. The mRNA expression of the adhesion molecules
E– and P–Selectins, known to promote inflammation by mediating rolling and extrava-
sation of leukocytes, were up–regulated soon (half hour) after brain death induction.
Additionally, platelet trapping, most probably due to platelet adhesion to the vas-
cular wall, was visualized as early as half hour after inducing the brain death. To
support arguments for an increased thrombogenicity status in brain dead donors, we
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report a significant increase in plasma levels of von Willebrand factor, that reflects
sustained platelet adhesion to the vascular wall. Additionally we show an increased
mRNA expression of Aα and Bβ fibrinogen, which will promote extracellular matrix
remodelling and thrombogenesis by forming the fibrin network and mediating platelet
adhesion. We found for the first time that the brain death related systemic inflam-
matory response induces an extrahepatic Aα and Bβ fibrinogen synthesis. Oxidative
stress started to increase after induction of brain death, and became significant only
after two hours of BD. Our data point at an ischemic/hypoxic oxidative stress, as
main cause of oxygen radicals production, during protracted periods of brain death.
BD–related donor kidney damage, reflected by urine concentration of heart–type fatty
acid binding protein and N–acetyl–glucosaminidase, was diagnosed as early as half
hour in renal tubules, with enhanced loss of viability when the state of brain death
was prolonged.
These data suggest that early anti–inflammatory and anti–coagulatory therapeutic
intervention should be instituted after declaration of brain death, aiming to reduce
endothelial activation, prevent platelet adhesion, and possibly slow down an ongoing
donor organ deterioration.
Our study also indicates that without effective cytoprotective agents, organ retrieval
should not be postponed longer than absolutely necessary, to prevent further injury
and loss of viability of scarce donor organs.
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Abstract
Study Objectives
To date, the standard preservation solution used during organ procurement and
preservation of most organs is the University of Wisconsin (UW) solution. Despite
its superiority over other cold storage solutions, the inclusion of hydroxyethyl starch
(HES) as one of the components of the UW solution has been both advocated and
denied. The aim of this study was to determine the effect of HES on red blood cell
aggregability and to correlate aggregation parameters with HES molecular weight.
Methods
Human RBC aggregability and deformability were investigated in vitro, at 4◦ C, with
a Laser–assisted optical rotation cell analyzer. The study of red blood cell aggrega-
tion in a binary HES–HES system gave an indication about the nature of HES–RBCs
interactions. Bright field microscopy and atomic force microscopy were used to mor-
phologically characterize the aggregates size and form.
Results
High molecular weight HES and UW solution had a potent hyper-aggregating effect;
low molecular weight HES had a hypo-aggregating effect on RBC. RBC aggregates
were of large size and their resistance to dissociation by flow induced shear stress was
high.
Conclusions
Our in vitro experiments conclusively showed that the physiological function of red
blood cells to form aggregates is significantly affected in the presence of hydroxyethyl
starch. The use of high molecular weight HES in UW solution accounts for extended
and accelerated aggregation of erythrocytes that may result in stasis of blood and




Reperfusion injury after cold ischemic storage prior to organ transplantation plays
a critical role in the occurrence of primary nonfunction and delayed graft function1
which have remained major problems in liver transplantation2. The viability of organ
grafts depends on several factors such as cold ischemia time, the perfusion procedure,
preservation methods and reperfusion quality. The efficacy of perfusion during the
initial wash–out procedure, however, has to be considered a major determinant of
functional recovery after transplantation3.
Preservation solutions have been designed to ameliorate the adverse physiological and
biochemical effects of ischemia under hypothermic conditions. Three principles are
important in effective cold storage. First, the vascular wash–out during harvest should
rapidly cool the organs, remove the blood and allow balance between the cold storage
solution and the tissue. Second, the cold storage solution should prevent cell swelling
and interstitial edema formation by including substances that are osmotically active
and impermeable to the cell. Impermeants and saccharides achieve homeostasis of the
intracellular water content. Homeostasis of the interstitial compartments is achieved
by counteracting a hydrostatic force during the initial wash–out using colloids. The
intravascular fluid compartment does not need an effective component in static cold–
storage. Third, the cold storage solutions should prevent excessive cellular acidosis
by containing sufficient concentration of hydrogen–ion buffer, histidine or citrate4,5.
Since its introduction by Belzer et al. in the late eighties, the University of Wisconsin
(UW) solution has become the standard solution for the preservation of most organs
in transplantation. Despite the fact that UW solution made extended cold preser-
vation feasible, some studies have demonstrated that prolonged cold ischemic time
of hepatic allografts enhance bacterial infection6, cause biliary and hepatic artery
complications7,8 and increase the frequency of primary non function posttransplant9.
The inclusion and importance of the colloid hydroxyethyl starch (HES) as one of the
components of the UW solution has been both advocated and denied. HES prevents
interstitial edema and has a beneficial effect on matrix metallo–proteinases10 but at
the price of a higher solution viscosity. Due to the presence of HES, the viscosity of
UW solution at 4◦ C increased by a factor of 2.5 when compared with the viscosity
of the same solution at 37◦ C11. Analyzing the effect of HES on the rheological prop-
erties of blood, Corry and collaborators have drawn the attention to the aggregating
effect of HES on RBC12.
The pathogenic potential of RBC aggregates prevails within the microcirculation,
leading to altered flow dynamics and microvessel occlusive events13,14. Further-
more, cell–cell interaction between platelets and erythrocytes can significantly en-
hance platelet reactivity with a prothrombotic effect15,16. There is also strong evi-
dence that RBC aggregation greatly enhances the tendencies of leukocytes to adhere
to the postcapillary endothelium, a process recognized as essential in inflammation17.
Considering these aspects, HES induced–RBC aggregability could significantly influ-
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ence the quality of organ preservation, increase damage due to ischemia/reperfusion
and affect the outcome after transplantation.
This study concerns an extension to a previous observation made by our group18 that
signalled a poor initial wash–out of rat liver when using UW solution. We concluded
at that time that this effect is most likely the consequence of aggregate–formation
induced by HES in combination with rat blood. The present study will reveal a
detailed evaluation of the extent and kinetics of HES–induced human RBC aggrega-
tion, as well as a morphological characterization of these aggregates. In addition, to
explain the mechanisms involved, red blood cell aggregation has been studied in a
binary HES–HES mixture.
7.2 Methods
RBC aggregability and deformability were investigated in vitro with a Laser–assisted
optical rotation cell analyzer (LORCA R&RMechatronics, Hoorn, The Netherlands)19,20.
This instrument, based on the ektacytometric principle, is equipped with a video
camera for detection of the laser diffraction pattern, a thermostation unit and an
ellipse–fit computer program calculating the Elongation Index and Aggregation Index
(AI). The experiments were performed at 4◦ C, after in vitro admixture of UW/HES
solutions with human fresh blood from healthy volunteers (n=8), drawn from the
antecubital vein into 0.1mM ethylenediamine tetracetic acid.
Three commercially available HES solutions (6% in 9 g/l sodium chloride) were se-
lected based on their molecular weight and substitution ratio: HES 450/0.7
(Mw=450 kDa, MS=0.7), HES 200/0.5 (Mw=200 kDa, MS=0.5), HES 130/0.5
(Mw=130 kDa, MS=0.5). Phosphate Buffered Saline (PBS, pH 7.4, 300mOsm/kg)
was used as buffer fluid for the HES solutions. The final concentration of the HES
solutions was 5%, pH=7.4, isotone. The University of Wisconsin solution was used
as commercially available (5% HES with a molecular weight cut off range of 100–
1000 kDa and a mean of 250 kDa). As a negative control, we tested the effect of a
HES–free UW solution (prepared according to the UW–recipe without the addition
of HES).
The samples were prepared not more than one hour before the measurements took
place, the mixing ratios were: blood:HES = 5:1, 7:1, 10:1; blood:UW / HES–free UW
= 5:1 , 2:1. The hematocrit (Hct) was adjusted in all the samples to a constant value
of 38%. A control (red blood cells suspended in autologous plasma, 38% Hct) was
considered for every set of samples.
Aggregation of human red blood cells in binary HES–HES mixtures, a competitive
assay: human erythrocytes were treated (as previous) with HES 450 kDa and HES
130 kDa solutions, using a mixing ratio of 5:1. After measuring the effect on the aggre-
gation, HES 130 kDa was added on the HES 450 kDa–treated samples and vice–versa,




For the evaluation of RBC aggregation we recorded several comparative parameters.
LORCA Measurements
For the determination of red cell aggregation, the blood is brought under a shear
rate of 500 s−1, after which the shear is stopped at t=0. The backscattered intensity
from the blood layer is measured during 120 s after shear stop. The intensity drops
because of red blood cell aggregation. We considered the beginning point of the
aggregation the extrapolated value of the decay curve towards t = 0. The kinetics of
the aggregation was studied using two parameters: aggregation index and the half time
(T1/2 = the time necessary to reach 50% aggregation). The minimal value of shear
rate that prevents aggregation gave an indication of the strength of the intercellular
interaction by determining the aggregates’ resistance to dissociation by flow–induced
shear stress.
The deformability of the red cells has been determined by repeatedly measuring the
diffraction pattern of red cells under various shear stresses in the range of 0.01–100Pa,
from which an Elongation Index has been calculated by LORCA software. The blood
was diluted 200 times in PolyVinylPyrolidone (5 g/l) in PBS (50mM).
Viscosity Measurements
For the measurements of the viscosity of blood and HES–treated blood we used an
automated dynamic shear rheometer with cone–plate geometry (AR1000 Rheometer,
TA Instruments). During measurements the temperature was set at 4◦ C and the shear
rate of operation equaled the value of the corresponding shear rate which prevented
aggregation for that specific sample.
Imaging Techniques
Light Microscopy and Atomic Force Microscopy were used to morphologically char-
acterize the aggregates’ size and form.
Bright field microscopy provided a direct, large scale, two–dimensional visualization
of the samples. Images were digitized and statistics of the aggregates’ area size were
generated using the Image Pro–Plus software (version 3.0.1 Media Cybernetics).
Tapping–Mode Atomic Force Microscopy provided three–dimensional imaging of un-
stained and uncoated RBC aggregates in air. Sample preparation consisted of a stan-
dard smear of 300 times diluted filtered blood on a glass surface. In this way, sample
preparations and imaging environments known to generate artifacts are eliminated
(e.g., dehydration, fixation, freezing, staining and coating).
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Statistical Analysis
Differences between physiological and experimental aggregation parameters in differ-
ent samples groups were evaluated using the paired two tailed Student T Test. A p




The molecular weight of HES had a highly significant influence on the kinetics of
RBC aggregation (Fig. 7.1a). For a blood:HES ratio of 5:1 the aggregation index in
the presence of HES 450 kDa was 39.76±5.99, an increase of more than 100% as com-
pared to the control aggregation index, 18.16±3.43, (p<0.01). In contrast, the low
molecular weight HES significantly reduced the RBC aggregability (p=0.019); the AI
measured in the HES 130 kDa treated samples was 13.64±1.96. In addition, we deter-
mined the concentration–dependent effects of HES on RBC aggregation. Decreasing
HES 450 kDa and HES 200 kDa concentrations resulted in a concomitant decrease of
aggregation index, although 10% HES 450 kDa still induced a significant increased
aggregation (p<0.01).
Figure 7.1: (a) Aggregation Index (AI) of human blood treated with different HES
in various ratios (mean±SD). (b) Aggregation Index (AI) of human blood treated
with UW solution/HES–free UW solution using different mixing ratios (mean±SD).




Shear rate Viscosity Shear stress
(s−1) (mPasec) (Pa)
mean±SD mean±SD mean±SD
UW solution–treated samples 175±29 14.9±0.3 2.5±0.2 ??
HES 450 kDa treated samples 240±70 12.4±0.2 3.4±0.2 ??
HES 200 kDa treated samples 140±12 15.1±0.5 2.0±0.1 ??
HES 130 kDa treated samples 86±15 18.2±0.5 1.5±0.05 ??
Controls 78±3 22.7±0.5 1.6±0.1
Table 7.1: The shear stress required to dissociate RBC aggregates. Highly significant
(p<0.01) differences as compared with whole blood samples (controls) are indicated
with ??.
The AI measured in the UW treated blood was 28.94±3.89 for the ratio 5:1 and
35.55±3.84 for the ratio 2:1; the control sample had an AI of 20.02±5.52. When
treating the blood with colloid free–UW solution in a ratio of blood:HES–free UW
solution = 2:1, the aggregation index decreased to 0.20±0.42 (Fig. 7.1b).
The kinetics of the aggregation process is also expressed by the half–time (T1/2)
value. Since T1/2 is the time necessary to reach 50% of complete aggregation level,
a lower T1/2 reflects a faster aggregation process. The RBC aggregates formed three
times faster when the cells came in contact with HES 450 kDa (T1/2=6.67±0.84 s), as
compared to the control (T1/2=20.43±4.59 s) (p<0.01). HES 130 kDa inhibited the
aggregation process, the half time necessary for RBC treated with HES 130 kDa to
reach complete aggregation (T1/2=29.17±6.68 s) was significantly higher (p=0.024)
when compared to control.
Resistance to dissociation by flow induced shear stress expresses the strength of the
aggregates. The shear stress required to dissociate the aggregates is calculated by
multiplying the minimum shear rate that prevents aggregation with the viscosity of
the blood at that shear rate:
Shear Stress (mPa) = Shear Rate (s−1) × Viscosity (mPa.s)
The measured shear rates that prevented aggregation, the viscosity values measured
for each sample at the corresponding shear rate, and the calculated shear stresses
are presented in Table 7.1. It was notable that the viscosity values of the control
were higher than the viscosity measured for the HES 130 kDa treated samples, the
conditions of the measurement being the same (shear rate = 80 s−1, temperature
4◦C).
Erythrocyte deformability measured by means of Elongation Index parameter with
LORCA, showed no significant differences between HES treated samples and control
samples.
Aggregation of human red blood cells in binary HES–HES mixtures, a competitive as-
say: for red blood cells pretreated with HES 450 kDa, aggregation index decreased
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Figure 7.2: Aggregation of human red blood cells in binary HES–HES mixtures, a
competitive assay. Box plots graph data represent statistical values. The boundary of
the box closest to zero indicates the 25th percentile, the line within the box marks the
median of 6 measurements, and the boundary of the box farthest from zero indicates
the 75th percentile. Whiskers above and below the box indicate the 90th and 10th
percentiles.
when adding small starch (from 65,8±4,7 to 55,4±2,6). For red blood cells pre-
treated with HES 130 kDa, large HES increased the aggregation index from 37,6±4,1
to 57,5±5,2. Concomitant adding of HES 450 kDa and HES 130 kDa to the red blood
cell suspension yielded values similar to those obtained by consecutive treatment with
HES 450 kDa and HES 130 kDa (Fig. 7.2).
Imaging Techniques
The large–scale light microscopic images showed clear differences between the extent
of aggregation in the HES–treated samples and the control samples. The statistics
on these images, given by Image Pro–Plus software are shown in Table 7.2.
The UW solution treatment of the RBC determined formation of branched rouleaux
networks with a range of 23–56 cells per aggregate (Fig. 7.3a). HES 450 kDa induced
formation of large size RBC aggregates with an irregular geometry: polymorph ery-
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throcyte clusters were clearly visualized (Fig. 7.3b). The morphology of the HES
130 kDa induced RBC aggregates consisted of various size linear rouleaux (Fig. 7.3c).
The image of the erythrocytes treated with HES–free UW solution confirmed the ab-
sence of RBC aggregation; at a magnification of 200× only 8 aggregates were counted,
with a range of 2–3 cells per aggregate. A control was considered as well (Fig. 7.3d).
Tapping–Mode atomic force microscopy technique revealed a three dimensional sur-
face profile of RBC aggregates with micrometer resolution. This visualization ap-
proach provided clear evidence of aggregation between intact red blood cells when
treated with high molecular weight hydroxyethyl starch/UW solution (Fig. 7.4a,b,
respectively).
Table 7.2: Statistics given by Image Pro–Plus Software after processing bright field
microscopy images taken at a magnification of 200×.
HES HES UW HES – CONTROL
450 kDa 130 kDa solution free UW
Total cell count 1881 1289 1545 349 164
Total aggregate count 154 216 64 8 4
Single cells (%) 4.9 35 2.9 95.1 94.5
Cells in aggregate (%) 95.1 65 97.1 4.9 5.5
Cells / aggregate (range) 10–28 4–7 23–56 2–3 2–3
Area Max. (µm2) 6740 1398 4332 72 137
7.4 Discussion
In the present study, we conducted a comparative analysis of various parameters
expressing the aggregation status of RBC in samples treated with University of Wis-
consin solution and different molecular weight HES solutions. Our findings indicate
that high molecular weight hydroxyethyl starch solutions (HES 450 kDa and HES
200 kDa) as well as UW solution have a potent hyperaggregating effect on human
RBC. RBC aggregates formed in the presence of this colloid are of large size; the
maximum size aggregate area was 6740µm2 in the HES 450 kDa treated samples and
4332µm2 in the UW–treated samples. In addition, their resistance to dissociation by
flow induced shear stress is increased by 50–100% compared to control samples. These
data suggest that gravity–induced hydrostatic perfusion pressures presently used in
procurement can not easily dissociate the abnormal RBC aggregates. Some authors
have advocated a more physiologic method in which the UW solution is flushed under
pressure (100mmHg) similar to the mean arterial blood pressure with the advantage
of perfusing the small intrahepatic vessels. Measurement of the microvascular blood
flow patterns in physiologic conditions using intravital microscopy shows that in ar-
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Figure 7.3: Bright field microscopy, magnification 500×. Bar scale represents 20µm.
(a) UW–induced branched RBC rouleaux networks, (b) HES 450 kDa induced RBC
polymorph clusters, (c) HES 130 kDa induced linear RBC rouleaux, (d) Control–
RBC suspended in autologus plasma.
terioles and venules, with a diameter of 24.7±9.1µm, the recorded shear rate has a
mean value of 201±163 s−1 21. The minimal value of the shear rate that prevented
UW–induced aggregation in our experiments was 175±29 s−1. These data indicate
that even with a high–pressure perfusion, the low shear rates generated in certain
areas and the small vessel diameter compared to the aggregates size make this ves-
sel category prone to mechanical obstruction. In addition, increasing the perfusion
pressures could represent and additional stress factor for sinusoidal endothelial cells.
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Figure 7.4: Tapping–Mode Atomic Force Microscopy. (a) HES 450 kDa treated
red blood cells cluster of 44.18µm/53.35µm with irregular geometry (scan size
60µm/60µm), (b) Branched RBC rouleaux network induced by UW solution – de-
tailed topography (scan size 30µm/30µm).
These cells are already particularly vulnerable to cold ischemia/reperfusion injury
and thus are believed to be the primary target of this injury22.
The presence of remaining host erythrocyte aggregates after the initial wash–out of the
donor organ could contribute to an inadequate microvascular perfusion with preser-
vation solution and therefore to a poor maintenance of graft viability during ischemic
storage. The areas of the respective organs that are only marginally equilibrated with
University of Wisconsin solution are less protected during the subsequent ischemic
storage period, thus contributing to an overall reduced structural and functional in-
tegrity of the organ23. Preservation injuries are considered to be major contributors to
primary allograft failure after liver transplantation. Inadequate preservation with UW
solution for 16 hours becomes histologically evident 24 hours after reperfusion: sub-
massive confluent necrosis of hepatocytes associated with loss of intercellular borders
mainly in the midzonal region, with selective sparing of periportal and centrilobular
zones22. In this respect, Busquets et al. reported the presence of preservation injuries
in 17% of the liver grafts preserved in UW solution and associated the presence of
these lesions with an increase of posttransplant biliary complications24.
In addition, mobilization of resting host red blood cells during reperfusion time, the
presence of lysed erythrocytes and endothelial cells due to cold ischemia and inade-
quate microvascular perfusion with preservation solution may lead to a local hyper-
coagulable state. Local activation of the coagulation system on graft reperfusion may
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cause intravascular and/or intracardiac thrombus formation and pulmonary throm-
boembolism25. Suriani et al. suggested that subclinical thromboembolism on graft
reperfusion is common. He reported echodense masses in the right atrium within one
min after reperfusion in 70% of the patients undergoing liver transplantation26. Thus,
it could be possible that by identifying the RBC hyperaggregating effect of UW solu-
tion as an etiology–related factor for these complications immediate function, patient
and graft survival would improve.
In our study, low molecular weight HES treatment of blood yielded a decline of blood
viscosity values. Furthermore it significantly decreased the red blood cell aggrega-
bility and slowed the process in time. The aggregate’s resistance to dissociation by
flow induced shear stress was significantly lower in the HES 130 kDa treated samples
when compared to control. The visualization revealed various sized linear rouleaux
morphology with a range of 4–7 red blood cells per aggregate.
Questions might arise regarding the efficacy of HES 130 kDa in maintaining the colloid
osmotic pressure during the wash–out procedure and preservation period. Hydrox-
yethyl starches have been used for many years in order to prevent and treat hypov-
olemia during major surgery: they decrease the transvascular fluid flux and edema
formation via maintenance of the colloid osmotic pressure and preservation of the
microvascular barrier. In that respect, HES 130 kDa is proved to be an efficacious
plasma volume expender in heart surgery27. In addition, Zikria et al.28 demon-
strated that 100 to 300 kDa fraction of HES significantly minimized tissue edema in
an ischemia–reperfusion model of increased vascular permeability, independent of the
colloid osmotic pressure effect. They hypothesized that this finding was related to a
biophysical effect of starch effectively sealing the separated endothelial junctions.
Under normal conditions erythrocytes deformability allows individual red blood cell
with a mean resting diameter of 7m to traverse capillaries with diameters no more
than 3–5µm. Rigid cells in the postoperative blood flow could present a block in
the microcirculatory passageway. Any decrease in the deformability would result in
impaired perfusion of organs and peripheral tissues29,30. Therefore the present study
was designed to investigate the influence of HES on RBC deformability as well. We
found no significant effect of HES on RBC deformability (p>0.05).
Theoretical models of erythrocyte aggregation
Membrane adhesion processes, including erythrocyte aggregation, can be classified
into two categories: specific binding and nonspecific binding. Specific binding oc-
curs via interaction of macromolecules with their specific receptors on the erythro-
cyte membrane. For nonspecific binding mechanism, two major theoretical mod-
els have been proposed31. The first theory is based on the surface adsorption of
macromolecules to form bridging configuration between adjacent erythrocytes. The
adsorption is believed to be favored by Van der Waals forces, hydrogen bounds or
electrostatic attractions. According to this theory, polymers and plasma protein with
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a large molecular mass insert between adjacent erythrocytes, increase the intercellular
distance and induce erythrocyte aggregation by decreasing the electrostatic repulsive
forces of erythrocytes32. The second theory suggests that the aggregation is induced
by macromolecular depletion from the membrane surface. In this theory the aggre-
gation is independent of both the molecular mass and the surface adsorption. The
attraction of colloid particles producing the aggregation is induced by variations in
the surface energy and differences in osmotic pressure due to a profile of polymer con-
centration existing in the suspending medium between the neighboring surfaces33.
Hypotheses on the mechanism of hydroxyethyl starch induced RBC aggre-
gation
Our study documented that the extent of HES induced RBC aggregation varied with
the molecular weight. Colloids with high molecular weights such as HES 450 kDa
and HES 200 kDa induced a significantly higher aggregation when compared to the
physiological aggregation. Concentration of the colloid was shown to be pivotal in
the aggregation process. The observed strong correlation of erythrocyte aggregation
with the molecular weight and concentration of HES can be explained by the theory of
macromolecular bridging. In contrast, the colloid with a small molecular weight, HES
130 kDa, had an inhibiting effect on the extent and kinetics of the aggregation. These
findings are consistent with the assumption that inhibition of aggregation occurs
because of increase of small molecules in the depletion region.
The study of red blood cell aggregation in a binary HES–HES system showed that
both hyper-aggregability induced by HES 450 kDa and hypo-aggregability induced by
HES 130 kDa are reversible phenomena, demonstrating in this way the nonspecific
nature of HES adsorption on the surface of the cell.
In summary, our experiments conclusively showed that the physiological function
of red blood cells to form aggregates is significantly affected in the presence of hy-
droxyethyl starch. The aggregation of erythrocytes was extended and accelerated
with increasing the molecular weight of HES and its concentration. As a new and
unexpected finding, a significantly lower aggregation was observed in HES 130 kDa–
treated erythrocytes compared to the aggregation in controls. In addition, the use of
a colloid–free UW solution resulted in a complete abolition of RBC aggregability.
The causes of hepatic dysfunction or allograft failure after liver transplantation are
multifactorial and identifying risk factors predictive of both patient and graft survival
is crucial to improve outcome after transplantation. To date, several risk factors have
been shown to negatively affect the graft survival, such as donor/recipient age34, size
of body/weight index, prolonged donor stay in the intensive care unit and long cold
ischemic time35, perfusion during initial wash–out and preservation methods3. Most
of these factors are static, but some of them are subject to manipulation, for example
the use of high molecular weight HES in the formulation of UW solution. We sug-
141
Bibliography
gest, on the basis of our experimental data, that the use of low molecular weight HES
(HES 130 kDa) will improve the quality of the University of Wisconsin solution, have
a beneficial effect on organ preservation and possibly reduce the chance of postreper-
fusion primary nonfunction and posttransplant biliary lesions with delayed recovery
in organ transplantation.
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Recent improvements in the clinical care of patients have their roots in two distinct
fields of modern medicine: biomedical research and clinical ethics. In order to improve
the ability of clinical medicine to apply successfully and ethically the new develop-
ments in medical science, research must be undertaken to understand the full effects
of medical treatments and the proper threshold for medical intervention. Moreover, it
is of critical importance how physicians understand the risks and benefits of treatment
and how to guide the decision making for individual patients. The ethical aspects of
treatment decisions are of equal importance, with emphasis on patients expectations
when they consent to manipulation involving risk factors and on their participation
in a treatment decision. Only by investing time and effort in both medical education
and research, the ethical ideals that underlie the physician–patient relationship can
be fulfilled.
The present thesis describes a generally recognized pathophysiologic mechanism: im-
pairment of organ perfusion with its diagnostic and therapeutic challenges. Out of
the multitude of possible etiologic factors for organ perfusion impairment, we chose
to investigate two extreme situations of acute organ support: (1) organ perfusion
during cardiopulmonary bypass with cardiac arrest and (2) organ perfusion during
145
General Discussion
organ donation and procurement prior to transplantation. Even if these two clinical
fields seemed to be segregated at a first approach, our results conclusively showed a
parallelism in etiology, pathologic mechanisms, and therapeutic approaches.
Using this original approach, we investigated several issues of concern for both cardiac
surgery and organ transplantation: use of artificial colloids, use of prophylactic cor-
ticosteroids, diagnostic value of organ injury markers, consequences of hemodilution,
hypothermia induced injury, and vascular endothelial activation.
Effects of hydroxyethyl starches (HES) on red blood cell aggregation
The use of HES solutions as priming and plasma substitution fluids in patient un-
dergoing cardiopulmonary bypass results in altered red blood cell aggregation. In
parallel with the decrease in red blood cell aggregation, blood viscosity declines also.
The subsequent variations in blood rheology activate the vascular endothelium with
pro–inflammatory and pro–thrombotic effects. A distinct effect of different molecular
weight starches was evident post–bypass. While the markers of endothelial activation
went down to baseline levels in HES 200/0.5 group, HES 130/0.4 was associated on
the first postoperative day with sustained endothelial activation.
In organ transplantation, the use of high molecular hydroxyethyl starches (HES
450/0.7 and higher) as components of the University of Wisconsin preservation so-
lution accounts for accelerated and augmented red blood cell aggregation. The ag-
gregates are of large size and their resistance to dissociation by flow induced shear
stress is high. These data suggest that gravity–induced hydrostatic perfusion pres-
sures presently used in procurement can not easily dissociate the abnormal red blood
cell aggregates. In addition, the small vessel diameter in marginal areas compared to
the aggregates size make these vessel category prone to mechanical obstruction during
organ procurement. The presence of remaining host erythrocyte aggregates, trapped
in the microvasculature after the initial wash–out of the donor organ could contribute
to an inadequate microvascular perfusion with preservation solution and therefore to
a poor maintenance of graft viability during ischemic storage. The areas of the re-
spective organs that are only marginally equilibrated with University of Wisconsin
solution are expected to be less protected during the subsequent ischemic storage
period, thus contributing to an overall reduced structural and functional integrity of
the organ. Low molecular weight HES treatment of blood yields a decline of blood
viscosity values, decreased the red blood cell aggregability and slows the process in
time.
Our results documenting the effect of hydroxyethyl starches on red blood cell ag-
gregation suggest the necessity of a more careful selection of HES solutions when
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considering a therapeutic strategy. In cardiac surgery, hypertensive and atheroscle-
rotic patients who have already a high basal levels of circulating von Willebrand factor
might benefit from HES 200/0.5. HES 130/0.4 could represent a first choice for pa-
tients with bleeding tendencies and patients with acquired von Willebrand syndrome
after aortic stenosis. In organ preservation prior to transplantation, the exclusive use
of low molecular weight HES will improve the quality of the University of Wiscon-
sin solution by preventing intravascular red blood cell aggregation. By preventing
mechanical obstruction during wash-out, use of HES 130/0.4 might have a beneficial
effect on organ preservation and possibly reduce the chance of postreperfusion pri-
mary nonfunction and posttransplant biliary lesions with delayed recovery in organ
transplantation.
Prophylactic corticosteroid treatment
The assumption that prophylactic corticosteroid therapy, by its virtue to inhibit the
inflammatory response, would also transfer a protective effect of organ injury associ-
ated with cardiopulmonary bypass, was rejected by the results presented in this thesis.
Dexamethasone treatment offered no protection against transient, perioperative renal,
intestinal and hepatic injury in patients undergoing on–pump coronary artery bypass
grafting. In fact, dexamethasone treatment seemed to be detrimental, resulting in
a pronounced postoperative pulmonary dysfunction, prolonged time to tracheal ex-
tubation and by initiating postoperative hyperglycaemia. An important observation
was the strong positive correlation found between high blood glucose level, as side
effect of dexamethasone, and end organ injury. The necessity of a stricter manage-
ment of serum glucose emerged, suggesting insulin therapy at serum glucose lower
than 10 mmol.L−1 (as standard) in order to avoid kidney and intestinal injury. This
message is also important for the clinicians responsible for the management of the
brain dead organ donors, confronted as well with the use of corticosteroid therapy
and glucose management.An early institution of insulin therapy might decrease brain
death–related donor organ damage.
Diagnostic value of organ injury markers
With the goal of diagnosing impairment in organ perfusion and subsequent organ
injury, the present work investigated in a multitude of clinical settings the use of both
standard and newly available organ injury biomarkers. Most of the standard labo-
ratory investigations proved to require long assay times, to lack sufficient specificity
and/or sensitivity. In contrary, using newly available, sensitive and specific organ
injury biomarkers we were able to document transient, subclinical cardiac, renal,
intestinal and hepatic tissue injury even in low risk patients undergoing cardiopul-
monary bypass. Similar, these new markers proved to be useful when investigating
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early brain death–related donor organ damage.
Fatty acid binding proteins (FABP) are cytosolic proteins with various tissue specific
isotypes, released in circulation and subsequently in urine in case of cellular dam-
age. We investigated the use of heart (H), intestinal (I), and liver (L) type fatty acid
binding proteins. In cardiac patients undergoing cardiopulmonary bypass, plasma
H–FABP correlated with other cardiac injury markers (cardiac Troponin I and crea-
tine kinase MB). The advantage of including H–FABP in the diagnosis of myocardial
injury is the early peak arising already one and a half hour after reperfusion, which
was significantly earlier than the peaks of cardiac Troponin I (fourteen hours) and
creatine kinase MB (sixteen hours). Urinary concentration of H–FABP proved to be a
better indication of kidney damage than of myocardial damage, explained possibly by
a primary release of H–FABP in urine from the damaged distal renal tubules. In our
study on the patients undergoing cardiac surgery, the urinary peak of H–FABP did
not correlate with the others cardiac markers but correlated strongly and significantly
with the urinary peak of N-acetyl-glucosaminidase (NAG, proximal tubules injury)
and peak microalbuminuria (glomerular injury). Similar,in brain dead rats donors,
H–FABP and NAG urine concentration reached significantly higher values as early as
half hour and one hour, respectively, after brain death induction, as compared with
sham operated animals. A highly positive correlation was documented between the
two renal tubules markers, consolidating the diagnose of renal tubular damage during
brain death.
I/L–FABP are cytosolic proteins readily released into the circulation following ente-
rocytes damage, with a 40-fold higher content of L–FABP, reported as useful urine
markers for the detection of intestinal injury. Both urinary I–FABP and L–FABP
increased significantly during CPB, reaching peak values in the urine collected during
the first two hours and six hours postoperative, respectively. Urine I–FABP corre-
lated significantly with urine L–FABP. The increased values of I–FABP and L–FABP
during CPB reported in this study verify the indirect evidence of mucosal integrity
loss during CPB reported previously as perioperative reduction in intramucosal pH,
increase in gut permeability and endogenous endotoxemia. Using the test of I–FABP
concentration in the urine of brain dead rats, we were able to detect intestinal injury
as early as two hours after brain death (data not shown).
Additional to fatty acid binding proteins, we would like to emphasize the utility of N–
acetyl–glucosaminidase in diagnosing proximal tubules injury, and of α-Glutathione
S–transferase in diagnosing hepatic injury.
Consequences of hemodilution
Using a complex operative strategy in patients undergoing on-pump coronary artery
bypass grafting, we showed an important attenuation of the transient renal and intesti-
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nal postoperative injury achieved by means of limiting intra–operative hemodilution
and blood transfusion requirements. Variation in hematocrit explained more than a
third of the variation of both postoperative NAG and I–FABP. A decrease with one
unit (1%) in hematocrit predicted significantly an increase with a quarter of the peak
postoperative NAG values. The same decrease with one unit (1%) in hematocrit pre-
dicted significantly an increase with a tenth of the peak postoperative I–FABP values
in patients undergoing on–pump cardiac surgery. Hemodilution, besides lowering the
oxygen carrying capacity of blood, alters as well blood rheology with possible patho-
logical consequences.
With the aim set on investigating variation in blood rheology during isovolemic
hemodilution and subsequent effects on vascular endothelial activation, we designed
an animal study to answer previously formulated hypothesis in clinical studies. To
bring relevance, the study addressed two different hydroxyethyl starch (HES) solu-
tions commonly used in the clinical practice as priming solutions for the heart–lung
machine and as plasma expanders. An important observation was that hemodilution
up to 50% resulted in negligible hypoxia/reperfusion injury, as quantified by the re-
active oxygen species production measured in the vital organs. Low red blood cell
aggregation, as documented in this model of acute isovolemic hemodilution, was asso-
ciated with activation of vascular endothelium, especially in lungs and small intestine.
Translation of these data in clinical terms suggests that acute hemodilution may lead
to inflammatory stress of pulmonary capillaries. Subsequent diffusion limitation may
be expected. Similar, an increased inflammatory response in the small intestine as-
sociated with acute hemodilution, might contribute to a loss in barrier function of
the intestinal mucosa with subsequent translocation of endotoxins and/or bacteria.
Additionally, the data presented in this study suggest a new pathway for the erythro-
cyte involvement in clot formation: due to their function to aggregate, erythrocytes
can modulate endothelial activation with von Willebrand factor release, with a sub-
sequent pro–thrombotic effect. The investigations on acute isovolemic hemodilution
might be clinically relevant for the patients undergoing on–pump cardiopulmonary
bypass, the patients in traumatic–hemorrhagic shock with sustained fluid resuscita-
tion, or the brain dead organ donors with large volume of fluid infusion to correct for
hypotension. Based on the results demonstrating increased endothelial activation, we
hypothesize that lower incidence of thrombotic events and decreased inflammatory
reactions could be achieved by avoiding excessive hemodilution.
Hypothermia–related injury
Contrary to conventional thinking about the benefits of corporeal hypothermia on
systemic protection against global ischemic injury during extracorporeal circulation,
an increasing number of clinical studies support corporeal normothermia. The re-
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sults of our clinical investigation comparing normothermia with hypothermia showed
a negative correlation between body temperature during cardiopulmonary bypass and
postoperative I–FABP urine concentrations. In other words, lower body temperatures
during CPB were associated with higher intestinal damage. These findings confirm
at a different level, the studies performed in organ transplantation that document a
higher organ damage when cold ischemic preservation time is extended. In the clinical
setting of organ transplantation, cooling down the organ followed by rewarming is a
generally recognized trigger of injury.
Vascular endothelial activation
Pro–inflammatory and pro–coagulatory vascular endothelial activation was demon-
strated to be a central pathological finding in both cardiac surgery and brain death
organ donation. In cardiac surgery with cardiopulmonary bypass, endothelial ac-
tivation was demonstrated to arise in the first hours after myocardial reperfusion,
as documented by elevated plasma concentrations of von Willebrand factor, throm-
bomodulin, tissue Plasminogen Activator and E–Selectin. At gene regulation level,
endothelial activation is shown in our pig experimental study to arise already three
hours after induction of isovolemic hemodilution. In brain dead donor rats, endothe-
lial activation was documented as early as half hour after brain death induction.
The etiology of endothelial activation is multifactorial: systemic inflammatory re-
sponse, surgical stress, and systemic mobilization of wound–release factors. As orig-
inal contribution, the present thesis introduces a new etiologic factor: decreased red
blood cell aggregation as a trigger of impaired blood rheology and thus mechanical
endothelial activation. We hypothesize that the drop in RBC aggregation added to
plasma viscosity reduction during hemodilution alone, or even more during extracor-
poreal circulation, are important factors contributing to variation in shear stress at
the vascular endothelial wall. The variation in shear is known to lead to a complex
signaling response eventuating in pro-inflammatory and pro–coagulatory vascular en-
dothelial activation.
In conclusion, the work described here aims to add a new foundation stone on the sci-
entific basis for diagnosing and treatment, by contributing to current clinical debates
and suggesting new directions for clinical and fundamental research. Additionally, the
results included in this thesis emphasize the need of collaborative decision making be-




Development and validation of new extracorporeal assist devices are highly desirable
when performing artificial organ support. Pulsatile perfusion remains a challenging
therapeutic choice. Either used as bridge to transplantation, bridge to recovery, or
during coronary artery bypass grafting with cardiac arrest, an effective pulsatile per-
fusion might improve clinical outcomes.
In the same line of research, hypothermic machine perfusion providing a pulsatile
blood flow is known to offer better protection against cold ischemic injury when com-
pared with cold storage in marginal donor organs. Special effort has to be invested
in testing in both experimental and clinical settings the benefits on graft viability
when perfused with this newly available hypothermic, pulsatile machine preservation
systems.
Last but not least, special scientific attention has to address the pathophysiology
of disease and placing it in a clinical relevant context. In this respect, our efforts in
documenting new mechanisms of endothelial activation related to variation in blood
rheology parameters, the potential consequences of red blood cell aggregation on (mi-





The aim of this work was to investigate the efficiency of organ perfusion during acute
organ support, as performed during extracorporeal mechanical blood circulation in
cardiac patients, donor management, organ procurement and organ preservation prior
to transplantation. The investigations were conducted in clinical studies, animal stud-
ies and in-vitro experimental settings. The efforts were concentrated on testing the
diagnostic value of new, specific and sensitive biomarkers for organ injury, in order to
help an early and effective therapeutic strategy.
Chapter 1 introduces the reader into the subject by offering basic theoretical knowl-
edge concerning cardiopulmonary bypass, organ preservation and organ donation prior
to transplantation.
The study presented in Chapter 2 was designed to document the effects of dex-
amethasone on cytokine release and perioperative myocardial, pulmonary, renal, in-
testinal and hepatic damage, as assessed by specific and sensitive (bio)markers. A
prospective, double–blind, placebo–controlled, randomized trial for dexamethasone
was conducted in 20 patients, receiving either dexamethasone (1mg/kg before anes-
thesia induction and 0.5mg/kg after 8 hours) or placebo. Different markers were used
to asses the inflammatory response: Interleukin–6, Interleukin–8, Interleukin–10, C–
reactive protein, tryptase. Organ damage was investigated using plasma heart–type
fatty acid binding protein, Troponin I, and Creatine kinase–MB to asses myocardial
injury, urine N–acetyl–glucosaminidase and microalbuminuria to investigate renal in-
jury, intestinal/liver type fatty acid binding protein to assess the small intestine injury,
and αGlutathione S–transferase for the hepatic injury.
Dexamethasone, as administered in this study, effectively inhibited the release of pro–
inflammatory interleukins and increased plasma concentration of anti–inflammatory
Summary
interleukins. However, dexamethasone treatment offered no protection against tran-
sient, perioperative renal, intestinal and hepatic injury in patients undergoing on–
pump coronary artery bypass grafting. Dexamethasone treatment resulted in more
pronounced postoperative pulmonary dysfunction, prolonged time to tracheal extuba-
tion and initiated postoperative hyperglycaemia. The high blood glucose levels were
found strong significant predictors for renal and intestinal tissue injury.
In Chapter 3 we described the experimental infrastructure and clinical application
of a comprehensive operative strategy that aimed to limit postoperative myocardial,
renal and intestinal tissue injury in patients undergoing heart–lung machine assisted
coronary artery bypass grafting. A prospective, pseudo–double blind, randomized
clinical trial, investigating the clinical benefits of the new experimental intraopera-
tive protocol was performed in 40 patients. The experimental operative protocol was
developed to meet multiple objectives: (1) homogeneous cooling of the myocardium
by combining cold crystalloid cardioplegia technique with intracavitary cooling of
the heart; (2) prevention of excessive hemodilution by autologous priming of the
extracorporeal circuit and partial recovery of the cardioplegic fluid; (3) corporeal nor-
mothermia, possible on the account of a more efficient topical cooling of the heart.
Clinical outcome and transient postoperative injury of the myocardium, kidneys, and
small intestine were investigated. Postoperative myocardial damage, as quantified
by plasma levels of creatine kinase MB, was significantly lower in the patients in
the experimental group. Transient proximal tubules injury was significantly attenu-
ated in the patients benefiting from the experimental operative protocol, as shown by
the urine concentrations of N–acetyl–beta–D glucosaminidase. Transient intestinal
damage, as quantified by the urinary excretion of intestinal–type fatty acid binding
protein, was significantly decreased in patients undergoing on pump coronary artery
bypass grafting according the experimental protocol.
With the aim set on investigating variation in blood rheology during cardiopulmonary
bypass and subsequent effects on (micro)circulation, we focused in Chapter 4 on red
blood cell aggregation and endothelial activation. The present study addresses two
different hydroxyethyl starch (HES) solutions commonly used in the clinical practice
as priming solutions for the heart–lung machine and as plasma expanders. Red blood
cell aggregation was measured by means of Laser–assisted Optical Rotation Cell An-
alyzer, in an in vitro study designed to mimic the human blood–material interactions
during extracorporeal circulation. A clinical study investigating endothelial activation
was conducted in 20 patients undergoing elective coronary bypass surgery, randomly
assigned for cardiopulmonary bypass using either HAES–steril 6% (HES 200/0.5) or
Voluven 6% (HES 130/0.4).
The property of red blood cells to form aggregates at low shear rates was profoundly
altered in our in vitro model mimicking the human blood–material interactions during
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extracorporeal circulation. In parallel with the decrease in red blood cell aggregation,
blood viscosity declined also. A functional and/or structural alteration of vascular en-
dothelial cells during extracorporeal circulation was documented by elevated plasma
concentrations of von Willebrand Factor, thrombomodulin, tissue plasminogen acti-
vator and E–Selectine. Differences between HES groups were evident post–bypass.
While the markers of endothelial activation recovered in HES 200/0.5 group, HES
130/0.4 was associated on the first postoperative day with further increase of vWF
and tPA.In parallel with the decrease in red blood cell aggregation, blood viscos-
ity declined also. A functional and/or structural alteration of vascular endothelial
cells during extracorporeal circulation was documented by elevated plasma concen-
trations of von Willebrand Factor, thrombomodulin, tissue plasminogen activator and
E–Selectine. Differences between HES groups were evident post–bypass. While the
markers of endothelial activation recovered in HES 200/0.5 group, HES 130/0.4 was
associated on the first postoperative day with further increase of vWF and tPA.
The observations made in vitro on red blood cell aggregability coupled to the obser-
vation made in vivo on endothelial cell activation suggest a hypothetical new patho-
physiological mechanism implicated in the post–cardiopulmonary bypass syndrome.
We hypothesized that the drop in red blood cell aggregation added to plasma viscos-
ity reduction and non–physiologic flow conditions during extracorporeal circulation,
are important factors contributing to variation of shear stress at the vascular wall,
leading to endothelial activation.
In Chapter 5, the hypothesis emerged in the previous chapter, concerning a pos-
sible interconnection between red blood cell aggregation and endothelial function, is
verified in an experimental animal model of isovolemic hemodilution.We induced acute
isovolemic hemodilution (30ml/kg exchange transfusion with colloid solutions) in an
“aggregating species” (pigs), and investigated the hypoxic oxidative stress (plasma
Malondialdehyde, ex–vivo oxygen radicals production in heart, lung, kidney, liver,
ileum tissue–biopsies), erythrocyte aggregation (LORCA), and endothelial activation
(Real Time Quantitative Taqman RT–PCR on von Willebrand Factor (vWF), E–
and P–Selectins, and endothelial nitric oxide synthase gene–expression in tissue biop-
sies). The production of superoxide and hydroxyl radicals, measured as H2O2 gen-
eration, was similar at all times in sham–operated and hemodiluted animals, which
indicates that a similar hypoxic oxidative stress is present, and oxygen delivery to
the tissue during acute hemodilution is maintained. Acute isovolemic hemodilu-
tion was followed by a dramatic drop in erythrocyte aggregation and immediate
pro–thrombotic (significant vWF mRNA up–regulation in heart, lungs, kidney, liver,
ileum) and pro–inflammatory (significant E– and P–Selectins mRNA up–regulation
in lungs and ileum) endothelial activation. Low erythrocyte aggregations were signifi-
cantly associated with increased mRNA–expressions of vWF (heart, liver, ileum) and
P–Selectin (lungs, ileum and heart). In this way, we were able to demonstrate that
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erythrocyte aggregation can actively modulate thrombogenicity and inflammation by
inducing release of endothelium–dependent pro–thrombotic factors and expression of
pro–inflammatory adhesion molecules.
Approaching the subject of organ perfusion in transplantation, the study presented in
Chapter 6 we investigated the time sequence for the progression of pro–inflammatory
and pro–coagulatory endothelial activation, oxidative stress and organ injury in brain
dead rat donors. The brain death model used in this study was a slow model, sim-
ulating the clinical condition of brain death due to intracranial hemorrhage. Brain
death was induced by slowly inflating a balloon–catheter inserted in the extradural
space. To assess time–dependant changes due to brain death, rats were sacrificed half
hour, one hour, two hours, and four hours after brain death induction and compared
to sham–operated controls.
The mRNA expression of the adhesion molecules E– and P–Selectins, known to pro-
mote inflammation by mediating rolling and extravasation of leukocytes, were up–
regulated shortly (half hour) after brain death induction. Additionally, platelet trap-
ping, most probably due to platelet adhesion to the vascular wall, was visualized as
early as half hour after inducing the brain death. A significant increase in plasma
levels of von Willebrand factor, and increased mRNA expression of Aα and Bβ fib-
rinogen, were observed.
Oxidative stress started to increase after induction of brain death, and became signif-
icant only after two hours of brain death. Brain death related donor kidney damage
was diagnosed as early as half hour in renal tubules, with enhanced loss of viability
when the state of brain death was prolonged.
When assessing the efficiency of organ procurement, the study in Chapter 7 aimed
to determine the effect of HES and University of Wisconsin solution on the extent
and kinetics of human red blood cell aggregation, and to morphologically characterize
these aggregates. Human red blood cell aggregability and deformability were inves-
tigated in vitro, at 4◦ C, with a Laser–assisted Optical Rotation Cell Analyzer. The
study of red blood cell aggregation in a binary HES–HES system gave an indication
about the nature of HES–red blood cells interactions. Bright field microscopy and
atomic force microscopy were used to morphologically characterize the aggregates size
and form.
High molecular weight HES and University of Wisconsin solution had a potent hyper-
aggregating effect. red blood cell aggregates were of large size and their resistance to
dissociation by flow induced shear stress was high. These data suggest that gravity–
induced hydrostatic perfusion pressures presently used in procurement can not easily
dissociate the abnormal red blood cell aggregates. In addition, the small vessel di-
ameter in marginal areas compared to the aggregates size make these vessel category
prone to mechanical obstruction during organ procurement. Low molecular weight
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Summary
HES treatment of blood yielded a decline of blood viscosity values, decreased the red
blood cell aggregability and slowed the process in time.
Perspectives
Development and validation of new extracorporeal assist devices are highly desirable
when performing artificial organ support. Pulsatile perfusion remains a challenging
therapeutic choice. Either used as bridge to transplantation, bridge to recovery, or
during coronary artery bypass grafting with cardiac arrest, an effective pulsatile per-
fusion might improve clinical outcomes.
In the same line of research, hypothermic machine perfusion providing a pulsatile
blood flow is known to offer better protection against cold ischemic injury when com-
pared with cold storage in marginal donor organs. Special effort has to be invested
in testing in both experimental and clinical settings the benefits on graft viability
when perfused with this newly available hypothermic, pulsatile machine preservation
systems.
Last but not least, special scientific attention has to address the pathophysiology
of disease and placing it in a clinical relevant context. In this respect, our efforts in
documenting new mechanisms of endothelial activation related to variation in blood
rheology parameters, the potential consequences of red blood cell aggregation on (mi-





Dit proefschrift beschrijft enkele experimentele en klinische onderzoek naar vroeg-
tijdige diagnostiek van orgaanschade. Met als doel een bijdrage te leveren aan een
optimale bescherming van organen in situaties waarin de normale bloedcirculatie ver-
stoord is.
Hoofdstuk 1 verschaft de lezer inzicht in de theoretische kennis op het gebied van
cardiopulmonary bypass, orgaan preservatie en orgaan donatie voor transplantatie.
Hoofdstuk 2 Omdat tijdens hartoperaties met behulp van een hart–long ma-
chine (cardiopulmonary bypass) een ontstekingsreactie wordt opgewekt, werd altijd
aangenomen dat corticostero¨ıden een beschermende werking zouden hebben; immers,
corticostero¨ıden remmen ontstekingsreacties. Talloze studies hebben inderdaad een
remming van de ontstekingsreactie door corticostero¨ıden tijdens hartoperaties aange-
toond, maar niet eerder is met gevoelige biochemische meetmethoden de specifieke
orgaanschade bestudeerd. Hoofdstuk 2 beschrijft een studie waarbij e´e´nmalig het
corticostero¨ıd dexamethason werd toegediend aan een groep patie¨nten vlak voordat
een hartoperatie werd uitgevoerd. Een vergelijkbare (controle) groep patie¨nten kreeg
geen corticostero¨ıden. Dexamethason bleek geen bescherming tegen nier–, darm– en
leverschade te bieden. Dexamethason bleek zelfs enkele nadelige gevolgen voor de
patie¨nt te hebben aangezien er een slechtere long functie direct na de operatie werd
geconstateerd, waardoor de kunstmatige beademing langer duurde. Daarnaast bleek
dat de bloedsuiker spiegel direct na de operatie sterk verhoogd was. Met name deze
sterk verhoogde bloedsuiker spiegel wordt verantwoordelijk geacht voor de orgaan-
schade. De onverwachte nadelige gevolgen van dexamethason konden mede verklaard
worden door de remming van tryptase, een enzym dat vrijkomt uit mestcellen tijdens
cardiopulmonary bypass. Dit enzym biedt mogelijk bescherming tegen orgaanschade;
tryptase gaat vaatvernauwing tegen welke juist optreedt door verhoogde bloedsuiker
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spiegels en door de verstoorde doorbloeding tijdens cardiopulmonary bypass. Deze
studie pleit daarom, met name bij gebruik van corticostero¨ıden, voor het tijdig toe-
dienen van insuline om de schade door te hoge bloedsuiker spiegels te voorkomen of
in elk geval te verminderen.
Hoofdstuk 3 Verdunnen van het bloed en het verlagen van de bloedtemperatuur
zijn twee methoden die vanaf het begin van het gebruik van een hart–long machi-
ne zijn toegepast om het lichaam te beschermen tijdens hartoperaties. Hoofdstuk
3 beschrijft onze studie waarbij het bloed van de patie¨nt zo weinig mogelijk wordt
veranderd. Hiermee bedoelen we het volgende; in het medisch centrum van de Vrije
Universiteit (VUMC) is een operatiestrategie ontwikkeld, waarmee het bloed nau-
welijks verdund wordt en alleen het hart gekoeld wordt. Daartoe wordt de canule
(waardoor het bloed tijdens de operatie vanuit de patie¨nt naar de hart–long machine
stroomt) zodanig aangepast dat het tevens een koelsysteem voor het hart bevat. Het
hart wordt hierdoor beter gekoeld, terwijl het lichaam bijna de normale temperatuur
blijft behouden. Bloedtransfusies worden hiermee beperkt, aangezien het bloed min-
der verdund wordt. Met behulp van deze nieuwe methode bleek de schade aan hart–,
nier– en darmweefsel in belangrijke mate beperkt te worden.
Hoofdstuk 4 Deze studie toont aan dat met het gebruik van bepaalde plasma
vervangende middelen de doorstroming van weefsels en de stolling van het bloed sterk
be¨ınvloed kan worden. Voorafgaand aan een hartoperatie wordt de hart–long machine
gevuld met een plasma vervangend middel, in totaal ongeveer 1,5 tot 2 liter. Hierna
wordt de hart–longmachine aangesloten aan de bloedcirculatie van de patie¨nt, waarna
het bloed en de plasma vervangende vloeistof worden vermengd. Plasma vervangende
middelen kunnen de eigenschappen veranderen van de rode bloedcellen (erythrocyten)
om te aggregeren. Dit aggregeren is een natuurlijk proces dat dient om het trans-
port van erythrocyten door de bloedcirculatie te verbeteren. In de grotere bloedvaten
vormen erythrocyten dergelijke aggregaten. Maar deze aggregaten moeten volledig
uit elkaar vallen zodra de erythrocyten de haarvaten zullen gaan passeren. De mole-
cuulgrootte van plasma vervangende middelen blijkt dit aggregeren te be¨ınvloeden en
daarmee de manier waarop de erythrocyten door de bloedvaten stromen. In dit hoofd-
stuk wordt een vergelijkende klinische studie beschreven waarin een plasma vervanger
HES 200 (grote moleculen, 200kD) vergeleken wordt met HES 130 (kleine moleculen,
130 kD). HES 200 heeft aggregerende eigenschappen die lijken op die van normaal
plasma. HES 130 daarentegen verlaagt de aggregatie van erythrocyten en verlaagt
daarmee de stroperigheid (viscositeit) van het bloed.
Daarenboven wordt de aggregatie van erythrocyten verlaagd door de bloedverdun-
ning die tegelijkertijd optreedt. Hoofdstuk 4 beschrijft verder nog het vrijkomen van
ontstekings– en stollinsproducten uit de bloedvaatwand (endotheel) tijdens gebruik
van HES 130. De veronderstelling is dat dit veroorzaakt wordt door een verander-
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de snelheidsgradie¨nt langs de vaatwand, waardoor endotheel–activatie plaatsvindt.
Aanvullend fundamenteel en klinisch onderzoek zijn nodig om dit vraagstuk verder
te ontrafelen.
Hoofdstuk 5 Hierin wordt een studie beschreven die bij varkens is uitgevoerd.
Het bloed (ongeveer 2 liter) van het varken werd vervangen door een HES 200 of
HES 130 oplossing. Aansluitend werd weefselschade gemeten. Zoals verwacht bleek
dat de erythrocyten aggregatie sterk verminderd was na deze bloedverdunning, maar
onverwacht werd in dit varkensmodel geen verschil aangetoond in be¨ınvloeding van
de erythrocyten aggregatie tussen HES 200 en HES 130. De zuurstof afgifte in de
weefsels bleek na verdunning nog steeds voldoende te zijn. Er werd echter een sterke
stijging van stollingsproducten en ontstekingsfactoren vanuit endotheelcellen aange-
toond in alle onderzochte organen (darmen, nier, lever, long en hart). Vooral in de
abdominale organen (darmen, nier, lever) werden grote veranderingen gemeten. Een
afname van complicaties kan dus bereikt worden door ernstige bloedverdunning te
voorkomen, hetgeen de bevindingen uit eerder genoemde klinische studies (Hoofdstuk
3 en 4) onderbouwt.
Nu we enig inzicht hebben gekregen in de orgaanschade bij verstoorde circulatie en
acute bloedverdunning en de rol van endotheelcellen daarin, is het interessant te we-
ten hoe groot de orgaanschade is indien er sprake is van ernstige afwijkingen in de
bloedcirculatie en endotheel activatie zoals bij orgaantransplantaties gebeurt. De vol-
gende twee hoofdstukken behandelen enkele van deze aspecten.
Hoofdstuk 6 Organen van patie¨nten met fataal hersenletsel hebben in een aan-
zienlijk aantal gevallen een tegenvallende orgaanfunctie. Een van de oorzaken daarvan
is de verandering (verslechtering) in de bloedcirculatie die optreedt na hersenschade.
In Hoofdstuk 6 wordt een studie bij ratten beschreven, waarin het optreden van or-
gaanschade in de tijd gemeten werd na het aanbrengen van hersenschade. Al een half
uur na hersendood werd in het bloed een toename gemeten van stollingsfactoren en
ontstekingsfactoren. Na 1 uur was ook schade aan de nier meetbaar, na 2 uur was de
productie van zuurstof radicalen verhoogd. De conclusies van deze studie suggereren
dat bij orgaandonoren het tijdig toedienen van middelen om de stolling en ontsteking
tegen te gaan orgaanschade zou kunnen beperken.
Hoofdstuk 7 Om o.a. stolselvorming in een donor orgaan te voorkomen, moet
het goed doorgespoeld worden. Daardoor kan de bewaarvloeistof goed doordringen
in het weefsel. Bewaarvloeistoffen bevatten plasma vervangende middelen om oedeem
te voorkomen. De meest gebruikte bewaarvloeistof, genaamd University of Wiconsin
Solution, bevat het plasma vervangende middel HES 450. In het onderzoek beschreven
in Hoofdstuk 7 wordt aangetoond dat de grote moleculen van HES 450 de aggregatie
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van erythrocyten zodanig versterkt, dat de aggregaten bijna niet meer uit elkaar val-
len en zo groot zijn dat de kleinere bloedvaten verstopt raken. Hierdoor is het niet
mogelijk de donor organen goed te doorspoelen en kan na transplantatie een deel van
het weefsel zelfs afsterven. Vervangen van HES 450 door HES 130 zou een logische
methode kunnen zijn om het genoemde probleem op te lossen.
Toekomstvisie
Ontwikkeling en validatie van nieuwe circulatie ondersteunende apparatuur zijn erg
belangrijk voor het handhaven van orgaanfuncties tijdens het ontbreken van normale
hartslag. Het onderzoek van het nut van pulserende circulatie blijft een uitdaging.
De kennis op het gebied van orgaanfunctie kan aangewerd worden om de effecten
van pulserende circulatie nauwkeuriger te onderzoeken. Dit kan het klinische eindre-
sultaat verbeteren tijdens overbrugging naar transplantatie, om het hart tijdelijk te
ontlasten, of tijdens een hartoperatie waarbij het hart stil staat.
Uit hetzelfde onderzoeksgebied is bekend dat machinale pulsatiele vloeistof circulatie
van een donororganen beter beschermt tegen weefsel schade dan statische koude pre-
servatie, waarbij het orgaan in ijs verpakt wordt. Het is van groot belang de voordelen
van deze nieuwe pulsatiele preservatie–machines te bepalen in zowel de experimentele
als klinische omgeving teneinde een groter aantal donor organen met succes te kunnen
transplanteren.
Tot slot, extra wetenschappelijk aandacht is nodig om de onderliggende oorzaken
van ziektes te onderzoeken. Onze inspanningen in het beschrijven van nieuwe mecha-
nismen van endotheel–activatie, gerelateerd aan veranderingen in de stromingseigen-
schappen van bloed, zouden zeer waardevol kunnen zijn voor een goede behandeling
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